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ABSTRACT
The world’s population is rapidly ageing, and with that has come a corresponding
increase in the number of people suffering age-related diseases. Dementia is a group of
age-related neurocognitive disorders, with the most common of these being Alzheimer’s
disease (AD). The number one risk factor for developing AD is advanced age, with the
incidence rising from 1 in 10,000 at age 60 to 1 in 3 by age 85. AD is characterised by
the deposition of extracellular amyloid-β aggregates (Aβ) and intracellular
neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau. Both Aβ and NFTs
spread throughout the brain by separate but predictable pathways during the progression
of the disease. Many studies have shown an involvement of membrane lipids, including
phospholipids, in the pathogenesis of AD. Less is known about the changes occurring in
membrane lipids such as phospholipids within the brain over the normal adult lifespan.
Lipids are major components of the brain comprising 40-55% of the dry matter present,
with phospholipids making up half of total brain lipid. The human brain undergoes a
number of structural changes during the course of ageing that could theoretically lead to
alterations in brain phospholipids. Changes to phospholipids with age within the human
brain could be driven by two current theories of ageing: i) the mitochondrial free radical
oxidative stress theory of ageing, which proposes that ageing is driven by damage to
macromolecules such as lipids by reactive oxygen species produced by the
mitochondria; or ii) the “inflammageing” theory, which suggests that ageing is driven
by chronic, low-grade inflammation over the lifetime of an organism. Several studies
conducted over twenty years ago attempted to characterise any changes occurring to
brain phospholipids with age, but newer methods utilising mass spectrometry to identify
and quantify lipids have become available since then. Understanding the changes
occurring to phospholipids during normal ageing may lead to a better interpretation of
the changes occurring during AD while also clarifying what fundamental mechanism
underpins ageing within the human brain.
Therefore, the aim of this thesis was to characterize any age-related changes occurring
to the three dominant phospholipid classes present in the human brain:
phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).
To accomplish this, post-mortem tissue (n = 36, age range 18-104 years) from five
different regions of the brain was obtained from neurologically normal donors via the
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New South Wales Tissue Resource Centre at the University of Sydney. These five areas
of the brain were chosen based on the spread of Aβ and NFTs during the progression of
AD. The dorsolateral prefrontal cortex, entorhinal cortex and hippocampus all develop
Aβ and NFTs during the progression of AD while the motor cortex and cerebellum
remain relatively unaffected. Tissue from each region was homogenised, fractionated
into a mitochondrial and microsomal component, and lipids were extracted. Molecular
phospholipids were identified by complementary positive and negative ion scans using
tandem mass spectrometry, and linear regression was performed to determine any agerelated changes. The fractionation of the tissue into mitochondrial and microsomal
membranes allowed the characterisation of any observed age-related changes to
phospholipids to a particular theory of ageing.
A variety of phospholipids underwent changes with age, with no specific trend
identified for one membrane fraction over another. No changes with age in total
quantified phospholipid levels were seen in either membrane fraction across the five
regions. Only the entorhinal cortex experienced age-related changes in a phospholipid
class, with increases in mitochondrial PC with age found alongside decreases in
mitochondrial PE. Several key age-related changes were seen in phospholipids across
the five brain regions. The phospholipid with the largest increase with age was PS
18:0_22:6 within the mitochondrial membranes of the hippocampus and both the
mitochondrial and microsomal membranes of the prefrontal cortex and cerebellum. PE
18:0_22:6 also underwent sizeable increases in both membrane fractions of the
cerebellum. The largest decrease with age was seen in PS 18:0_18:1 in both membrane
fractions of the cerebellum. This was followed by PE 18:0_20:4 in the mitochondria of
the prefrontal cortex, the microsomes of the entorhinal cortex, and in both membrane
fractions within the cerebellum. The cerebellum showed the largest number of changes
to its phospholipids with age in both the mitochondrial and microsomal membranes
while the entorhinal and motor cortices experienced the fewest. The only phospholipid
to show consistent age-related changes across all five regions was an increase in
mitochondrial PC 16:0_18:2. A trend was identified across the five brain regions for
increases in phospholipids containing a 22:6 fatty acid (docosahexaenoic acid, DHA)
with age, while those containing 20:4 (arachidonic acid, AA) or 22:4 (adrenic acid)
tended to decrease. All three fatty acids are polyunsaturated fatty acids that can be
classified into omega-3 (DHA) and omega-6 (AA and adrenic acid). Further regressions
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with age were conducted to confirm these findings across all five regions of the brain.
Total DHA levels increased significantly with age within the mitochondrial and
microsomal membranes of the prefrontal cortex and cerebellum. These increases with
age were driven by rises in PS-DHA in both of these regions, and by PE-DHA in the
cerebellum. Likewise, decreases were seen with age for AA and adrenic acid across
both membrane fractions in nearly all regions of the brain examined. This finding
suggests that there is a loss of long-chain omega-6 fatty acids within the brain over the
adult lifespan, while the omega-3 fatty acids increase.
Compared to the previous literature, the novel finding of this thesis is that the level of
DHA increases within specific regions of the brain in neurologically normal subjects
over the course of the adult lifespan. This differs drastically from what is seen in the
brain during the progression of AD, in which levels of DHA within the affected brain
regions are severely reduced. Due to this increase in DHA within both membrane
fractions of the brain with age, it was determined that the findings of this thesis aligned
more closely with the “inflammageing” theory of ageing than the mitochondrial free
radical oxidative theory. Several key pathways involved in the production of
phospholipids primarily containing DHA were identified as being useful targets for
future research. Future research should also focus on eicosanoid production pathways in
order to confirm the involvement of phospholipids in low-grade, chronic inflammation,
and the role that this may play in healthy ageing in the human brain.
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Chapter 1 Thesis Overview
1.1 Introduction
An increase in lifespan has led to a dramatic shift in the age demographic of the
population worldwide, with the number of people over the age of 65 years projected to
triple to 1.5 billion by 2050 [1]. Within Australia, our total population has increased
fivefold over the 20th century, but the number of people aged 65 years and over
increased more than fifteen-fold in the same period [2]. This aged population is also
expected to continue to rise from 13% in 2007 to 23-25% of the population by 2056 [3].
Alongside this increasingly aged population is a corresponding increase in the number
of people suffering from age-related disease. Dementia is a group of neurocognitive
disorders resulting in the disturbance of higher cortical functions, including memory,
thinking, comprehension, language and learning ability. An estimated 35.6 million
people were living with dementia worldwide in 2011, with that number predicted to
double every 20 years [4]. The economic burden of dementia is staggering, with the
global societal costs of the disease estimated at around US$604 billion in 2010 [4]. In
Australia alone there were an estimated 298,000 people suffering from dementia
nationally in 2011, which resulted in direct and indirect costs of around $4.9 billion [5].
With an increasingly older population and a rising rate of dementia incidence
worldwide, research into effective prevention and treatment strategies for such agerelated diseases are becoming more and more important.
Alzheimer’s disease (AD), the most common form of dementia, is a neurodegenerative
disease typified by synaptic loss and increased neuron apoptosis that leads to the
extreme atrophy of several brain regions, particularly those involved in memory, speech
and behaviour. AD is characterised by the presence of intracellular protein aggregates
formed from amyloid-β (Aβ) peptides and extracellular neurofibrillary tangles (NFTs)
of hyperphosphorylated Tau. The deposition of Aβ plaques and NFTs follow a different
progression to each other during the pathogenesis of AD, but both pathways follow
predictable patterns of spread within the brain with little variation between individuals
[6,7]. Aβ accumulation can be divided into three stages (Figure 1-1) [7]. Aβ plaques are
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Figure 1-1: The progression of deposition of amyloid-β plaques (upper, stages A
through C) and neurofibrillary tangles formed from hyperphosphorylated tau (lower,
stages I-VI) in the human brain during the pathogenesis of Alzheimer’s disease. From
Braak and Braak [7].
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initially found within the isocortex (particularly in the basal regions of the frontal,
temporal and occipital lobes), and during the progression of the disease spread to almost
all of the isocortical association areas. Only the primary sensory and motor cortices
remain free of Aβ in the late stages of AD. Aβ accumulation occurs in the hippocampus
and entorhinal cortex from the middle stages onwards. Levels of Aβ do not necessarily
correlate with cognitive performance, with Aβ plaques commonly seen in the brain of
non-demented elderly on autopsy [8] and by imaging techniques in vivo [9].
Conversely, NFTs are first present in the region bordering the entorhinal cortex and
temporal cortex. In the middle stages, NFTs are found in the limbic system, particularly
the hippocampus, which produces mild cognitive impairment and personality changes
[6]. In the final stages, large numbers of NFTs are displayed throughout virtually all
subdivisions of the neocortex, alongside severe destruction of neocortical association
areas. The highest risk factor for developing AD is advanced age with incidence rising
sharply from 1 in 10,000 at age to 60 to 1 in 3 by age 85 [10]. Most cases of AD are
sporadic in nature with the genetic causes being largely unknown; however, the few
genetic associations that are known point towards an involvement of lipid metabolism
in the pathogenesis of AD. The strongest known genetic risk factor for AD is
homozygosity of the APOE-ε4 allele [11,12]. The APOE gene encodes for
apolipoprotein E, which is involved in the trafficking of lipids in the brain. Recent
genome-wide association studies have also unearthed several other genetic markers of
late-onset AD, several loci of which have roles directly or indirectly in lipid metabolism
within the brain [13–15]. Alongside these genetic risk factors, there is increasing
evidence for a cell membrane defect in AD, with alterations in phospholipids and other
membrane lipids being observed in the disease (reviewed in Chapter 2).
Given that the principal risk factor for AD is advanced age, there is surprisingly little
information available on the changes occurring in membrane lipids such as
phospholipids during normal ageing. The few studies that have been conducted on
normal ageing in the brain were performed over twenty years ago (reviewed in Chapter
2). The human brain undergoes a number of structural changes during ageing, including
decreases in cortical thickness [16–21], volume [16,19,22–26], density [27], surface
area [16,18], and white matter volume [21,23,26]. Declines in brain metabolic
parameters such as oxygen consumption and blood flow [28] with age are also seen. All
of these recorded age-related changes could feasibly lead to alterations in brain
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phospholipid composition. Since the publication of these past studies on age-related
changes in human brain phospholipids, newer methods that use mass spectrometry to
examine phospholipids at a molecular level have been developed [29]. Filling this gap
in the literature would lead to a better understanding of the changes occurring in
phospholipids as a result of neurodegenerative diseases such as AD, and potentially a
better understanding of the cellular mechanisms of ageing.

1.2 Statement of the problem
The overall aim of this thesis is to address the current deficit in knowledge regarding the
changes occurring in the phospholipid composition of the human brain during normal
ageing. A secondary aim is to compare and contrast these age-related changes in the
phospholipids of the human brain to those previously reported in the literature for AD.
AD was chosen specifically due to the established involvement of phospholipids and
other membrane lipids in the pathogenesis of the disease compared to other types of
dementia (reviewed in Chapter 2). To achieve the aims of this thesis, the phospholipids
of five regions of the brain were systematically analysed using state-of-the-art mass
spectrometry techniques. To aid in pinpointing the specific subcellular location where
age-related changes occur, the brain tissue from each region was fractionated to give a
mitochondrial-enriched and microsomal (mixed cellular membrane) fraction. This
fractionation method required substantial method development (Chapter 3). The five
brain regions examined in this thesis are shown in Figure 1-2. Three of these five
regions were chosen based on their involvement in the pathogenesis of AD (Figure 1-1).
They consisted of the dorsolateral prefrontal cortex (Chapter 4), hippocampus (Chapter
5), and entorhinal cortex (Chapter 6) (Figure 1-2). The remaining two brain regions, the
cerebellum (Chapter 7), and the motor cortex (Chapter 8) undergo few changes during
AD. Due to this they are often used as control brain regions when studying the disease
(Figure 1-2). Comparison of the five regions was also conducted to establish any
region-specific changes in phospholipid during normal ageing, as well as
recommendations for future research (Chapter 9).
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Figure 1-2: Model of the human brain highlighting the five regions analysed within this
thesis : dorsolateral prefrontal cortex (purple), hippocampus (green), entorhinal cortex
(yellow), cerebellum (red) and motor cortex (blue). The dorsolateral prefrontal cortex,
hippocampus, and entorhinal cortex all undergo substantial changes during the
pathogenesis of AD, while the cerebellum and motor cortex remain relatively spared (as
shown in Figure 1-1).
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Chapter 2 Literature review
2.1 The importance of phospholipids in the brain
2.1.1

Phospholipids

The bilayer present in cellular membranes is formed by a range of lipid molecules, with
the primary type of lipid present being phospholipids. Glycerophospholipids, more
commonly known as phospholipids, are amphipathic molecules consisting of a polar
head group and two fatty acids attached to a glycerol backbone (Figure 2-1). Different
combinations of head group and fatty acids in a phospholipid can produce up to 10 000
different molecular species [30]. Such variation in their structure can in turn affect
membrane properties including membrane fluidity and the modulation of membranebound protein activity [31–33].
Glycerophospholipids
Phospholipids
R = fatty acids
Saturated
(no double bonds)
Monounsaturated
(1 double bond)
Polyunsaturated
(>1 double bond)

X = head group:
Phosphatidyl
Choline
Phosphatidic
acid
Phosphatidyl
Ethanolamine
Phosphatidyl
Serine
Phosphatidyl
Glycerol

Phosphatidyl
inositol

Figure 2-1: Glycerophospholipids. The structural diagrams show possible head group (X)
and fatty acid placement (R; see Figure 2-2).
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Saturated fatty acid (no double bonds)

Stearic Acid (18:0)

Monounsaturated fatty acid (one double bond)

Oleic Acid (18:1n-9)

Linoleic Acid (18:2n-6)

Omega-6 Polyunsaturated Fatty Acid

(two or more double bonds; first double bond at the 6th carbon from the methyl end)

α-Linolenic Acid (18:3n-3)

Omega-3 Polyunsaturated Fatty Acid

(two or more double bonds; first double bond at the 3rd carbon from the methyl end)

Figure 2-2: Examples of different fatty acids from the 18-carbon series.
The

three

most

common

phospholipid

classes

found

in

mammals

are

phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).
The head groups are linked to the glycerol backbone by phosphate in the sn-3 position
(Figure 2-1). Other less common phospholipid classes include phosphatidic acid,
phosphatidylglyercol and phosphatidylinositol. The fatty acids of phospholipids are
esterified to the sn-1 and sn-2 positions of glycerol, and can be classified by their chain
length (number of carbons). Fatty acids can also be classified by the number of double
bonds present: saturated (no double bonds), monounsaturated (one double bond) and
polyunsaturated (more than one double bond) (Figure 2-2). Polyunsaturated fatty acids
(PUFA) can be further classified by the position of the first double bond from their
methyl end into omega-3 (n-3) and omega-6 (n-6) fatty acids. Phospholipids can also
contain ether-linked fatty acids, which are joined to the glycerol backbone by either an
alkyl or alkenyl ether bond. In this literature review, the focus will be mainly on the
three predominant phospholipids present in mammalian cellular membranes, PC, PE
and PS.
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2.1.2

Phospholipids in the human brain

Lipids are found in high amounts in the human brain, making up around 40-55% of the
dry matter present, but this can be considerably higher in myelinated neurons, rising to
around 80% of total dry matter [34]. Phospholipids are the dominant lipid found in
cellular membranes and comprise around half of the lipids present in the dry matter of
the human brain [34]. The overall phospholipid composition of the top three
phospholipids found in the adult brain is approximately 35-40% PC, 35-40% PE and
20% PS [35]. Compared with other tissues, the brain is highly enriched in phospholipids
containing PUFA, particularly docosahexaenoic acid (DHA, 22:6n-3), which is found
mostly in the PE and PS classes of phospholipids. Within the grey matter of the human
cerebral cortex, both PE and PS phospholipids consist of approximately 20-25% DHA
[35]. Other PUFA, such as arachidonic acid (AA, 20:4n-6), are also present in high
levels in the human brain, particularly in PC and PE, making up approximately 15% of
the fatty acid present in each class [35]. PUFA have many important biological roles
within cell membranes, including the modulation of membrane fluidity, influencing the
activity of membrane-bound proteins, and acting as secondary messengers in
inflammatory pathways [31,36–38]. Described below are the ways in which
phospholipids and their fatty acids are synthesised within mammalian tissues.
2.1.3

Synthesis of phospholipids

Phospholipids present in cellular membranes can be obtained directly from the diet,
synthesised de novo or produced via deacylation and reacylation pathways which
remodel the fatty acids present in membranes. Only a few phospholipid molecular
species can be synthesised de novo, with the vast array of structural diversity seen in
phospholipids being the result of the remodelling pathways [39]. Little is known about
specific pathways of phospholipid synthesis in the human brain, and as such this section
will focus on general phospholipid biosynthesis pathways in mammalian tissues.
Both PC and PE follow a parallel pathway during de novo synthesis (Figure 2-3) [40].
The first step in PC synthesis is the phosphorylation of choline by choline kinase.
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Figure 2-3: Synthesis of the three most abundant phospholipids present in mammalian
cellular membranes . CK choline kinase; CPT CDP-choline:1,2-diacylglycerol
cholinephosphotransferase; CT CTP:phosphocholine cytidylyltransferase; DAG
diacylglycerol; EK ethanolamine kinase; EPT CDP-ethanolamine:1,2-diacylglycerol
ethanolaminephosphotransferase; ET CTP:phosphoethanolamine cytidylyltransferase;
PC
phosphatidylcholine;
PE
phosphatidylethanolamine;
PEMT
phosphatidylethanolamine N-methyl transferase; PS phosphatidylserine; PSD
phosphatidylserine decarboxylase; PSS1 phosphatidylserine synthase 1; PSS2
phosphatidylserine synthase 2.
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Next, CDP is added to phosphocholine by CTP:phosphocholine cytidylyltransferase.
Finally, CDP-choline is transferred to diacylglycerol by CDP-choline:1,2-diacylglycerol
cholinephosphotransferase

(CPT)

to

form

phosphatidylcholine.

Phosphatidyl-

ethanolamines are synthesised de novo following the same steps as phosphatidylcholine,
but by ethanolamine-specific enzymes (Figure 2-3). The synthesis of PC and PE
phospholipids takes place in the smooth endoplasmic reticulum (sER), but both CPT
and CDP-ethanolamine:1,2-diacylglycerol ethanolaminephosphotransferase (EPT) can
also be localised to a specific portion of the sER known as the mitochondria-associated
membranes (MAM) [41]. CPT is also present in the outer mitochondrial membrane,
allowing the mitochondria to synthesise PC phospholipids de novo, but EPT is only
present on the sER. There are four primary PC and PE molecular phospholipids that are
known to be synthesised de novo via these pathways: 16:0/18:2n-6, 16:0/18:1,
16:0/22:6n-3 and 18:1/18:2n-6 [42]. The vast bulk of structural diversity seen within
phospholipids is not the result of de novo synthesis, but arises from deacylation and
reacylation pathways that remodel the fatty acids present in phospholipids.
Phospholipase A1 and A2 cleave fatty acids from the sn-1 and sn-2 positions of
phospholipids respectively to form lysophospholipids. Acyl-CoA:lysophospholipid
acyltransferases specific to both phospholipid head group and sn position esterify fatty
acids onto lysophospholipids to reform diacyl phospholipids. The net result of these
processes are phospholipids predominately with a saturated fatty acid present in the sn-1
position and an unsaturated fatty acid in the sn-2 position (reviewed by Yamashita et al.
[43]).
In contrast to PC and PE, there are no de novo synthesis pathways for the synthesis of
PS in mammalian membranes. Rather, PS is synthesised through a calcium-dependent
serine base-exchange reaction from PC by phosphatidylserine synthase 1 (PSS1) and
from PE by phosphatidylserine synthase 2 (PSS2, Figure 2-3). Both PSS1 and PSS2 are
located in the sER, primarily within the MAM [44], with the close proximity of the two
membranes allowing the transfer of PS into the mitochondrial membranes after
synthesis [40]. PSS2, in particular, is highly expressed in the brain of mammals, yet
mice with PSS2-deficiency have normal membrane phospholipid content [45]. PSS2
displays a preference for PE phospholipids containing DHA in the sn-2 position over
those containing other fatty acids such as AA or oleic acid (18:1) [46]. This preference
leads to the high level of polyunsaturation seen in PS phospholipids in the brain.
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Increases in PS synthesis via serine-base exchanges have been reported in aged rats in
the cerebellum and cerebral cortex, both with and without the addition of exogenous
calcium [47].
PC and PE phospholipid can also be synthesised via remodelling pathways. Within the
inner mitochondrial membrane, the synthesis of PE phospholipids occur by
decarboxylation of PS by phosphatidylserine decarboxylase (PSD, Figure 2-3). This
pathway displays a preference for generating phospholipids containing PUFA in the sn2 position [48] but is thought to only account for 7% of total PE production within the
brain [49]. Deletion of PSD in mice causes embryonic death at day 9.5, with
morphologically aberrant, fragmented mitochondria present [50,51]. No changes in the
activity of PSD have been observed in the cerebral cortex or cerebellum of aged rats
[47]. PC phospholipids can also be generated by the methylation of PE via
phosphatidylethanolamine N-methyl transferase (PEMT, Figure 2-3). PEMT activity is
present in the sER, and immunoreactive PEMT has also been identified in the MAM
[52]. Although a seemingly redundant pathway, mice with homozygous deletion of
PEMT show liver failure within three days when choline is eliminated from the diet,
with no overt changes in the phospholipid composition of any other tissue [53]. PEMT
activity has been found to increase with age in the cerebral cortex of rats [47].
Alterations to PEMT structure and activity may also be involved in AD, with a single
nucleotide polymorphism in PEMT associated with sporadic AD in a Han Chinese
population [54]. Decreased levels of PEMT activity have also been seen in the cerebral
cortex of people with AD [55].
2.1.4

Synthesis of polyunsaturated fatty acids

Unlike saturated and monounsaturated fatty acids, n-3 and n-6 PUFA are considered to
be essential in the diet because they cannot be synthesised de novo by mammals.
However, long-chain PUFA of 20 carbons or longer can be synthesised through
elongation and desaturation of shorter-chain precursors via a pathway common to both
n-3 and n-6 fatty acids (Figure 2-4). This pathway begins with either linoleic (LA,
18:2n-6) or α-linolenic (ALA, 18:3n-3) acid in the endoplasmic reticulum. Both of these
fatty acids undergo a series of alternating double bond insertions (desaturation) by Δ6
and Δ5 desaturases, followed by the addition of two carbons (elongation) via elongases.
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Figure 2-4: Biosynthesis of long-chain polyunsaturated fatty acids (PUFA) in humans
from precursor omega-3 (n-3) and omega-6 (n-6) PUFA, which occurs via a common
desaturase/elongase system. In the endoplasmic reticulum Δ6- and Δ5-desaturases
introduce double bonds at the sixth and fifth carbons from the carboxyl end
respectively, while several elongase isoforms increase the fatty acid chain length by two
carbons at the carboxyl end. Long chain PUFAs containing 22 carbons are synthesised
via additional β-oxidation steps in the peroxisomes Adapted from [56].
Initially, it was assumed that the 22 carbon series PUFA such as docosapentaenoic acid
(22:5n-6) and DHA were converted from AA and eicosapentaenoic acid (EPA, 20:5n-3)
respectively in humans and mammals by elongation and subsequent desaturation by a
Δ4 desaturase within the endoplasmic reticulum. However, experiments by Voss et al.
[57] in rat microsomes using either

14

C labelled docosapentaenoic acid (22:5n-3) or

tetracosapentaenoic acid (24:5n-3) and tetracosahexaenoic acid (24:6n-3) resulted in the
production of radiolabelled DHA. This finding indicated that at least one round of βoxidation of 24-carbon series PUFA was required for DHA synthesis. Unknown at this
time was whether this β-oxidation step was occurring in the mitochondria or the
peroxisomes. Martinez and colleagues [58,59] had noted that people suffering from the
peroxisomal disorder Zellweger syndrome were massively deficient in long chain
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PUFA such as docosapentaenoic acid (both n-3 and n-6) and DHA, particularly in the
brain, hinting that the peroxisomes are required for the synthesis of long chain PUFA.
This deficiency in DHA is so severe that children with Zellweger syndrome suffer acute
neurological impairment and rarely survive past their first year of life. To test this,
Christensen et al. [60] incubated

14

C radiolabelled adrenic acid (22:4n-6) and

docosapentaenoic acid (22:5n-3) in both normal and Zellweger fibroblasts. They found
that the Zellweger fibroblasts were unable to retroconvert these fatty acids to AA and
EPA respectively, demonstrating that the peroxisomes were required for the β-oxidation
step needed to synthesise long-chain PUFA. This finding was confirmed by Moore et
al., [61] who found an inability of Zellweger fibroblasts to produce DHA from

14

C

radiolabelled ALA, docosapentaenoic, tetracosapentaenoic or tetracosahexaenoic acid.
There are three possible ways to meet the brain’s high requirement for DHA: local
synthesis from short chain precursors within the brain, synthesis by other organs such as
the liver, or incorporation from the diet. Whether the human brain itself can synthesise
adequate levels of DHA from ALA has not been well studied. Cho et al. [62] described
abundant amounts of Δ6 desaturase mRNA within male adult human brain from postmortem tissue. However, experiments in rats have shown that the use of DHA by the
brain vastly outweighs its ability to synthesise it from ALA, with a 10-fold increase in
the rate of liver DHA synthesis compensating for this deficiency [63]. Experiments in
vitro have found a low capacity for cultured neurons to make their own DHA from ALA
or EPA [64], but marked increases in the synthesis of DHA and AA from ALA or LA
respectively have been reported in cocultures of astrocytes with brain endothelial cells
[65,66]. Regardless, the production of DHA from either ALA or EPA is known to be
quite inefficient overall in adult humans [67,68]. Both n-3 and n-6 PUFA use the same
enzymatic pathway for synthesis and compete for use of this pathway (Figure 2-4).
Under normal conditions desaturases have a preference for n-3 over n-6 PUFA, but LA
is so highly abundant in the average Western diet that levels of long-chain n-6 PUFA
such as AA never fall below optimum levels (except in cases of severe dietary fatty acid
deprivation) [69]. By comparison, the levels of ALA in the diet are much lower and
combined with an overall inefficient conversion to long chain PUFA in humans this
results in a lower available pool of EPA and DHA. Indeed, most of the DHA present
within the brain accumulates very early on in development [70], either prior to or in the
first few months after birth [71–73]. However, newer research suggests some capacity
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for transport of long-chain n-3 PUFA in the brain of adults [74,75], which likely serves
to maintain levels of PUFA accrued during infant brain development [76]. Due to the
brain's lifelong need for long-chain n-3 PUFA, this has led to the belief that both EPA
and DHA should be considered essential dietary fatty acids [69,77].
2.1.5

Ether-linked phospholipids

The human brain is also highly enriched in phospholipids that contain ether-linked fatty
acids; mainly the vinyl-ether phospholipids known as plasmalogens. Two types of
ether-linked phospholipids exist: 1-O-alkyl-2-acyl phospholipids, which contain an
alkyl ether- linked fatty acid in the sn-1 position and an esterified fatty acid in the
second; and 1-O-alkenyl-2-acyl phospholipids, which have an alkenyl (or vinyl) ether
bond linking the fatty acid at the sn-1 position (Figure 2-5). 1-O-alkenyl-2-acyl
phospholipids are better known by their common name, plasmalogens, and are
particularly abundant within the PE class of phospholipids in the human brain,
comprising one-half to two-thirds of this phospholipid class [78]. These PE
plasmalogens contain PUFA such as DHA and AA in the sn-2 position mostly. Etherlinked phospholipids are synthesised de novo in the peroxisomes and endoplasmic
reticulum (reviewed by [79,80], Figure 2-6). Biosynthesis of alkyl-ether phospholipids
and plasmalogens begins in the peroxisomes, where 1-alkyl-dihydroxyacetone
phosphate is formed from dihydroxyacetone phosphate via a series of steps. 1-alkyldihydroxyacetone

phosphate

can

then

be

reduced

to

1-alkyl-2-hydroxy-sn-

glycerophosphate by an acyl/alkyl reductase located on the outside of both peroxisomal
and endoplasmic reticulum membranes. Within the endoplasmic reticulum, the
phosphate group is removed by phosphatidic acid phosphatase and an acyl group is
placed in the sn-2 position to form 1-alkyl-2-acyl-sn-glycerol. From here it is converted
to either a PC or PE either by the same CPT and EPT that add CDP-choline and CDPethanolamine on diacylglycerol to produce diacyl PC or PE (discussed in section 2.1.3),
forming an alkyl-ether containing PC and PE phospholipids. The vinyl-ether bond seen
in plasmalogens is introduced by Δ-1’-desaturase, with 1-alkyl-2-acyl-PE being the
preferred substrate. Choline plasmalogens are primarily formed from hydrolysis of
ethanolamine plasmalogens followed by the addition of choline via choline-transferase
[81]. The final fatty acid composition of both alkyl-ether phospholipids and
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1-octadecanoyl-2-docosahexaenoyl-phosphatidylethanolamine

PE 18:0/22:6

1-O-octadecyl-2-docosahexaenoyl-phosphatidylethanolamine

PE O-18:0/22:6

1-O-octadecenyl-2-docosahexaenoyl-phosphatidylethanolamine

PE P-18:0/22:6

Figure 2-5: Three subclasses of phospholipids bearing either 1,2-acyl (top), 1-O-alky-2acyl (middle) or 1-O-alkenyl-2-acyl (bottom) fatty acids. 1-O-alkenyl-2-acyl
phospholipids are more commonly known as plasmalogens. Shorthand notation for each
type of phospholipid is indicated on the right. The different sn-1 linkages are
highlighted in red.
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Figure 2-6: Synthesis of ether-linked phospholipids within mammalian cells. Δ-1’ Δ-1’
desaturase; AADHAP-R alkyl/acyl DHAP reductase; AAGP-AT acyl/alkyl
glycerophosphate acyltransferase; AGPS alkylglycerone phosphate synthase; CPT CDPcholine:1,2-diacylglycerol cholinephosphotransferase; DHAP dihydroxyacetone
phosphate;
EPT
CDP-ethanolamine:1,2-diacylglycerol
ethanolaminephosphotransferase; GPA glycerophosphate; GNPAT glyceronephosphate-Oacyltransferase; PAP phosphatidic acid phosphatase; PC phosphatidylcholine; PE
phosphatidylethanolamine. Adapted from [79,80].
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plasmalogens is mostly attained via the fatty acid remodelling process described above
in section 2.1.3.
Plasmalogens and alkyl-ether lipids have several distinct biological roles. Firstly, their
presence can alter membrane properties by decreasing fluidity, increasing order, and
promoting the formation of non-bilayer phases at lower temperatures, a process needed
for membrane fission and fusion events [79]. Plasmalogens are highly enriched in lipid
raft domains of the plasma membrane [82,83]. The vinyl ether bond present on
plasmalogens is also thought to be preferentially oxidised by free radicals and singlet
oxygen, protecting nearby unsaturated fatty acids [79,80,84]. A deficiency of
plasmalogens within cell membranes has been observed in several diseases, including
AD [85–87]. The changes that occur to plasmalogens in AD will be discussed in more
detail below (section 2.3).
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2.2 Changes to phospholipids in the brain during normal ageing
It is known that throughout infancy and childhood development DHA accumulates in
the brain within PE and PC phospholipids [70]. Surprisingly little is known about the
changes occurring in the composition of phospholipids in the human brain over the
adult lifespan. The current knowledge regarding age-related changes in phospholipids of
the human brain and animal models (predominately rat) is reviewed below.
2.2.1

Human studies

2.2.1.1 Total phospholipids
The level of total phospholipid within the different regions of the human brain either
decreases or remains unchanged with advanced age (Table 2-1). Decreases with age in
total phospholipids have been noted in whole cerebral cortex [88] frontal cortex
(including grey matter) [89–91], temporal cortex (including grey matter) [89,91], and
hippocampus [90]. No changes in total phospholipids with age have been reported in the
cerebellum [88,90] or temporal white matter [91].
2.2.1.2 Phospholipid classes
Only three studies have examined the changes occurring in individual phospholipids
classes during normal ageing (Table 2-2). The combined weight of evidence suggests
that there are no changes with age to total PC, PE or PS within the frontal cortex or
cerebellum [90,92]. However, there is some disagreement within the literature as to
whether total PC and PE change with age within the hippocampus, with an equal

Table 2-1: Summary of the available literature on changes in total brain phospholipids
within different regions of the human brain during normal ageing.
Total phospholipids
Change with age
Decreased[88]
Whole cerebral cortex
Decreased[89]
Frontal Cortex
Decreased[90,91,93]
- Grey
No change[91]
Decreased[90,93]
- White
Decreased[89]
Temporal Cortex
Decreased[91]
- Grey
No change[91]
- White
Decreased[90,93]
Hippocampus
No change[88,90]
Cerebellum
Phospholipids determined by phosphorous assay in all studies.
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Table 2-2: Summary of the available literature on changes in phospholipid classes
within different regions of the human brain during normal ageing.
Phospholipid
class
PC

Change
Frontal
Cerebellum Hippocampus
with age
Cortex
No change
[90,92]
[90]
[90]
Decrease
[93]
[93]
No change
[90,92,93]
[90]
[90]
PE
Decrease
[93]
No change
[90,92]
[90]
[90]
PS
Phospholipid classes separated by thin-layer chromatography and determined by
phosphorous assay[90,93] or densitometry [92].
number of studies finding either no change [90] or decreases with age [93] in both PC
and PE.
2.2.1.3 Total phospholipid-fatty acids
Five studies have previously examined the human brain for any age-related changes in
the total phospholipid fatty acids (Table 2-3). The frontal cortex is the most highly
studied brain region for changes to phospholipid-fatty acids with age, with all four
studies finding few changes to the fatty acids of total phospholipids with age. Increases
have been reported with age in myristic acid (14:0) within the frontal cortex [94,95], as
well as in the level of arachidic acid (20:0) [94]. Many of the results within this region
were conflicting though, with an equal number of studies reporting either no change
[94,96] or a decrease [92,95] in 22:5n-6 with age, as well as age-related increases [94]
or no change [96] in 22:5n-3. Carver et al. [94] observed several decreases with age
within the frontal cortex in long-chain n-6 PUFA, including dihomo-γ-linolenic acid
(20:3n-6) and adrenic acid, but neither finding was replicated by other studies of this
brain region [95,96]. The other regions examined,were the temporal and parietal
cortices, as well as the hippocampus, showed no changes to any phospholipid-fatty
acids with age [93,96], but these regions have each only been examined in a single
study and more work is needed to confirm these findings.
2.2.1.4 Phospholipid fatty acids by class
Only a single study has looked for any age-related changes in fatty acids within separate
phospholipid classes in the human brain. No changes were found in either PC or PE
fatty acids during normal ageing in either the frontal cortex, pons or hippocampus [93].
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Table 2-3: Summary of the available literature showing changes in total phospholipid
fatty acids within different regions of the human brain during normal ageing
Change
Frontal
Temporal
Parietal
Hippocampus
with age
Cortex
Cortex
Cortex
Increased
[94,95]
14:0
No change
[96]
[96]
[96]
No change
[92]
15:0
Increased
[94]
No change
[92,93,96]
[96]
[96]
[93]
16:0
Decreased
[95]
Increased
[95]
16:1
No change
[92,96]
[96]
[96]
No change
[92–94,96]
[96]
[96]
[93]
18:0
Decreased
[95]
No change
[93]
[93]
18:1
Increased
[95]
18:1(n-7)
No change
[92,96]
[96]
[96]
Increased
[95]
18:1(n-9)
No change
[92,94,96]
[96]
[96]
Increased
[94]
18:2(n-6)
No change
[92,95,96]
[96]
[96]
Increased
[94]
20:0
Increased
[95]
20:1
No change
[92–94,96]
[96]
[96]
[93]
No change
[94]
20:2(n-6)
No change
[95,96]
[96]
[96]
20:3(n-6)
Decreased
[94]
No change
[92–94,96]
[96]
[96]
[93]
20:4(n-6)
Decreased
[95]
No change
[94]
22:0
No
change
[92]
22:2
No change
[93,95,96]
[96]
[96]
[93]
22:4(n-6)
Decreased
[94]
22:5
Increased
[94]
22:5(n-3)
No change
[96]
[96]
[96]
No change
[94,96]
[96]
[96]
22:5(n-6)
Decreased
[92,95]
No change
[92–94,96]
[96]
[96]
[93]
22:6(n-3)
Decreased
[95]
No change
[94]
24:0
No changes
[94]
24:1
Total phospholipid fatty acids were determined by the following methods:
phospholipids transmethylated [92–94] or saponified [95,96], and fatty acid methyl
esters quantified by gas chromatography.
Fatty acid
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2.2.2

Animal models

Changes in the phospholipid composition of the brain during normal ageing have also
been studied using animal models, most notably in the rat. One of the most common
findings across studies of the rat brain during normal ageing is a reduction in the
amount of PUFA present in phospholipids, particularly in DHA [97–103]. These agerelated losses of DHA have been reported in PC [100], PE [97,99], and PS [100], as
well as in total phospholipids fatty acids [98,99,101,103]. DHA is also reported to
decrease with age in the mouse brain [104]. Other losses of PUFA with age in the rat
brain included AA in PC [100], PS [102] and in total phospholipids [101,103]; LA in PS
and PC [102] and in total phospholipids [101,103]; and in adrenic acid in PS [100].
Increases with age have been seen consistently in the rat brain monounsaturated fatty
acids, principally in PE [98,100] and total phospholipids [103]. Changes in total amount
of phospholipid within the classes have also been reported with age in rat and mouse
brain, with decreases seen in PC [105,106] , PE [98,105,106], PS [106] and total
phospholipids [99] with age. Conversely, Modi, Katyare and Patel [105] reported
increases in PS phospholipids with age in the rat brain, while Fabelo et al. [107] found
increases in both PE and total phospholipids with age.

2.3 Changes to phospholipids in the brain during dementia
Compared to normal ageing, the changes occurring to phospholipids in the human brain
as a result of dementia have been better studied. AD, the most common form of
dementia, has been particularly well studied for such changes. A summary of what is
currently known about the changes occurring within the human brain during different
dementias is detailed below.
2.3.1

Alzheimer’s disease

AD is not only the most common type of dementia, but also the best-studied dementia
in terms of phospholipid changes to the human brain. As stated in Chapter 1 (section
1.1), there is strong evidence for an involvement of membrane lipids in the pathogenesis
of AD. The strongest known genetic risk factor for AD is homozygosity of the APOEε4 allele, with apolipoprotein E being involved in lipid trafficking and metabolism
within the brain [11,12]. Several genome-wide association studies have also unearthed
other genetic markers of AD, with many loci being either indirectly or directly involved
in lipid metabolism [13–15]. Over twenty studies to date have looked for any
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relationship between brain phospholipids and Alzheimer’s disease, and typically
included subjects aged between 60 and 100 years of age. However, two studies also
included subjects less than 60 years old in both control and Alzheimer’s disease groups
[96,108].
Decreased amounts of total phospholipid have been reported in the hippocampus in AD
[86,109,110], with possible increases seen in the temporal cortex [109,111]. No changes
to total phospholipid amount have been seen in AD in the frontal cortex [87,108],
occipital cortex or cerebellum [111]. Within the individual phospholipid classes, the
combined available evidence suggests no changes have been reported in AD in the total
amount of PC in the frontal [87,92,108,111–116], entorhinal [116], occipital [111–113],
temporal [111–115,117] or parietal cortices [111–114], or in the cerebellum
[111,112,115,116]. Similarly, no changes have been observed in total PE in AD within
the frontal [87,92,108,111–114], parietal [111–114], entorhinal [116] or occipital
cortices [111–113], or in the cerebellum [85,111,112,116]. However, decreases in total
PE in AD have been observed in the hippocampus [86,111,113], while an equal number
of studies have reported either no change [111,114,117] or decreases [85,112,113] in
total PE within the temporal cortex. Interestingly, there were two studies that reported
decreases in total PE in AD within the frontal cortex that used mass spectrometry
techniques [85,116]. Within the PE class, there is conflicting information available on
what occurs to the levels of plasmalogens in AD. Decreases in PE plasmalogen have
been observed in the hippocampus in AD [86]. No changes have been observed in PEplasmalogen levels in the occipital [112] or entorhinal cortices [116], as well as in the
cerebellum [85,112,116] in AD. In the frontal cortex, one study reported increases in
PE-plasmalogens in AD [112] while others reported no change [87,116] or decreases in
PE-plasmalogens in AD [85,86]. Similarly, either increases [112] or decreases [85] in
PE-plasmalogens have been reported in AD in the temporal cortex, as well as either no
change [112] or decreases [85] in the parietal cortex. Levels of total PS have also been
found to not change in AD within the frontal [86,87,92,108,111–114,116,117], temporal
[111,112,114,117], parietal [111,113,114,117], occipital [111,113], or entorhinal
cortices [116], or in the cerebellum [111,112] and hippocampus [86,111].
In terms of fatty acids present in phospholipids, several literature reviews have stated
that there is a distinct loss of PUFA in AD [38,118–120]. However, examination of the
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available literature suggests that this conclusion is far from clear. In the frontal cortex,
the brain region best studied for changes to phospholipids in AD, a number of n-6 and
n-3 phospholipid-fatty acids have shown no changes in total amount in AD, including:
LA [87,92,96], dihomo-γ-linolenic acid [87,96], AA [87,92,96,121], EPA [87], adrenic
acid [87,96], docosapentaenoic acid (both 22:5n-3 [87,96] and 22:5 n-6 [87,92,96]), and
DHA [87,96,121]. Only a single study has looked at the total phospholipid fatty acids in
either the temporal cortex [96] or parahippocampus [121], with both cited studies also
examining the parietal cortex. Correspondingly, these two studies also reported a lack of
change to many PUFA in AD, with only decreases in adrenic acid observed in the
temporal cortex [96]. When the fatty acids of the three phospholipid classes PC, PE and
PS are analysed separately, changes to PUFA in AD have been noted. For most PC-fatty
acids in the frontal cortex, it appears that there are no changes in their amount in AD in
the frontal cortex [86,93,108]; however, an equal number of studies found either no
changes [86,108] or decreases [93,122] in the level of PC-AA. Similar results were seen
for PC-DHA in the frontal cortex, with both no changes [86,108] or decreases [87,93]
reported in AD. No changes in AD have been observed in PC fatty acids within the
parahippocampus/hippocampus [93,122,123]. Only a single study has looked at PCfatty acid changes in AD in the pons [93], as well as the temporal and parietal cortices
and cerebellum [123], finding decreases in cerebellar DHA only. Similarly, few changes
have been reported for PE-fatty acids within the brain in AD. Of note are possible
increases in PE-myristic acid [93] and decreases in PE-EPA [87] in the frontal cortex,
decreases in PE-AA [93,122,123], PE-adrenic acid [93,122] and PE-DHA [93,123] in
the parahippocampus/hippocampus, decreases in PE-stearic acid (18:0), PE-oleic acid
and PE-AA in the parietal cortex [123]. In the pons increases in PE-myristic acid, PEpalmitic acid (16:0) and PE-stearic acid have been reported in AD while decreases have
been seen in PE-AA, PE-adrenic acid and PE-DHA [93]. PS is the least well-studied
phospholipid class for changes to its fatty acids in AD, but similar to the other two
phospholipids few changes have been reported in AD when all the current literature is
compared. Decreases in PS-EPA [87], PS-docosapentaenoic acid (n-3 [87] and n-6
[87,108]) have been reported in the frontal cortex, with no change to PS-DHA in AD
[87,108]. Within the parahippocampus/hippocampus, decreases in AD have been
observed in PS-adrenic acid only [122], as well as in PS-DHA in both the temporal and
parietal cortices [114].
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There are several problems that are driving the ambiguity surrounding many of the
changes observed in phospholipids in AD. The largest problem is that there are several
different methods that have been used to analyse phospholipids extracted from tissue.
Historically, phospholipid classes have been separated and quantified by thin-layer
chromatography, either by densitometry or by scraping off the various separated classes
and quantifying by the phosphorous assay. Phospholipid fatty acids have been typically
analysed by gas chromatography after transmethylation or saponification of the
phospholipids, sometimes in conjunction with thin-layer chromatography for class
separation. Newer techniques have been developed for the accurate identification and
quantification of phospholipids from tissue extracts; however, such instruments are
costly to purchase and maintain. This idea will be further explored in Chapter 3. Only a
few studies so far have applied mass spectrometry to the study of phospholipids changes
in the human brain during AD [85,115]. It is expected that as more studies are
conducted using such techniques that the changes occurring to phospholipids in the
human brain as a result of AD will become clearer.
2.3.2

Other dementias

2.3.2.1 Parkinson’s disease
Only a single study has examined changes in phospholipid composition in Parkinson’s
disease (age range of controls: 79-102 years, Parkinson’s: 66-91 years) [124]. This
study used liquid chromatography mass spectrometry (LC-MS) to identify a number of
changes to phospholipids of the visual cortex, amygdala and anterior cingulate cortex. A
number of phospholipid bruto species (phospholipid class and total fatty acids carbonchain length and unsaturation) decreased in the brains of those with Parkinson’s disease,
particularly in the PE-class within the visual cortex. No losses of any particular type of
unsaturated fatty acid were reported; however, it is unclear if the authors performed
such an analysis.
2.3.2.2 Vascular/multi-infarct dementia
Vascular dementia (also known as multi-infarct dementia) is caused by problems in
blood supply to the brain, typically by a minor stroke. Occasionally vascular dementia
can overlap with the presence of lesions typical of AD, leading to the classification of
mixed dementia.
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Only a single study has examined the changes occurring to phospholipids in vascular
and mixed dementia, which used LC-MS to identify and quantify phospholipids of the
temporal lobe (average ages of controls 79.9±2 years, vascular dementia 85.3±3 years,
and mixed dementia 83.4±3 years) [125]. Total PC and PS were observed to increase in
the white matter in vascular dementia, with no change in grey matter for PC, PE or PS.
Conversely, levels of both total PC and PE decreased in the grey matter of those
afflicted with mixed dementia. Bruto phospholipids were also analysed in the grey and
white matter of the temporal cortex in both vascular and mixed dementia. Increased
amounts of PC and PS phospholipids were seen in the white matter in vascular dementia
while decreases in PC phospholipid were mostly observed in the grey matter of mixed
dementia patients. Given the different aetiologies of vascular dementia and AD, it is not
surprising that such opposing differences were found between vascular and mixed
dementia. Further research is needed to understand why these differences occur, and if
the same pattern is repeated in other parts of the brain affected in vascular and mixed
dementia.
2.3.2.3 Huntington’s disease
The only study of changes in phospholipids in Huntington’s disease to date found no
differences in the ratio of PE-plasmalogen to diacyl PE within the caudate nucleus in
Huntington’s disease (average age of controls 77±4 years, Huntington’s 55±5 years)
[126].
2.3.2.4 Creutzfeld-Jakob disease
Two studies have been performed to ascertain any changes in phospholipid content in
Creutzfeld-Jakob disease (CJD) [127,128]. In a case-control study (n=1 per group)
Federicco, Annunziata and Malentacchi [128] observed decreases in total phospholipids
in CJD, with increases found in PE in the white matter and PS in grey matter.
Corresponding reductions in PS and PC were observed in the white matter in CJD,
alongside decreases in PC and PE in the grey matter (age of control and CJD subject
both 67 years). Conversely, Tamai et al. [127] found no changes to any phospholipid
class in CJD, nor within the fatty acids of PC and PS phospholipids (age of subjects not
stated). However, they did observe marked increases in PE-oleic acid and decreases in
PE-adrenic acid and PE-DHA in the brain tissue of humans with CJD. Although CJD
can be transmitted to humans and from animals to humans via ingestion of or exposure
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to infected tissues (variant CJD), CJD can also be sporadic or familial in nature. Further
research is needed to ascertain whether there is a membrane lipid involvement in the
pathogenesis of CJD, particularly in familial cases.
2.3.2.5 Frontotemporal dementia
No studies currently exist that have examined changes in phospholipid composition in
frontotemporal dementia.
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2.4 The involvement of phospholipids in the current theories of ageing
2.4.1

Why do we age?

There are many proposed theories that attempt to explain the mechanism behind the
ageing process. Many such theories fall into two broad categories: programmed or error
theories [129]. According to the programmed theory of ageing, ageing depends upon the
regulation of the body’s internal “biological clock” through the different stages of
growth, development, maturity and old age via the switching on and off of certain genes
[129]. Alternatively, the error theory of ageing proposes that ageing is a result of
continual environmental stress at the molecular, cellular and whole-organism level,
resulting in cumulative damage and dysfunction over the lifespan and, eventually,
death. There are two main error theories of ageing that could apply to changes in
phospholipids during normal ageing within the human brain, and these theories will be
explored in the final part of this literature review: the mitochondrial free radical
oxidative theory of ageing and the “inflammageing” theory.
2.4.2

Mitochondrial free radical oxidative theory of ageing

Over the lifetime of an organism, many mutations occur within mitochondrial DNA
(mtDNA) leading to the progressive loss of mitochondrial function with age. This agedependent accumulation of mtDNA mutations can be a result of i) the inherent error rate
of the mtDNA polymerase γ [130]; or ii) due to the accumulation of reactive oxygen
species (ROS) generated as byproducts of oxidative phosphorylation over time which
overwhelm the few existing mtDNA repair mechanisms [131]. mtDNA is thought to be
especially vulnerable to damage by ROS due to its proximity to the electron transport
chain, a lack of repair mechanisms and an absence of protective histones [132,133].
ROS produced by the mitochondria have the capability to damage macromolecules such
as DNA, proteins and lipids. Over time, these macromolecules become progressively
more damaged, leading to the production of more ROS, which leads to a vicious cycle
of ROS production and macromolecule damage; the net result of which is thought to be
ageing [134]. The principle ROS generated by oxidative phosphorylation is superoxide,
but other ROS of significance include hydroxyl radicals, hydrogen peroxide and singlet
oxygen [135].
Harman first proposed the free radical theory of ageing in the 1950s [136], and this
theory was further strengthened by the discovery of superoxide dismutase in the late
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1960s [137]. Superoxide dismutase is an essential antioxidant defence enzyme that
catalyses the ROS superoxide into hydrogen peroxide and oxygen. Hydrogen peroxide
can then be transformed into water by catalase or glutathione peroxidase. Nonenzymatic
ROS scavengers (also known as antioxidants) also exist within cells, including
ascorbate, flavonoids, carotenoids and glutathione. In regards to phospholipids, it is the
fatty acids that are susceptible to oxidative damage by ROS such as superoxide. The
susceptibility of fatty acids to oxidative damage by ROS is known to be dependent upon
the degree of unsaturation (i.e. number of double bonds present). Bisallylic methylene
groups are particularly susceptible to oxidation as the presence of the double bonds
weakens the bond energy of this group, allowing the extraction of a proton by ROS to
form a lipid peroxyl radical (Figure 2-7). Due to this, PUFAs with a large number of
methylene-interrupted double bonds such as DHA are particularly susceptible to
oxidative damage [138]. A number of oxidative molecules can be derived from lipid
peroxyl radicals, including lipid peroxides, aldehydes such as malondialdehyde and

Figure 2-7: Lipid peroxidation initiation and propagation : 1. a hydrogen is removed
from a bisallylic group on a PUFA, forming a carbon radical. 2. molecular
rearrangement occurs to form a more stable conjugated diene. 3. the carbon radical
reacts with molecular oxygen (O2) to form a lipid peroxyl radical. 4. A second hydrogen
is then abstracted from a neighbouring PUFA, forming a lipid hydroperoxide and
propagating the peroxidation cycle. Both lipid hydroperoxides and peroxyl radicals then
undergo further reactions to form an array of biologically active carbonyls. HHE 4hydroxy-2-hexanal,, HNE 4-hydroxy-2-nonenal,
MDA malondialdehyde, PUFA
polyunsaturated fatty acid, ROS reactive oxygen species.
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4-hydroxy-2-nonenal (4-HNE), and isoprostanes such as F2-isoprostanes and F4neuroprostanes. Elevated levels of malondialdehyde have been observed in the brain
tissue of aged rats [139–143] and humans [144]. Increases in 4-HNE have also been
reported in the brains of aged mice [145], senescence-accelerated mice [146], rats [147],
and dogs [148]. Changes with isoprostanes during normal ageing have been better
studied in humans using cerebrospinal fluid, with increases reported in F2-isoprostanes
with age [149,150]. However, in the brain tissue of rats there has been no reported
changes in F2-isoprostanes or F4-neuroprostanes with age [151]. Elevated amounts of
lipid oxidation products have also been reported in age-related neurodegenerative
diseases such as AD [152].
If the mitochondrial free radical oxidative theory of ageing is one of the main driving
forces behind ageing, then from a phospholipid perspective it is likely that decreases in
phospholipids containing PUFA within the human brain would occur with age.
Theoretically, long chain PUFA, particularly DHA, would be most susceptible to
damage by ROS due to the high number of methylene-interrupted double bonds present
in this fatty acid. The n-6 fatty acids AA and adrenic acid are also expected to be
significantly reduced with age according to the free radical oxidative theory of ageing.
Due to the high proportion of PUFA present in the PE and PS phospholipids of the
human brain we would also expect to see a corresponding reduction in these
phospholipid classes with age or a corresponding increase in saturated or
monounsaturated fatty acids. On a subcellular level, as superoxide is unable to cross
cellular membranes [153,154] and is primarily generated within the mitochondria, we
would expect to see a greater loss of phospholipids containing PUFA in the
mitochondrial membranes with age over other cellular membranes.
2.4.3

“Inflammageing” theory of ageing

The term “inflammageing” was first coined by Franceshci and colleagues in 2000 [155]
and represents the idea that ageing is driven by the presence of low-grade, chronic
inflammation throughout the lifespan. Franceshci and colleagues have pointed to
increases in inflammatory markers such as interleukins and tumour necrosis factors with
age [155–157]; however, it is theoretically possible that phospholipids may be involved
in this process too. AA is the precursor for a number of pro-inflammatory molecules
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Figure 2-8: Synthesis of inflammatory eicosanoids from arachidonic acid after cleavage
from phospholipids by phospholipase A2. Image adapted from [158]
including prostaglandins, leukotrienes and thromboxanes (Figure 2-8). AA is liberated
from phospholipids within cellular membranes by phospholipase A2 [159], and this free
AA can then be converted to leukotrienes via the lipoxygenase pathway, or
prostaglandins and thromboxanes via the cyclooxygenase (COX) pathway. The
cytosolic phospholipid A2 isoforms primarily present within the brain [160] have a high
specificity for AA in the sn-2 position [161]. Within mammalian tissues, there are two
COX present: COX-1 and COX-2. COX-1 is expressed ubiquitously in many tissues
and cell types, and has a role in maintaining general cell physiology and homeostasis
while COX-2 shows greater restriction and is known for its role as a respondent to stress
and insult [162–164]. COX-2 is also known to be expressed throughout the
hippocampus and cortex [165]. Both COX enzymes convert AA into prostaglandin H2,
which can then be selectively converted into a number of prostanoids by specific
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synthases. COX-2 expression within the brain is normally very low but is markedly
increased in age-related neurodegenerative diseases such as AD [166,167]. There is also
some evidence implicating changes during ageing to prostaglandin levels and to COX-2
expression and activity levels in animal models [168]. Both COX-1 and COX-2 can also
utilise other PUFA such as EPA to produce a range of anti-inflammatory eicosanoids
including resolvin E1 in non-neural cells [169]. Such metabolites of EPA are yet to be
detected within brain tissue, possibly due to the low level of PL-EPA present within
neural membranes. COX-2 can also utilise DHA as a substrate to produce various
docosanoids [170–172], but a rate approximately 7-fold lower than AA [171].
If the “inflammageing” theory of ageing is one of the main driving forces behind normal
ageing in the human brain, then we would expect to see substantial decreases in n-6
fatty acids such as AA and adrenic acid over the adult lifespan. Inflammatory
eicosanoids are known to be produced from adrenic acid in kidney [175], but it is also
likely that adrenic will undergo β-oxidation in the peroxisomes to replenish the pool of
available AA (section 2.1.4, Figure 2-4). Assuming no change to PUFA synthesis rates
in humans with age, if the pool of available AA decreases within the membrane then we
would expect to see a corresponding age-related decrease in adrenic acid in order to
maintain membrane homeostasis. Levels of long chain n-3 fatty acids such as DHA
within the cellular membranes would theoretically be minimally impacted in advanced
age under this theory due to the preference for AA exhibited by inflammatory enzymes
[159,161,170–172]. Unlike the mitochondrial free radical theory of ageing, where the
loss of n-6 PUFA with age would theoretically be confined to the mitochondria, in the
inflammageing theory of ageing it is hypothesised that all of the membranes making up
the various organelles of the cell would be affected.
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2.5 Summary and conclusion
In this review the importance of phospholipids in the human brain was established,
particularly those that contain long-chain PUFA such as DHA and AA. The known
changes to phospholipids within the human brain during normal ageing were detailed,
with very few studies having been performed in this area. To make up for this deficit in
the literature, normal ageing in the brains of animal models were also discussed.
Between animals and human, there appears to be some loss of total PC and PE
phospholipids with age while animal studies alone showed significant decreases in
PUFA within the brain over the lifespan. The changes in phospholipid composition in
the brain as a result of AD have not only been better studied than normal ageing, but
also more thoroughly than other types of dementia. However, the abundance of
literature available on the topic (particularly within the frontal cortex), compounded
with the range of different methods used have produced conflicting results. The sum of
the available literature suggests that there are perturbations in the total amounts of each
phospholipid class in several regions of the brain in AD, with possible changes in the
fatty acid composition. Finally, the current theories of ageing in which phospholipids
could be involved were explored. In particular, the mitochondrial free radical theory of
ageing was discussed, as well as the inflammation theory of ageing.
In order to understand how any changes to the phospholipids of the human brain fit into
either theory of ageing, there is a requirement to isolate particular organelles by
subcellular fractionation in order to examine their membranes separately. The next
chapter will detail the method development of such a technique, as well as refinements
to the shotgun lipidomic method used to profile membrane composition.
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Chapter 3 Method development
3.1 Introduction
There are many methods described for the fractionation of subcellular components from
cell culture and fresh tissues. These methods often rely on differences in sedimentation
rates and buoyant density between different subcellular organelles and components.
Subcellular fractionation of frozen tissue, however, requires more consideration. The
use of frozen tissue samples are necessary for the study of the human brain, as fresh
tissue collection is unfeasible, and human tissue banks store their archived samples
snap-frozen at -80°C. Frozen tissue that has undergone multiple freeze/thaw cycles
becomes unsuitable for subcellular fractionation, as freezing and thawing can lead to
large ice crystal formation which causes lysis of organelles [176,177]. Therefore, the
first step was to develop a suitable method for the fractionation of frozen human brain
tissue.
The method developed for the subcellular fractionation of frozen tissue also had to be
suitable for the extraction and analysis of both membrane lipids and proteins. While the
focus of this thesis was age-related changes in membrane lipids in the human brain, this
work formed part of a larger study also examining age-related changes to membrane
proteins. The most commonly used method for membrane lipid extraction is a biphasic
organic solvent system that requires very little starting sample, but this method is
incompatible with samples containing a large amount of salt or water. Conversely, the
conventional methods used for protein extraction and analysis require large amounts of
starting material, plus buffered salt and detergent solutions that would interfere with
lipid extraction and analysis. Thus, several potential methods were investigated in order
to achieve a compatible method for both membrane lipid and protein analysis from the
same tissue specimens.
In this chapter, method development will be presented and discussed, including the final
method used for subcellular fractionation and analysis of membrane lipids from frozen
post-mortem human brain tissue.
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3.2 Results/Discussion
3.2.1

Subcellular fractionation of frozen tissue

The first step in method development was to find a subcellular fractionation method for
use with frozen tissue. Method development was conducted using lamb brain sourced
from a local butcher. This tissue was purchased for use directly after delivery from the
abattoir, which ensured that the tissue had not been previously frozen. Approximately
10 mm sections of frontal lobe (anterior to ansate sulcus) from both hemispheres were
dissected from the lamb brain and snap frozen in liquid nitrogen. The samples were then
stored at -80°C until required.
3.2.1.1 Subcellular fractionation: method one
The first fractionation method assessed followed the procedure outlined by Bourova et
al. [178]. Frozen lamb brain tissue (250 mg, n = 6) was homogenised using a glass
dounce homogeniser in an ice-cold buffer consisting of: 250 mM sucrose, 20 mM TrisHCl (pH 7.4), 3 mM MgCl2, 1 mM ethylenediaminetetraacetic acid (EDTA), and
complete protease inhibitor cocktail. After centrifugation to remove large cellular debris
(1000 x g, 10 min), the homogenate was filtered (80 µm pore) and applied to the top of
a 30% Percoll solution. Ultracentrifugation (65 000 x g, 30 min) was then used to
separate mitochondria from the other cellular membranes. Two visible layers were
expected after the 30 min centrifugation; however, this did not occur. Accordingly, the
filtered homogenate was subjected to a second centrifugation (65 000 x g, 30 min).
After the second centrifugation two layers were present: a thick, viscous upper layer
identified by Bourova et al. [178] as the “plasma membrane layer”, and a second
mitochondrial layer under a compacted layer of Percoll sediment. The upper plasma
membrane layer was collected; however the mitochondrial layer was small and unable
to be separated from the compacted Percoll. The collected plasma membrane layer was
resuspended in the same buffer, and any remaining Percoll was removed by
ultracentrifugation (175 000 x g 90 min). Following this, the plasma membrane fraction
(n = 3) was suspended in a second buffer containing: 150 mM NaCl, 20 mM Tris-HCl
pH (7.4), 3 mM MgCl2, and 1 mM EDTA, and applied to a density gradient consisting
of 1.5 mL layers of 15%, 20%, 25%, 30%, 35% sucrose. This gradient was
ultracentrifuged (187 000 x g 24 hours) to separate the plasma membrane into two
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Figure 3-1: Sucrose density gradient profile of total protein as a plasma membrane
marker. Total protein was measured from n=3 samples, and results reported as mean ±
S.E.M
layers. These layers were identified by Bourova et al. [178] as being “low density
(myelin)” and “bulk plasma membrane”. As neither of these fractions were clearly
visible, the gradient was collected from the top to the bottom in 1 mL aliquots and
subjected to a protein assay for determination of membrane location (Figure 3-1).
According to the results of Bourova et al. [178], the bulk plasma membrane fraction
should have been easily located in fractions 7-8 by the highest levels of total protein.
However, our results showed that fraction 12 contained the largest amount of total
protein (Figure 3-1). Examination of the literature revealed that the subcellular
fractionation of frozen tissue is difficult to perform successfully as freeze-thaw cycles
tend to lyse the cells and their subcellular compartments [176,177]. Since our
experiment used frozen tissue this would explain the abundance of protein present in the
lowest fraction: the lamb brain tissue may have been exposed to multiple freeze-thaw
cycles, damaging membrane integrity and resulting in fragmentation which prevented
the cellular membranes from fractionating completely. Bourova et al. [178] used fresh
rat brain tissue in their study, which meant that they would not suffer the same
problems. Therefore, an alternative method was needed for use in this study.
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3.2.1.2 Subcellular fractionation: method two
With that in mind, a simpler method using differential centrifugation was trialled. The
advantage of subcellular fractionation by differential centrifugation without a gradient
such as sucrose or Percoll is that it requires fewer purification steps, which can increase
the yield of the available substrate [179]. This method also had the advantage of having
been successfully applied to frozen human brain tissue with a sufficient degree of
specificity for the isolation of the intended subcellular compartment [177]. To explore
the suitability of this method, approximately 100 mg of frozen lamb brain was
homogenised using a bead homogeniser (FastPrep®-24 Instrument, MP Biomedicals,
NSW, Australia) with 1.4 mm zirconium oxide beads at a speed of 6.0 m/s, in 1 mL of
an ice-cold 20 mM Tris buffer (pH 7.4) containing: 250 mM sucrose, 2 mM of EDTA, 2
mM of dithiothreitol (DTT) and complete protease inhibitor. The homogenate was
centrifuged (1000 x g, 10 min) to give a pellet containing nuclei and large cellular
debris, which was discarded. The supernatant was collected and centrifuged (35 min, 10
000 x g) to produce a pellet enriched in mitochondria. The supernatant was centrifuged
again (40 min, 100 000 x g) to produce a microsomal pellet (endomembranous system
comprised of Golgi, endoplasmic reticulum and plasma membrane) and cytosolic
supernatant. Both the mitochondrial and microsomal pellets were resuspended in milliQ
H2O (4°C) prior to being prepared for lipid and protein analysis.
3.2.1.3 Western blotting
To test whether this subcellular fractionation method isolated the correct fraction, a
series of Western blots were performed looking for specific subcellular markers. Both
the microsomal and mitochondrial fractions were obtained from lamb brain using the
second fractionation method (section 3.2.1.2). Whole mitochondrial and microsomal
pellets were solubilised in 500 µL and 100 µL respectively of a solution consisting of 7
M Urea, 10 mM Tris buffer (pH 8.0) and 5 µL of 1 mM DTT. Both 1x and 2x dilutions
were made for both membrane fractions, and these were incubated with cracking buffer
(100°C, 10 min). The dilutions of both fractions were separated by electrophoresis on a
12.5% sodium dodecyl sulphate-polyacrylamide gel electrophoresis gel and transferred
to a polyvinylidene fluoride (PVDF) membrane. The PVDF membrane was probed for 2
hours at 4°C with a primary antibody corresponding to a marker of a particular
subcellular organelle. Sodium-potassium-ATPase were used as a plasma membrane
marker (1:5000, Sapphire Biosciences, Australia), cytochrome c for mitochondria
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(1:1000, Sigma-Aldrich, Australia) and β-actin as a control (1:4000, Sigma-Aldrich,
Australia). An additional marker for endoplasmic reticulum was also trialed (ERP29,
Sigma-Aldrich, Australia), but this antibody was found to be unsuitable for use with
lamb brain. After incubation with the primary antibodies the membrane was washed in
TBST (3 times, 5 mins each), and incubated with horseradish peroxidase-conjugated
IgGs (anti-rabbit or anti-mouse depending on primary antibodies, 1:2000, Sapphire
Biosciences, Australia) at room temperature for 1 hour. Following this the membrane
was washed again in TBST (3 times, 5 mins each) and developed colourmetrically using
0.05% 3,3’-diaminobenzidine

and 30% hydrogen peroxide. After 2-5 mins of

incubation with 0.05% 3,3’-diaminobenzidine, the membrane was washed in milliQ
H2O and stored in PBS. The bands typically developed their maximum colour overnight
while stored in PBS, after which they were recorded using a densitometer (GS-800™,
BioRad, USA). The results of the Western blotting for the subcellular markers can be
seen in Figure 3-2.
Immunoblotting of the mitochondrial and microsomal subcellular fractions showed that
the sodium-potassium-ATPase was primarily located in the microsomal fraction. Lower
amounts

sodium-potassium-ATPase

were

also

seen

in

the

mitochondrial

Figure 3-2: Western blot of mitochondrial (Mito) and microsomal (Micro) subcellular
fractions obtained from frozen lamb brain. Fractions were run either undiluted (1x) or
at 1:1 dilution (2x) in buffer containing 7M urea and 10mM Tris (pH 8.0). Primary
antibodies used included sodium-potassium-ATPase (Na-K-ATPase) as a plasma
membrane marker, and cytochrome c as the mitochondrial marker, with β-actin run as a
control. The labelled bands were visualised colourmetrically by developing with 3,3'diaminobenzidine and hydrogen peroxide after application of secondary antibodies.
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fraction as well, but this was expected with this crude method of fractionation.
Cytochrome c appeared in the mitochondrial fraction as a tetramer at around 50-60 kDa,
but most importantly it was not present in the microsomes, indicating that there was no
mitochondria present in the microsomal fraction. These results show that while crude,
this fractionation method was suitable for use with frozen brain tissue in this study.
3.2.2

Membrane lipid extraction and analysis

Recent advances in mass spectrometry techniques such as electrospray ionisation have
enabled increased sensitivity in the detection and accurate characterization,
identification, and quantitation of membrane lipid species from biological samples. A
shotgun lipidomic approach involves direct infusion of extracted lipid mixtures from
biological samples into the mass spectrometer without any prior chromatographic
separation. The most commonly reported method for extraction of membrane lipids
from biological samples is the Folch method [180]. The Folch method is a biphasic
solvent system consisting of a 2:1 v/v mixture of chloroform:methanol which separates
into an organic phase and an aqueous phase upon the addition of water and salt,
allowing the partitioning of polar and non-polar lipids from the tissue homogenate. This
method also results in the precipitation of any proteins in the extract, which appear as a
layer at the interface between the organic and aqueous phases. In the present study, 2
mL of the chloroform:methanol solvent mixture was added directly to the mitochondrial
and microsomal pellets obtained from lamb brain tissue, along with butylated
hydroxytoluene (BHT; 0.01% w/v) to prevent oxidation of the lipids during extraction.
3.2.2.1 Membrane lipid extraction: method one
An internal standard solution was employed during initial experiments for use in lipid
quantification and consisted of the following lipids stored in chloroform:methanol (2:1,
v/v): 250 µM PC 19:0/19:0, 188 µM PE 17:0/17:0, 188 µM PS 17:0/17:0, 25 µM
phosphatidylglycerol 17:0/17:0, 25 µM phosphatidic acid 17:0/17:0, 25 µM cardiolipin
14:0/14:0/14:0/14:0, 250 µM dihydrosphingomyelin 12:0, 25 µM lyso-PC 17:0, 25 µM
lyso-PE 14:0 and 13 µM ceramide 17:0. Internal standards were added to the whole
fractionated mitochondrial and microsomal pellets at a volume of 20 µL and 10 µL
respectively. After the addition of the internal standards, all samples were allowed to
rotate overnight at 4°C. Lipid extraction then followed a modified Folch extraction
method reported by Deeley et al. [181]. Firstly, 500µL of 0.15 M ammonium acetate
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was added to each sample. Samples were vortexed vigorously and centrifuged (1000 x
g, 10 min) in order to separate the aqueous (upper) and organic (lower) phases. The
organic (lipid-containing) phase was then removed and a second 2 mL volume of
chloroform:methanol (2:1 v/v with 0.01% BHT) was added. Following a second round
of vortexing and centrifugation the lower phase was again removed and combined with
the first organic phase. A second 500 µL of 0.15 M ammonium acetate was added to the
combined organic phases, and the samples were vortexed and centrifuged a final time.
The upper aqueous phase was removed, and the lower phase dried at 37°C under
nitrogen. The dried lipids were then reconstituted in 1 – 1.5 mL of chloroform:methanol
(1:2 v/v with 0.01% BHT) and stored at -20°C until mass spectrometry was performed.
3.2.2.2 Membrane lipid analysis by mass spectrometry
Nano-electrospray ionization (nano-ESI) mass spectrometry of lipid extracts was
performed using a hybrid triple quadrupole linear ion trap mass spectrometer (QTRAP®
5500 AB Sciex, USA) equipped with an automated chip-based nano-ESI source
(TriVersa Nanomate™, Advion Biosciences, USA). Samples were diluted to
approximately 10 µM for total phospholipids, spiked with 5 mM of ammonium acetate,
and loaded onto a 96-well plate. The plate was centrifuged (2200 x g, 10 min) prior to
direct infusion. Spray parameters were set at a gas pressure of 0.4 psi and a voltage of
1.2 and 1.1 kV for positive and negative ion mode respectively for all acquisitions.
Phospholipid data was acquired by targeted ion scans using multi-channel acquisition
(Table 3-1). A faster scan rate (1000 Da/s) was used for negative ion fatty acid scans to
ensure spectra could be obtained within one hour (average maximum stability of
nanospray for 10 µL of sample).
Lipidview™ software (version 1.2, AB Sciex, USA) was used to quantify phospholipids
from internal standards present in positive ion head group scans. Processing settings in
LipidView™ were set with a mass tolerance of 0.5 Da, with a minimum intensity of
0.1% and a minimum signal/noise of 10. Isotopic correction was also used. Any
phospholipids comprising less than 0.5% of each class across the cohort were removed
from the final analysis.

41 | P a g e

CHAPTER 3

Table 3-1: nanoESI-MS settings for targeted ion scans used to acquire phospholipid
data in human brain mitochondria and microsomes
Lipid
Ion Mode Scan
CE Mass range (Da)
Head group scans
PC
+ve
PI 184.1 47
640-1000
PE
+ve
NL 141.0 30
685-950
PS
+ve
NL 185.0 30
755-965
Lyso-PC +ve
PI 184.1 47
450-600
Lyso-PE +ve
NL 141.0 30
400-600
Fatty acyl chain scans
14:0
-ve
PI 227.2 -55 580-900
16:1
-ve
PI 253.2 -55 600-900
16:0
-ve
PI 255.2 -55 600-900
17:0
-ve
PI 269.3 -55 560-900
18:2
-ve
PI 279.2 -40 600-900
18:1
-ve
PI 281.3 -55 600-900
18:0
-ve
PI 283.3 -55 600-900
19:0
-ve
PI 297.3 -55 600-900
20:5
-ve
PI 301.2 -40 500-1000
20:4
-ve
PI 303.2 -40 600-1000
20:3
-ve
PI 305.2 -40 600-1000
20:2
-ve
PI 307.2 -40 600-1000
20:1
-ve
PI 309.2 -55 600-1000
20:0
-ve
PI 311.2 -55 600-1000
22:6
-ve
PI 327.2 -40 700-1000
22:5
-ve
PI 329.2 -40 700-1000
22:4
-ve
PI 331.2 -40 700-1000
22:3
-ve
PI 333.3 -40 600-1000
Scan rate for positive ion mode was 200 Da/s, for negative ion mode 1000 Da/s. Mass
shifting was prevented in negative ion mode by increasing the number of summed
scans. PI Precursor ion, NL neutral loss, CE collision energy.
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Figure 3-3: Phosphatidylcholines (PC) obtained from microsomal and mitochondrial
fractions of lamb brain (n = 4, error bars show S.E.M.). PC was detected from both
fractions by tandem mass spectrometry from a precursor ion scan of 184.1 m/z. PCs are
shown as: A) amount of each phospholipid detected (nmol/sample), and B) as a
percentage of total PC detected.
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3.2.2.3 Analysis of results for membrane lipids
Due to the inability to obtain an accurate weight for the mitochondrial and microsomal
fractions, the internal standards were initially added to the fractions in a specific amount
(20 µL and 10 µL respectively). However, this became problematic during
quantification as the differences seen in the amount of each molecular phospholipid
between the two fractions was based on the quantity of total lipid present in the pellet of
each membrane fraction without considering individual pellet yield of each fraction
(Figure 3-3A). The mitochondrial fraction produced a much larger pellet during
fractionation than the microsomes, and when both fractions were plotted against each
other all phospholipids detected in the mitochondria were higher in abundance than
those in the microsomes. Plotting the phospholipids as a proportion of total PC (Figure
3-3B) shows the profile of the two species to be almost equal, however. Therefore it
was determined that addition of the internal standards should be on the basis of a
common factor between the two fractions, such as total protein amount, to better show
any differences in each phospholipid independent of pellet mass per membrane fraction.
3.2.2.4 Membrane lipid extraction: method two
To that end, the internal standards were adjusted to 20 µM each of: PC 19:0/19:0, PE
17:0/17:0, PS 17:0/17:0, phosphatidylglycerol 17:0/17:0, phosphatidic acid 17:0/17:0,
cardiolipin 14:0/14:0/14:0/14:0 and dihydrosphingomyelin 12:0; along with 10 µM of
lyso-PC 17:0, lyso-PE 14:0 and ceramide (17:0). Aliquots (75 µg of total protein) from
the mitochondrial and microsomal fractions were added to chloroform:methanol (2 mL,
2:1 v/v with 0.01% BHT) with 50 µL of the adjusted internal standard mixture. Lipid
extraction then followed the method previously outlined above in section 3.2.2.1.
Results from the analysis of PC from both the microsomal and mitochondrial fractions
of lamb brain with the new internal standard formulation can be seen in Figure 3-4. In
Figure 3-4A it can be seen that the quantified values of the microsomal fraction are no
longer consistently lower than the mitochondrial fraction, and variation in the amount of
individual phospholipids are seen between the two membrane fractions. The standard
error of each quantified phospholipid is also significantly reduced. This result
demonstrates that this second method of quantification using total protein as a
denominator is superior to the first method trialled, and is more suitable for use in the
extraction and analysis of lipids from fractionated human brain issue.
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Figure 3-4: Phosphatidylcholines (PC) obtained from microsomal (n = 6) and
mitochondrial fractions of lamb brain (n = 5), with error bars showing S.E.M. PC was
detected from both fractions by tandem mass spectrometry from a precursor ion scan of
184.1 m/z. PCs are shown as: A amount of each phospholipid detected (pmol/µg total
protein) and B as a percentage of total PC detected.
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3.2.2.5 Development of a method for analysing complete phospholipids
The final hurdle in the development of a method for the extraction, detection, and
analysis of membrane lipids from the mitochondrial and microsomal fractions of human
brain tissue was to produce an automated method to characterise all phospholipids
within a sample complete with fatty acyl chain pairing. The analysis of phospholipids is
conducted using both positive and negative ion scans by tandem mass spectrometry
(Table 3-1). These positive precursor ion and neutral loss scans are used to detect the
head groups for PC, PE and PS, and with the use of Lipidview™ (version 1.2) the bruto
structure of the phospholipids can be obtained, including the total number of carbons in
both fatty acids and the presence of any double bonds (i.e PC 34:1). This result does not
give any specific information on the identity of each of the individual fatty acids present
on the phospholipid though (i.e. PC 16:0_18:1). The fatty acid data is detected in the
negative precursor ion scans, but the version of Lipidview™ available at the time of this
analysis did not allow the concurrent analysis of both positive and negative ion spectra
to obtain complete molecular phospholipid structure. This procedure has been
previously performed manually in our laboratory by inspecting the spectra and looking
for complementary positive and negative ions. An example of how such an analysis can
be achieved is shown in Figure 3-5. Completing the analysis of the molecular
phospholipids manually for this study was unfeasible though, due to the high number of
samples. Therefore, there was a need to develop an automated method for the
quantification of complete phospholipids with fatty acid pairs.
The first step in developing this method was to quantify all detected phospholipids from
the positive ion precursor ion and neutral loss scans using Lipidview™ as described
previously (section 3.2.2.2). Next, each phospholipid quantified by Lipidview™ was
assessed for possible isobaric molecular phospholipids (i.e. phospholipid species of the
same mass but with a different fatty acid combination) using the lipid catalogue tool in
Lipidview™, and a target list of all possible fatty acid pairs for each phospholipid
detected in positive ion mode was generated. An example of the target list entry for PC
34:1 can be seen in Table 3-2. Acetate adducts were used in negative precursor ion
scans for PC fatty acids, while deprotonated ions were used for the fatty acids of PE and
PS. Once generated, this target list was then applied to the negative precursor ion scans
for fatty acids using Lipidview™ with the same settings as described above (section
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Figure 3-5: Example of how phospholipid composition can be determined using
negative-ion mass spectra. Neutral loss scan with an offset of -87 Da identifies
phospholipids with a phosphatidylserine head group. (b) Precursor ion scan for m/z 255
identifies phospholipids with a palmitate (16:0) acyl chain. (c) Precursor ion scan for
m/z 281 identifies phospholipids with an oleate (18:1) acyl chain. Observation of m/z
760 in all three scans identifies the presence of glycerophosphatidyl serine (16:0_18:1)
in the extract. Figure from Blanskby and Mitchell[29]
3.2.2.2). After analysis by Lipidview™ the peak areas of each fatty acid detected were
grouped by molecular phospholipid and exported for further analysis in Microsoft®
Excel (2010).
A spreadsheet was developed using Microsoft® Excel (2010) to quantify complete
molecular species of phospholipids by combining the results of the negative ion fatty
acid peak areas with the gross phospholipid structure quantified from the positive ions.
This was achieved for diacyl phospholipids (phospholipids with two esterified fatty
acids) by several steps. An example of how this spreadsheet quantifies complete
phospholipid molecular species is shown in Figure 3-6 for six samples of the prefrontal
cortex using PC 34:1. The target list generated from the negative ion Lipidview™
analysis contained fatty acid pairs arranged by mass (see Table 3-2 for example), and
from this peak areas could be generated and exported directly as a spreadsheet in
Microsoft® Excel. The next step adds the peak areas for corresponding fatty acids
together to represent the total peak area for a given molecular phospholipid. Both fatty
acids within the phospholipid had to have a peak area greater than zero for it to be
included in the analysis. The following step determines the proportion of a given
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Table 3-2: Example of target list entry used for phospholipid molecular species determination of PC 34:1 in negative ion mode.
Mass Precursor
Ion
Fatty acid
(m/z)
ion scan
Mode
818.6
227.20
Negative
14:0
PC 14:0_20:1+AcO
818.6
309.20
Negative
20:1
PC 14:0_20:1+AcO
818.6
281.30
Negative
18:1
PC 16:0_18:1+AcO
818.6
255.20
Negative
16:0
PC 16:0_18:1+AcO
818.6
253.20
Negative
16:1
PC 16:1_18:0+AcO
818.6
283.30
Negative
18:0
PC 16:1_18:0+AcO
Phospholipid PL Phosphatidylcholine PC Acetate adduct +AcO
PL molecular species

PL Class

PL species

PC
PC
PC
PC
PC
PC

PC 34:1+AcO
PC 34:1+AcO
PC 34:1+AcO
PC 34:1+AcO
PC 34:1+AcO
PC 34:1+AcO

Isotope
correction factor
1.6420
1.6420
1.6420
1.6420
1.6420
1.6420

CHAPTER 3

Figure 3-6: Example of the spreadsheet used for identification and quantification of
phospholipids with isobaric fatty acids. Peak areas used in this example come from 6
microsomal fraction samples taken from the human prefrontal cortex. Peak area PA.
* Only added if the peak area from both fatty acids is present
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phospholipid within the total isobaric molecular phospholipids. Using the example of PC
34:1 from Figure 3-6, the peak area of PC 16:0_18:1 is divided by the sum of the peak
areas from PC 14:0_20:1, PC 16:0_18:1 and PC 16:1_18:0 to obtain PC 16:0_18:1 as a
proportion of total PC 34:1. This ratio could then be multiplied by the amount quantified
for PC 34:1, giving the total quantified amount of PC 16:0_18:1 in the sample. Using a
worked example from Figure 3-6, in sample 10F Micro PC 16:0_18:1 made up 99% of all
isobaric phospholipids detected for PC 34:1. Total PC 34:1 was quantified as being134.07
pmol/µg membrane protein in the same sample from the positive ion spectra. Therefore
the quantified amount of PC 16:0_18:1 in sample 10F Micro is 99% of 134.07 pmol/µg
membrane protein, which is equal to 132.08 pmol/µg membrane protein. This same
process is used for every sample in all regions examined in this study, with the
spreadsheet designed to handle up to 36 samples. Isobaric phospholipids containing either
an odd-chain or ether-linked fatty acids in the sn-1 position required a different approach
to that used for to diacyl phospholipids. The odd-chain fatty acids, being esterified to
glycerol, can be detected using the negative precursor ion scans. The ether-linked fatty
acids, however, are not able to be detected as the energy required to break the ether bond
is not accessible in a triple quadrupole mass spectrometer [182]. The sn-2 esterified fatty
acid can also be detected, but the peak area measured for this fatty acid will be the total
peak area for both isobaric species. For example, PE 15:0_22:6 is isobaric with PE O16:0_22:6, and in negative ion mode both will have a deprotonated mass of 748.6 m/z.
We can detect the 15:0 and 22:6 fatty acids for both isobaric species with our precursor
ion scans, but not O-16:0. We cannot determine the proportion of PE O-16:0_22:6 from
this data by subtracting the peak area measured for 15:0 from that of 22:6 either due to
differences in fragmentation efficiency between sn-1 and sn-2 positional fatty acids [183].
Therefore we can only say that either isobaric phospholipid may be present at this mass,
and report it as being either phospholipid (i.e. PE 15:0_22:6/O-16:0_22:6).
However, there are some limitations to this method of determining complete
phospholipids, including the previously mentioned inability to separate isobaric species
with either odd-chain or ether-linked fatty acids. The second limitation is that we cannot
definitively distinguish between phospholipids containing an alkenyl ether versus
phospholipids with an alkyl ether-linked fatty acid containing a double bond. Alkenyl
ethers (also known as plasmalogens) are fatty acids that contain a vinyl ether bond (i.e. a
double bond on the first carbon from the ether end). With the mass spectrometry
50 | P a g e

CHAPTER 3
technique used in this study, it is impossible to tell the position of that double bond along
the fatty acid chain. Therefore, we can only say that the double bond is present in an
ether-linked fatty acid, rather than identifying it specifically as a plasmalogen. Due to the
presence of the vinyl ether bond in the sn-1 position, plasmalogen PEs do not show
abundant peaks when detected by the neutral loss of 141 Da compared to diacyl PE
phospholipids [184,185], and a correction factor is commonly applied to account for this
[186]. Because we could not definitively distinguish plasmalogens in this study no such
correction factor was used, and due to this plasmalogen levels will likely be
underestimated. Likewise we were unable to determine double bond position for PUFA,
and thus could not distinguish between n-3 and n-6 fatty acids. Putative classification of
n-3 and n-6 fatty acids can be made, however, based on their synthesis as this pathway
produces specific fatty acid isomers. Identification of the fatty acids can also be made
from previous studies of human brain lipids that used analysis techniques with the ability
separate n-3/n-6 isomers (such as gas chromatography). The final limitation is that we
cannot tell which sn position the fatty acids are in on the glycerol backbone using this
mass spectrometry technique; we can only assume sn position for fatty acids based on the
previous literature. Hence, the nomenclature employed in this thesis follows that set out
by Liebisch et al.[187] for fatty acids with unknown positional information, with the two
fatty acids identified being separated by an underscore.

3.3 Conclusions
Described in this chapter are the preliminary stages of this thesis, which investigated
methods for the subcellular fractionation of frozen post-mortem human brain tissue. Also
developed were methods for the extraction and analysis of membrane lipids from the
fractionated tissue.
The fractionation of frozen human brain tissue into its subcellular components required
consideration. Only a small amount of tissue could be obtained, and the method needed to
overcome the problems associated with frozen tissue such as multiple freeze/thaw cycles
leading to damage of organelles. The methods used were also required to be compatible
with the downstream analysis of membrane lipids and protein, both of which require very
different conditions. To that end, a simple but crude fractionation method was developed
which relied on the differences in sedimentation rates between the various fractions.
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While crude, this method was specific for the organelles being examined (section 3.2.1.3)
and gave a sufficient yield of fraction for analysis of lipids.
After the fractionation method had been developed, procedures for the analysis of
membrane lipids were examined. Methods for the extraction and analysis of membrane
lipids had previously been developed in our laboratory, and these methods were tested for
compatibility with this study. An adjustment to how the internal standards were added to
the subcellular fractions was required to improve quantification. Additionally, a
spreadsheet to quantify phospholipids complete with fatty acid data from both the positive
and negative ion mass spectrometry data was developed for this study.
The details of the final methods for membrane lipid extraction and analysis as determined
by these investigations are given in detail in section 3.4 below, as well as the final
demographics of the cohort from which the brain tissue for all regions studied was
obtained. These methods for subcellular fractionation and membrane lipid extraction and
analysis were then applied to the studies described in the following chapters.

3.4 Method
3.4.1

Post-mortem human brain tissue

Neurologically normal frozen post mortem human brain tissue from five different regions
was obtained from the New South Wales Tissue Resource Centre at the University of
Sydney. These regions included the dorsolateral prefrontal cortex, hippocampus,
entorhinal cortex, primary motor cortex, and cerebellum. The complete demographics for
these samples are listed in Table 3-3. No differences between the two sexes were
observed in post-mortem interval and brain pH, but females were significantly older than
males (71.4±7.0 years versus 52.7±3.9 respectively, p < 0.05). The samples were shipped
on dry ice and stored at -80°C prior to analysis. The brain tissue was pulverised on dry ice
prior to being accurately weighed for subcellular fractionation. All experiments were
approved by and conducted in accordance with the Human Research Ethics Committee of
the University of Wollongong (HE11/267).
3.4.2

Subcellular Fractionation

Approximately 100 mg of pulverised brain tissue from each brain region was
homogenised with a bead homogeniser (FastPrep®-24 instrument, MP Biomedicals,
NSW, Australia) set at a speed of 6.0 m/s for 40 seconds, using 1.4mm zirconium oxide
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beads in 1 mL of an ice-cold 20 mM Tris buffer (pH 7.4) containing 250 mM sucrose, 2
mM EDTA, 2 mM DTT and complete protease inhibitor. The homogenate was then
centrifuged (1000 x g, 10 min) to give a pellet containing nuclei and large cellular debris.
The supernatant was collected and centrifuged (10 000 x g, 35 min) to produce a pellet
enriched in mitochondria. The supernatant was centrifuged again (100 000 x g, 40 min) to
produce a microsomal pellet and cytosolic supernatant. All centrifugation steps were
performed at 4°C. Both the mitochondrial and microsomal pellets were resuspended in
milliQ H2O, and total protein content was determined using the BCA assay
(ThermoFisher, USA).
3.4.3

Lipid extraction

Aliquots (75 µg of total protein) from the mitochondrial and microsomal fractions were
added to chloroform:methanol (2 mL, 2:1 v/v with 0.01% BHT) with 50 µL of internal
standard mixture (as described in 3.2.2.4). Lipids were extracted using a modified Folch
method as previously outlined in this chapter (section 3.2.2.1). Extracted lipids were
reconstituted in chloroform:methanol (1 mL, 1:2 v/v with 0.01% BHT), and stored at 20°C until analysed. All solvents used were of HPLC-grade or higher.
3.4.4

Mass spectrometry and lipid analysis

NanoESI mass spectrometry of lipid extracts was performed using a hybrid triple
quadrupole linear ion trap mass spectrometer (QTRAP® 5500 AB Sciex, MA, USA)
equipped with an automated chip-based nanoESI source (TriVersa Nanomate™, Advion
Biosciences, NY, USA). Samples were diluted to approximately 10 µM for total
phospholipids, spiked with 5 mM of ammonium acetate, and loaded onto a 96-well plate.
The plate was then centrifuged (10 min, 2200 x g) prior to direct infusion. Spray
parameters were set at a gas pressure of 0.4 psi and a voltage of 1.2 kV and 1.1 kV for
positive and negative ion mode respectively for all acquisitions. Phospholipid data was
acquired by targeted ion scans using multi-channel acquisition (Table 3-1).
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Table 3-3: Demographics and cause of death of donors from which all brain tissue was
obtained.
Age
(Years)

Gender

PMI Brain pH
(hours)

Cause of death
category

Cause of death
clinical

Primary cardiac arrhythmia
Primary cardiac arrhythmia
Blunt trauma
Undetermined (but consistent with idiopathic cardiac
arrhythmia).
Cardiac arrhythmia; myocardial fibrosis
Acute chronic cardiac failure
Presumed Cardiac Dysrhythmia due to natural cause
Unascertained.
1.a) Pulmonary thromboemboli b) deep venous
thrombosis
Ischaemic heart disease.
Ischaemic heart disease. Coronary artery atheroma
Coronary Artery Disease
Haemopericardium
Acute Myocardial infarction
cardiomegaly
Undetermined.
Myocardial Infarction
Ischaemic heart disease.
Hypertensive and atherosclerotic heart disease
Hypertensive and atherosclerotic heart disease
Haemopericardium
cardiomegaly
Hypertensive Heart disease
Coronary Artery Disease and asthma
Atherosclerotic cardiovascular disease
Atherosclerotic cardiovascular disease.
Cancer of breast, liver and bone metastases
Multiple drug toxicity (7-amino nitrazepam, nitrazepam
and dextropropoxyphene)
Emphysema
Heart Failure
Pulmonary embolus
Septicaemia; gangrenous foot; peripheral vascular
disease
Metastatic breast cancer
Pneumonia; Debility; Chronic obstructive airways
disease
Pneumonia; congestive cardiac failure
Bilateral bronchopneumonia

18
21
22
24

Male
Female
Male
Male

28.5
39.5
50
43

6.7
6.83
6.86
6.27

Cardiac
Cardiac
Trauma
Cardiac

33
36
37
37
40

Female
Male
Male
Male
Male

24
34
14.5
24
27

6.77
6.67
6.46
6.7
6.79

Cardiac
Cardiac
Cardiac

47
48
49
50
50
51
52
57
58
59
62
64
66
67
69
72
73
74
78

Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Female
Male
Male
Male
Female
Female
Female
Female
Female

27
17
38
40
34
35
36
18
39
15
35
17
32
25
39
25
45
20
45

6.66
6.62
6.92
6.87
6.77
7
6.82
6.39
6.49
6.54
6.06
6.55
6.66
6.7
6.72
7
6.86
6.59
6.05

Cardiac
Cardiac
Cardiac
Cardiac
Cardiac
Cardiac

80
81
83
86

Male
Male
Male
Female

12
29
10
14.5

6.5
6.57
6.67
6.36

Respiratory
Cardiac
Respiratory
Infection

87
88

Female
Male

5
9

6.38
6.36

Cancer
Respiratory

98
104

Female
Female

6
27

6.7
5.89

Respiratory
Respiratory

Vascular

Cardiac
Cardiac
Cardiac
Cardiac
Cardiac
Cardiac
Cardiac
Cardiac
Cardiac
Cardiac
Cancer
Toxcity
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Lipidview™ software (version 1.2, AB Sciex, MA, USA) was used to quantify
phospholipid species against internal standards using positive ion head group scans.
Processing settings in LipidView™ were set at a mass tolerance of 0.5 Da, with a
minimum intensity of 0.1% and a minimum signal-to-noise ratio of 10. Any phospholipid
species comprising less than 0.5% of each phospholipid class across the cohort were
removed from the analysis. Each phospholipid quantified was then assessed for possible
isobaric molecular phospholipids using the lipid catalogue tool from Lipidview™, and
confirmatory ions from the negative ion fatty acid precursor scans were used to identify
the amount of each molecular phospholipid present in each sample. Isobaric
phospholipids containing either an odd-chain or ether-linked fatty acid were unable to be
separated using this method and were reported as being either species. Due to this no
correction factor was applied to ether-linked PEs (see section 3.2.2.5). Molecular
phospholipids that appeared in less than 75% of samples were removed prior to statistical
analysis. Phospholipids are reported using nomenclature outlined by Liebisch et al. [187],
as normalised values relative to total phospholipid detected in each phospholipid class to
reduce variation between the samples. Regression parameters for phospholipids showing
significant age-related changes in quantified amount (pmol of phospholipid/µg total
membrane protein) have been included for comparison.
3.4.5

Statistical analysis

All statistical analysis in the following chapters was performed using SPSS Statistics
(version 19, IBM Corp., NY, USA). The Wilcoxon signed-rank test was used for
comparisons of phospholipid classes between the mitochondrial and microsomal
fractions. To examine the relationship between age and phospholipids, or age and total
protein content, linear regression was used with sex as a second independent variable,
with significance set a level of p < 0.05. Normality of the dependent variable was
assessed by examining the histograms of the residuals, and non-normal data was
transformed where required. Positively skewed residuals were transformed using
logarithmic or reciprocal transformations depending on the level of skew present while
negatively skewed data used the reflection of these transformations. Outliers were
identified as being greater than three standard deviations from the mean of the
standardised residuals, and were dealt with by either transformation of the dependent
variable or removal from the analysis. Normality of the dependent variable was assessed
by examining the histograms of the standardised residuals, and non-normal data was
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transformed where required. Influential data points were identified by a cook’s distance
of greater than one and were removed from the analysis. Where the dependent variable
was transformed, data is displayed in figures as untransformed scatterplots with
transformed beta-coefficients and p value to allow direct comparison between
phospholipids. As this was an exploratory study a correction for multiple comparisons
was not applied.
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Chapter 4 The Dorsolateral Prefrontal Cortex
This chapter is an amended version of the published manuscript: Norris SE, Friedrich
MG, Mitchell TW, Truscott, RJW, Else PL, (2015) Human prefrontal cortex
phospholipids containing docosahexaenoic acid increase during normal adult aging,
whereas those containing arachidonic acid decrease. Neurobiology of Aging,
36(4)1659-69.

4.1 Introduction
This chapter will examine the changes seen during normal ageing in PC, PE and PS
phospholipids present in the mitochondrial and microsomal membranes of the
dorsolateral prefrontal cortex.
The dorsolateral prefrontal cortex (henceforth referred to as the prefrontal cortex) is
located in the middle frontal gyrus (see Chapter 1 Figure 1-2), and has connections to
many brain regions including the orbitofrontal cortex, the thalamus, the hippocampus,
and the primary and secondary association areas of the neocortex [188]. The functions
of this region include executive functions such as working memory, cognitive
flexibility, as well as planning and inhibition [188].
Changes to phospholipid composition have been particularly well-studied in different
parts of the frontal and prefrontal cortex in AD [85–87,92,93,111,113,115,116,189].
Both Svennerholm [88] and Söderberg et al. [90,93] have reported losses of total
phospholipid with age in whole human neocortex and frontal cortex respectively over
the adult lifespan. Losses of PC and PE within the frontal cortex with advanced age
have also been reported by Söderberg et al. [93].
Thus, the aim of this chapter was to expand on the limited knowledge available on agerelated changes in phospholipids of the mitochondrial and microsomal membranes of
the human prefrontal cortex.

4.2 Results
4.2.1

Age-related changes to total protein content in subcellular fractions

No changes with age in total protein concentration (mg/g tissue) were seen in the whole
tissue homogenate, or in the mitochondrial and microsomal membranes.
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4.2.2

Major phospholipid classes of mitochondrial and microsomal fractions

The three major phospholipid classes PC, PE and PS showed similar abundances in the
mitochondrial and microsomal membranes when expressed as a percentage of total
phospholipid (Figure 4-1). Overall, PC represented approximately 56%, PE 29% and PS
15% of total phospholipid. Small differences in abundance were seen between the
membrane fractions, including a slightly higher level of PE in the mitochondria (p <
0.001) and a marginally higher level of PC in the microsomal membranes (p < 0.01). No
significant differences were seen in the abundance of PS between the two membrane
fractions.
No differences were observed between the mitochondrial and microsomal fractions for
any phospholipid class or in total phospholipid content when analysed as a quantified
amount (i.e. pmol phospholipid/µg of membrane protein). Additionally, no age-related
changes were seen for any of the three phospholipid classes or total phospholipids in
either the mitochondrial or microsomal fraction when expressed as either percent of
total phospholipid class or as quantified amounts.

Figure 4-1: Percent composition of the three major phospholipid classes within the
mitochondrial (left) and microsomal (right) fractions in normal human prefrontal cortex.
Values are the mean ± SEM for the entire cohort. The microsomal membranes showed
significantly higher amounts of total phosphatidylcholine (PC) compared to
mitochondria (p < 0.01, Wilcoxon signed-rank test), while the mitochondria contained
more phosphatidylethanolamine (PE) (p < 0.001, Wilcoxon signed-rank test). There
were no differences between membrane fractions for phosphatidylserine (PS).
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4.2.3

Changes in mitochondrial phospholipids with age

4.2.3.1 Phosphatidylcholines
The composition of PC, PE and PS phospholipids detected in the mitochondrial
membranes of the entorhinal cortex can be seen in (Figure 4-2). The most abundant
phospholipid found in the mitochondrial membranes of the prefrontal cortex was PC
16:0_18:1, representing approximately 25% of all phospholipids measured. From ages
20 to 100 years, PC 16:0_18:1 increased from 41% to 44% of all PC molecules
analysed, representing a 7% increase from its initial abundance over the 80 year period
(Figure 4-3, Table 4-1). Six other PCs also changed with age in abundance when
expressed as percent composition (percent of total PC), including PC 16:0_22:6, PC
18:0_18:2, PC 16:0_18:2, PC 14:0_16:0, lyso-PC 16:0, and PC 15:0_16:0/O-16:0_16:0.
Of these six phospholipids only lyso-PC 16:0 decreased in abundance over the adult
lifespan.
Analysis of quantified phospholipids (as pmol/µg of membrane protein) found that PC
16:0_18:0 and lyso-PC 16:0 decreased with age, while PC O-16:1_18:0 increased in
quantified amount with age (Table 4-2).
4.2.3.2 Phosphatidylethanolamines
Ten mitochondrial PEs changed in their percent composition with age in the human
prefrontal cortex (Figure 4-4 & Table 4-1). Decreases with age were seen in the secondmost abundant mitochondrial PE, PE 18:0_20:4, which declined from approximately
19% of total mitochondrial PE to 15% from ages 20 to 100. Considering the abundance
of this phospholipid, this represents the largest change with age seen in any
mitochondrial PE. A second highly abundant mitochondrial PE, PE 18:0_22:4, also
decreased by 24% from ages 20 to 100. Decreases with age were also seen in PE
18:0_18:1 and PE 16:0_18:1, two moderately abundant phospholipids that together
comprise approximately 6.7% of total mitochondrial PEs (Figure 4-2). PE 16:0_20:4,
PE 17:0_22:6/O-18:0_22:6 and PE O-16:1_22:4 also decreased across the adult lifespan
in the prefrontal cortex, but these phospholipids are only of low abundance in the
mitochondria.
Increases with age were reported for three mitochondrial PEs, PE 18:1_22:6, PE O18:1_22:6 and PE O-18:1_22:5, which increased in abundance by 42%, 60%, and 133%
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Figure 4-2: Phospholipids detected within PC, PE and PS in the mitochondrial fraction
of human prefrontal cortex (as a percent of total phospholipid within each class).
Phospholipids were quantified as described in materials and methods. Values are mean
across
the
cohort
±
SEM.
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Figure 4-3: Mitochondrial PCs changing significantly with age (as a percent of total PC)
in normal human prefrontal cortex (n = 30-36). Regression model was adjusted for sex:
males (●), females (○). T indicates dependent variable transformed for linear regression,
with transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 4-1.

Table 4-1: Mitochondrial phospholipids (percent of phospholipid within phospholipid
class) changing significantly with age in the human prefrontal cortex.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
Lyso-PC 16:0
-0.0025 -0.0043 -0.0008 -0.522 2,33
-2.946 0.006**
0.0003
0.0042
PC 14:0_16:0
0.0022
0.408 2,33
2.397 0.022*
0.0559
PC 16:0_18:1
0.0339 0.0119
0.543 2,31
3.148 0.0036**
L
0.0030
PC 16:0_18:2
0.0016 0.0002
0.453 2,30
2.295 0.029*
0.0108
PC 16:0_22:6
0.0058 0.0008
0.430 2,33
2.338 0.026*
I
0.0002
0.0054
PC 18:0_18:2
0.0028
0.415 2,27
2.207 0.036*
PC 15:0_16:0
0.0017 0.0002
0.0032
0.448 2,28
2.274 0.031*
/O-16:0_16:0IR
Phosphatidylethanolamine
PE 16:0_18:1
-0.0184 -0.0284 -0.0084 -0.689 2,21
-3.842 0.0009***
PE 16:0_20:4
-0.0077 -0.0152 -0.0001 -0.376 2,32
-2.066 0.047*
-0.0246
-0.0049
PE 18:0_18:1
-0.0147
-0.606 2,21
-3.103 0.005**
PE 18:0_20:4I
-0.0002 -0.0003 -0.00002 -0.424 2,33
-2.299 0.028*
I
PE 18:0_22:4
-0.0006 -0.0011 -0.0001 -0.555 2,27
-2.705 0.012**
0.0150
PE 18:1_22:6
0.0105 0.0060
0.723 2,30
4.773 0.00004***
PE 17:0_22:6
-0.0096 -0.0158 -0.0033 -0.615 2,23
-3.167 0.004**
/O-18:0_22:6
PE O-16:1_22:4
-0.0026 -0.0052 -0.0001 -0.390 2,33
-2.089 0.045*
0.0256
PE O-18:1_22:5
0.0147 0.0039
0.548 2,31
2.763 0.0095**
0.0153
PE O-18:1_22:6
0.0109 0.0065
0.702 2,31
5.041 0.00002***
Phosphatidylserine
PS 18:0_20:4
-0.0198 -0.0327 -0.0069 -0.588 2,25
-3.163 0.004**
0.2981
PS 18:0_22:6
0.1605 0.0229
0.425 2,30
2.383 0.024*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: L logarithm, I reciprocal, IR
reflect and reciprocal. * P <0.05 ** P <0.01 *** P <0.001
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Table 4-2: Quantified mitochondrial phospholipids (pmol/µg total membrane protein)
changing significantly with age in the human prefrontal cortex.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
-0.0020 -0.512 2,33
Lyso-PC 16:0
-0.0070 -0.0120
-2.871 0.007**
-0.0003 -0.384 2,31
PC 16:0_18:0
-0.0216 -0.0428
-2.073 0.047*
PC O-16:1_18:0
0.0118
0.0024
0.0211
0.538 2,20
2.627 0.016*
Phosphatidylethanolamine
PE 18:0_22:4
-0.0404 -0.0750
-0.0057 -0.503 2,27
-2.391 0.024*
IR
PE 18:1_22:6
0.0005
0.0001
0.0009
0.456 2,32
2.563 0.015*
PE 17:0_22:6
-0.0106 -0.0194
-0.0018 -0.516 2,23
-2.494 0.020*
/O-18:0_22:6
PE O-18:1_22:5
0.0174
0.0040
0.0309
0.526 2,31
2.646 0.013*
PE O-18:1_22:6
0.0122
0.0047
0.0197
0.540 2,33
3.323 0.002**
Phosphatidylserine
PS 18:0_20:4
-0.0091 -0.0181 -0.00002 -0.427 2,25
-2.065 0.049*
PS 18:0_22:4
-0.0017 -0.0031
-0.0002 -0.440 2,30
-2.337 0.026*
I
PS 18:1_20:1
-0.0037 -0.0071
-0.0002 -0.424 2,28
-2.188 0.037*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: I reciprocal, IR reflect and recipr
ocal. * P <0.05 ** P <0.01 *** P <0.001
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Figure 4-4: Mitochondrial PEs changing significantly with age (as a percent of total PE)
in normal human prefrontal cortex (n = 24-36). Regression model was adjusted for sex:
males (●), females (○). T indicates dependent variable transformed for linear regression,
with transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 4-1.
respectively across the 80 year period. While seemingly substantial increases were seen
in PE O-18:1_22:5 with age, this phospholipid is only of low abundance and comprises
less than 2% of total mitochondrial PE (Figure 4-2) and 0.4% of total mitochondrial
phospholipid.
Analysis of the quantified data (pmol/µg membrane protein) showed similar trends for
all PE phospholipids measured. PE 18:0_22:4 and PE 17:0_22:6/O-18:0_22:6 continued
to decrease significantly with age, while PE 18:1_22:6, PE O-18:1_22:6 and PE O18:1_22:6 all maintained age-related increases (Table 4-2).
4.2.3.3 Phosphatidylserines
Two PS phospholipids, PS 18:0_22:6 and PS 18:0_20:4, changed with age in their
percent composition in the mitochondrial membranes of the human prefrontal cortex
(Figure 4-5, Table 4-1). PS 18:0_22:6 is the principal PS found in mitochondrial
membranes, representing just over half of all mitochondrial PS (Figure 4-2) and 8.3% of
total mitochondrial phospholipids. PS 18:0_22:6 increased by 34% in abundance over
80 years, rising from approximately 44% of total PS phospholipids at age 20 to 57% at
100 years of age. This represents the largest change with age in abundance for any
mitochondrial phospholipid.
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Figure 4-5: Mitochondrial PSs changing significantly with age (as a percent of total PC)
in normal human prefrontal cortex (n = 28-33). Regression model was adjusted for sex:
males (●), females (○). Regression parameters are shown in Table 4-1.
In contrast, PS 18:0_20:4 decreased with age by 85% when expressed as a percent of
total PS (Figure 4-5, Table 4-1) and by 70% quantitatively (pmol/µg membrane protein,
Table 4-2) over the age range studied. Two other mitochondrial PSs changed across the
80 year period in their quantitative amount, with PS 18:0_22:4 decreasing and PS
18:1_20:1 increasing with age (Table 4-2).
4.2.4

Changes in microsomal phospholipids with age

4.2.4.1 Phosphatidylcholines
The composition of PC, PE and PS phospholipids detected in the microsomal
membranes of the prefrontal cortex can be seen in (Figure 4-6). Age-related changes in
PC phospholipids in microsomal membranes of the prefrontal cortex were small, with
only three relatively minor phospholipids changing significantly with age in their
percent composition (Figure 4-7, Table 4-3). These included PC 16:0_20:4, PC
16:0_18:2, and PC 14:0_16:0. PC 16:0_20:4 decreased in abundance with age by 14%
from age 20 to 100, while PC 16:0_18:2 and PC 14:0_16:0 increased by 32% and 14%
respectively. These three phospholipids are of low to moderate abundance, however,
comprising only 3.3% of the total microsomal phospholipid when combined.
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Figure 4-6: Phospholipids detected within PC, PE and PS in the microsomal fraction of
human prefrontal cortex (as a percent of total phospholipid within each class).
Phospholipids were quantified as described in materials and methods. Values are mean
across the cohort ± SEM.
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Figure 4-7: Microsomal PCs changing significantly with age (as a percent of total PC)
in normal human prefrontal cortex (n = 30-34). Males (●), females (○).Regression
model was adjusted for sex: males (●), females (○). T indicates dependent variable
transformed for linear regression, with transformed beta-coefficient and p-value
reported on original scatterplot for comparison. Regression parameters are shown in
Table 4-3.
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Table 4-3: Microsomal phospholipids (percent of phospholipid within phospholipid
class) changing significantly with age in the human prefrontal cortex.

Phospholipid

Slope

95% CI
Lower Upper

β

df

t

P value

Phosphatidylcholine
PC 14:0_16:0
0.0021 0.0004 0.0037
0.437 2,32
2.575 0.015*
I
PC 16:0_18:2
0.0017 0.0002 0.0032
0.426 2,27
2.295 0.030*
PC 16:0_20:4
-0.0062 -0.0120 -0.0004 -0.422 2,31
-2.198 0.036*
Phosphatidylethanolamine
Lyso-PE 22:4
-0.0055 -0.0091 -0.0018 -0.493 2,32
-3.032 0.005**
Lyso-PE 22:6
-0.0079 -0.0132 -0.0026 -0.515 2,33
-3.015 0.005**
PE 16:0_20:4
-0.0047 -0.0083 -0.0011 -0.539 2,29
-2.644 0.013*
L
-0.0031
-0.0009
PE 18:0_18:1
-0.0020
-0.693 2,26
-3.830 0.0007***
PE 18:0_22:5
-0.0255 -0.0422 -0.0087 -0.561 2,29
-3.107 0.004**
L
PE 18:1_18:1
-0.0019 -0.0030 -0.0007 -0.588 2,30
-3.294 0.003**
PE 18:1_22:6
0.0069 0.0014 0.0122
0.494 2,32
2.581 0.015*
PE 17:0_22:4
-0.0040 -0.0068 -0.0011 -0.498 2,30
-2.821 0.008**
/O-18:0_22:4
PE O-16:1_22:4I
-0.0009 -0.0014 -0.0004 -0.599 2,33
-3.558 0.001**
I
PE O-18:1_20:4
-0.0007 -0.0014 -0.0001 -0.491 2,31
-2.444 0.020*
Phosphatidylserine
PS 18:0_22:6
0.1915 0.0217 0.3614
0.424 2,32
2.297 0.028*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: L logarithm, I reciprocal.
* P <0.05 ** P <0.01 *** P <0.001

Table 4-4: Quantified microsomal phospholipids (pmol/µg total membrane protein)
changing significantly with age in the human prefrontal cortex.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylethanolamine
PE 15:0_22:6
0.0070 0.0007
0.0133
0.395 1,32
2.275 0.030*
/O-16:0_22:6
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. * P <0.05
70 | P a g e

CHAPTER 4

Analysis of the quantified data for PC phospholipids (as pmol/µg of membrane protein)
showed similar trends to those reported for the percent data, but no PC reached
statistical significance in the microsomal fraction.
4.2.4.2 Phosphatidylethanolamines
Ten microsomal PEs showed significant age-related changes in the prefrontal cortex
(Figure 4-8, Table 4-3). PE 18:1_18:1, PE 18:0_18:1 and PE 18:0_22:5 are all
moderately abundant PEs present in the microsomes, and these phospholipids decreased
in abundance by 30%, 31% and 61% respectively from ages 20 to 100. The remaining
six microsomal PEs that decreased with age were of low abundance, and included lysoPE 22:6, PE 16:0_20:4, PE O-18:1_20:4, PE 17:0_22:4/O-18:0_22:4, lyso-PE 22:4 and
PE O-16:1_22:4. The only microsomal PE to increase in abundance with age was PE
18:1_22:6, a phospholipid which is also of low abundance in the microsomal
membranes (0.6% of all microsomal phospholipids). All of the major microsomal PEs,
including PE 16:0_22:6, PE 18:0_22:6, PE 18:0_20:4 and PE 18:0_22:4 (Figure 4-6),
showed no changes with age in the human prefrontal cortex.

PE 15:0_22:6/O-

16:0_22:6 was the only microsomal phospholipid that increased in quantitative amount
(pmol of phospholipid/µg of membrane protein) in the prefrontal cortex (Table 4-4).
The quantified PE data showed similar trends to those reported for the percent data, but
none of these phospholipids reached statistical significance.
4.2.4.3 Phosphatidylserines
Only a single microsomal PS phospholipid, PS 18:0_22:6, changed in its percent
composition with age in the human prefrontal cortex (Figure 4-9, Table 4-3). This
phospholipid is the primary PS found in microsomal membranes representing
approximately 50% of all microsomal PS (Figure 4-6) and 7.5% of all phospholipids.
PS 18:0_22:6 increased by 35% in abundance from ages 20 to 100 (Figure 4-9, Table
4-3).
No age-related changes were found for any PS phospholipids in the quantified
microsomal data (pmol/µg of membrane protein).
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Figure 4-8: Microsomal PEs changing significantly with age (as a percent of total PC)
in normal human prefrontal cortex (n = 29-36). Regression model was adjusted for sex:
males (●), females (○). T indicates dependent variable transformed for linear regression,
with transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 4-3.

Figure 4-9: Microsomal PSs changing significantly with age (as a percent of total PC) in
normal human prefrontal cortex (n = 35). Regression model was adjusted for sex: males
(●), females (○). Regression parameters are shown in Table 4-3.

73 | P a g e

CHAPTER 4

4.3 Discussion
This chapter examined age-related changes in the major phospholipids present in both
the mitochondrial and microsomal membranes of normal human prefrontal cortex over
the adult lifespan. A diverse range of molecular phospholipids were found to undergo
changes with age in both membrane fractions, with none of these changes being limited
to a particular class of phospholipid.
The largest age-related change for a single molecular phospholipid was seen in PS
18:0_22:6 in both the mitochondrial and microsomal membranes (Figure 4-5 & Figure
4-9). This one phospholipid makes up around 8.3% and 7.5% of the total phospholipid
present in mitochondrial and microsomal membranes respectively, and a substantial
age-related increase of approximately one third in abundance was found in both
membrane fractions. Several other phospholipids containing 22:6 (DHA) also increased
with age in both membrane fractions, including mitochondrial PC 16:0_22:6 (Figure
4-3, Table S3) and PE O-18:1_22:6 (Figure 4-4, Table S3), and both mitochondrial and
microsomal PE 18:1_22:6 (Figure 4-4 & Figure 4-8; Table 4-1 & Table 4-3 ).
Significant increases in DHA have been reported previously in early childhood
development [70]. DHA is known to incorporate itself preferentially into amino
phospholipids such as PE or PS in the brain [190]. The importance of PS containing
DHA in neuronal survival has been shown in vitro with decreased cell death reported in
neuro-2A cells supplemented with both DHA and serine together over DHA alone,
indicating that accumulation of DHA in PS is responsible for this protective effect
[191]. Further evidence for the importance of DHA in the human brain has been seen in
patients with Zellweger syndrome, a peroxisomal disorder where depletion of long
chain PUFA such as DHA results in severe brain abnormalities and death within the
first year of life [58]. Depletion of DHA in the human frontal cortex has been reported
in AD [92,93], but several other studies have also reported no changes in DHA levels
with the disease [86,87,108,121].
In the present chapter many phospholipids containing a 20:4 fatty acid decreased
significantly in abundance with age in both the mitochondrial and microsomal fractions.
Although double bond position cannot be definitively determined by the mass
spectrometry technique used in this thesis, 20:4 can be putatively classified as the n-6
PUFA AA as the n-3 isomer has not been detected in any previous studies of the human
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brain. The primary AA-containing phospholipid decreasing with age in the
mitochondrial membranes was PE 18:0_20:4, a phospholipid which comprises 16% of
total PE (Figure 4-2). Mitochondrial PE 18:0_20:4 declined by 25% in abundance
across the 80 year period studied (Figure 4-4, Table 4-1). Other less abundant
mitochondrial phospholipids containing a AA fatty acid that also declined in abundance
with age included PE 16:0_20:4, which showed a 20% loss from ages 20 to 100 (Figure
4-4, Table 4-1), and PS 18:0_20:4 which declined by 82% (Figure 4-5, Table 4-1).
Microsomal phospholipids containing AA that decreased with age included PE
16:0_20:4 and PE O-18:1_20:4 (Figure 4-8, Table 4-3). PE 18:0_20:4 showed a trend
towards decreasing with age within the microsomal membranes but failed to reach
statistical significance (β=-0.416, p=0.051). Interestingly several 22:4-containing
phospholipids also decreased in abundance with age, including mitochondrial PE O16:1_22:4 (34% loss, Figure 4-4, Table 4-1), and microsomal PE O-16:1_22:4 (46%
loss), PE 17:0_22:4/O-18:0_22:4 (33% loss), and lyso-PE 22:4 (54% loss, Figure 4-8,
Table 4-3). 22:4 can be putatively classified as an n-6 fatty acid (adrenic acid) based on
its synthesis via the elongation and desaturation pathway (see Chapter 2 section 2.1.4)
[56].
Because of the age-related changes identified for phospholipids containing either DHA,
AA or adrenic acid further regressions with age were carried out for both the
mitochondrial and microsomal membranes (Table 4-5 & Table 4-6 respectively).
Increases with age were seen in the abundance of DHA in the combined phospholipids,
which was driven by a rise in PS-DHA in both membrane fractions. In contrast, AA
decreased in both mitochondrial and microsomal combined phospholipids, with
decreases seen in mitochondrial PE-AA and microsomal PE-AA and PS-AA. Adrenic
acid did not show many statistically significant decreases with age in any of the three
phospholipid classes in either membrane fraction aside from a reduction in
mitochondrial PC. Interestingly, when the two n-6 fatty acids were combined with
mitochondrial PC one of the most statistically significant changes in this study was seen
(Table 4-5). Previous studies have also reported significant decreases with age in n-6
fatty acids in the human frontal cortex across the adult lifespan [94,95]. Contrary to the
present study, Carver et al. [94] reported no changes for DHA with age while
McNamara [95] described significant decreases. Other age-related changes reported in
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Table 4-5: Linear regression of the most abundant polyunsaturated fatty acids (percent
of total fatty acids within phospholipid class) in the mitochondrial membranes with age
in human prefrontal cortex
95% CI
Mitochondrial
Slope
β
df
t
P value
fatty acids
Lower
Upper
Combined phospholipids
-0.0011 -0.0002 -0.515 2,33
20:4IR
-0.0007
-2.913 0.006**
-0.0197
0.0083 -0.159 2,33
22:4
-0.0057
-0.827 0.414
-0.0347 -0.0030 -0.424 2,33
20:4 + 22:4
-0.0189
-2.425 0.021*
0.0075
0.0663
22:6
0.0369
0.431 2,33
2.554 0.015*
Phosphatidylcholine
-0.0227
0.0073 -0.205 2,33
20:4
-0.0077
-1.047 0.303
L
-0.0075 -0.0015 -0.518 2,33
22:4
-0.0045
-3.049 0.004**
LR
0.0013
0.0034
20:4 + 22:4
0.0023
0.676 2,33
4.444 0.00009***
-0.0026
0.0072
22:6
0.0023
0.185 2,33
0.939 0.354
Phosphatidylethanolamine
-0.0005 -0.00002 -0.411 2,33
20:4I
-0.0003
-2.215 0.034*
-0.0299
0.0391
22:4
0.0046
0.054 2,33
0.274 0.786
-0.00006
0.0002
20:4 + 22:4
0.00009
0.241 2,33
1.237 0.225
-0.0205
0.0895
22:6
0.0345
0.246 2,33
1.279 0.210
Phosphatidylserine
-0.0119
0.0002 -0.322 2,33
20:4
-0.0059
-1.980 0.056
-0.0070
0.0591
22:4
0.0261
0.301 2,33
1.604 0.118
-0.0308
0.0015 -0.345 2,30
20:4 + 22:4
-0.0146
-1.848 0.074
0.0115
0.1490
22:6
0.0803
0.425 2,30
2.383 0.024*
Fatty acids calculated from phospholipid molecular species data. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression: L logarithm, LR reflect and logarithm, I reciprocal, IR reflect and reciprocal. *
P <0.05 ** P <0.01 *** P <0.001
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Table 4-6: Linear regression of most abundant polyunsaturated fatty acids (percent of
total fatty acids within phospholipid class) in the microsomal membranes with age in
human prefrontal cortex
95% CI
Microsomal
Slope
β
df
t
P value
fatty acids
Lower
Upper
Combined phospholipids
20:4
-0.0151 -0.0256 -0.0046 -0.507 2,33
-2.931 0.006**
0.0168
22:4
0.0071 -0.0026
0.285 2,33
1.484 0.147
0.0049 -0.244 2,33
20:4 + 22:4
-0.0080 -0.0209
-1.266 0.215
0.0224
0.0703
22:6
0.0464
0.645 2,33
3.941 0.0004***
Phosphatidylcholine
0.0013 -0.350 2,33
20:4
-0.0122 -0.0256
-1.844 0.074
0.0131
22:4
0.0013 -0.0104
0.046 2,33
0.233 0.817
IR
20:4 + 22:4
-0.0006 -0.0011 -0.0002 -0.492 2,33
-2.760 0.009**
0.0067
22:6
0.0023 -0.0022
0.201 2,33
1.028 0.312
Phosphatidylethanolamine
20:4I
-0.0003 -0.0005 -0.0002 -0.631 2,32
-3.972 0.0004***
IR
0.0008
22:4
0.0004 0.00004
0.348 2,33
1.834 0.076
0.0252 -0.084 2,31
20:4 + 22:4
-0.0059 -0.0371
-0.390 0.699
0.0626
22:6
0.0294 -0.0037
0.375 2,31
1.809 0.080
Phosphatidylserine
20:4I
-0.0042 -0.0079 -0.0004 -0.413 2,32
-2.239 0.032*
0.0158 -0.155 2,31
22:4
-0.0096 -0.0350
-0.722 0.445
0.0083 -0.275 2,31
20:4 + 22:4
-0.0181 -0.0445
-1.398 0.172
0.0108
0.1807
22:6
0.0958
0.424 2,31
2.297 0.028*
Fatty acids calculated from phospholipid molecular species data. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression: I reciprocal, IR reflect and reciprocal. * P <0.05 ** P <0.01 *** P <0.001
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the literature includes a loss of total phospholipid in human frontal cortex [88,90,93], a
result which was not seen in this study in either the mitochondrial or microsomal
membranes. In a later study, Söderberg et al. [93] reported a significant age-related
decline in total PC phospholipids in frontal grey matter, a finding which was also not
replicated in the present study.
Several significant age-related changes also occurred in highly abundant phospholipids
containing saturated and/or monounsaturated fatty acids. The most abundant
phospholipid of this type was mitochondrial PC 16:0_18:1, which increased from
approximately 41% of total mitochondrial PC phospholipids at age 20 to 44% by 100
years of age (Figure 4-3, Table 4-1). The next most abundant mitochondrial
phospholipid showing significant age-related changes was PE 18:0_18:1, which
declined by 30% in abundance over the 80 year period studied, followed by PE
16:0_18:1 with a 37% loss. In the microsomal membranes the most abundant
phospholipids of this type showing significant changes with age were PE’s 18:0_18:1
and 18:1_18:1, both of which contribute approximately 1% each to total phospholipids
detected (Figure 4-8, Table 4-3). Both of these microsomal PE phospholipids declined
in abundance by 35% and 32% respectively from ages 20 to 100. While these findings
are noteworthy, the specific functions of phospholipids containing saturated and/or
monounsaturated fatty acids in the human brain are mostly unknown. Current in vitro
evidence suggests a potential role for such phospholipids as modulators of membrane
bilayer fluidity [192,193].
In summary, many different phospholipids changed significantly with age in the
mitochondrial and microsomal membranes of normal human prefrontal cortex, and
these changes were not confined to a particular class of phospholipid in either
membrane fraction. Notable phospholipids increasing over the adult lifespan included
mitochondrial and microsomal PS 18:0_22:6 and other phospholipids containing DHA.
Decreases were seen in phospholipids containing AA or adrenic acid, including the
highly abundant mitochondrial PE 18:0_20:4. While increases in DHA have previously
been reported in early childhood, to our knowledge this is first time age-related changes
have been reported for individual phospholipids during normal adult ageing in the
human brain, as well as being the first report of increases in phospholipids containing
DHA over the adult lifespan.
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Chapter 5 The Hippocampus
This chapter is an amended version of the published manuscript: Hancock SE,
Friedrich MG, Mitchell TW, Truscott, RJW, Else PL, (2015) Decreases are seen in
the human hippocampus over the adult lifespan in phospholipids containing adrenic
and arachidonic acids, Lipids, 50(9);861-872

5.1 Introduction
This chapter will examine the changes seen during normal ageing in PC, PE and PS
phospholipids present in the mitochondrial and microsomal membranes of the
hippocampus.
The hippocampus is located in the medial temporal lobe of the brain and belongs to the
limbic system (see Chapter 1, Figure 1-2). It has important roles in the consolidation of
short-term memory to long-term [194,195], as well as spatial navigation [196]. The
hippocampus is one of the earliest sites where atrophy is exhibited in the development
of AD [197,198]. Less severe atrophy of this region is also seen during normal ageing
[199]. The presence of Aβ deposits characteristic of AD within the medial temporal
region is thought to accelerate atrophy within the hippocampus and other brain
structures of the medial temporal region [200]. Additionally, the hippocampus is
believed to be one of the initial sites of the development of NFTs [7].
The phospholipids of the hippocampus have been examined for their role in the
pathogenesis of AD in several studies over the past few decades [86,111,113,121–123],
but very few studies have examined the changes occurring in hippocampal
phospholipids during normal ageing [90,93]. Decreases in total phospholipids with age
have been reported after age 60 in the hippocampus [90], alongside reductions in total
PC and PE [93]. No age-related changes have previously been reported for the fatty
acids of either PC or PE phospholipids in the human hippocampus [93].
Therefore, the aim of this chapter was to expand on the current knowledge of the
changes occurring to the PC, PE and PS phospholipids of the human hippocampus
during normal ageing.
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5.2 Results
5.2.1

Age-related changes to total protein content in subcellular fractions

Statistically significant age-related declines were seen in the total protein content of the
microsomal fraction of the hippocampus, but no changes with age were found for either
the whole tissue homogenate or mitochondrial fraction (Figure 5-1, Table 5-1). Total
protein decreased in the microsomal membranes from 2.5 µg/mg wet weight of tissue to
1.9 µg/mg wet weight of tissue from ages 20 to 100, representing a decrease of 48%. A
trend was seen for a decline in total protein with age within the whole tissue
homogenate, but this failed to reach statistical significance (β = -0.356, p = 0.055).
5.2.2

Major phospholipid classes of mitochondrial and microsomal fractions

The ratio of the three major phospholipid classes PC, PE and PS showed a similar
distribution between the mitochondrial and microsomal membranes (Figure 5-2).
Overall, PC comprised 43%, PE 36% and PS 21% of total phospholipids measured in
each fraction with some small differences in phospholipid content between the two
membrane fractions. A slightly higher percentage of PE was present in the mitochondria
(p < 0.001) while the microsomes contained more PC (p < 0.001). There were no
differences in the percent abundance of PS between the two membrane fractions. The
percent contribution of total PC, PE, PS, and total phospholipids were also examined for
any age-related changes in the mitochondrial and microsomal fractions, with no
significant age-related changes seen.
The quantified amount of each phospholipid class (as pmol/µg membrane protein)
between the two membrane fractions was also analysed, with the microsomal fraction
found to contain higher amounts of PC (p < 0.001) and PS (p = 0.005). Total quantified
phospholipids were also greater in the microsomes than in the mitochondria (p = 0.001).
Regression of quantified phospholipids (pmol/µg membrane protein) with age showed
no statistically significant age-related changes for any phospholipid class in either
membrane fraction, including total quantified phospholipids.
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Figure 5-1: Linear regression of age against total protein amount (mg/g wet tissue)
measured in whole tissue homogenate and subcellular fractions derived from normal
human hippocampus. Total protein was measured using BCA assay as described in
methods and materials. Regression model was adjusted for sex: males (●), females (○).
T
indicates dependent variable transformed for linear regression, with transformed betacoefficient and p-value reported on original scatterplot for comparison. Regression
parameters are shown in Table 5-1.
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Table 5-1: Linear regression of total protein (mg/g of tissue) with age in the whole
tissue homogenate and subcellular fractions of normal human hippocampus

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Whole tissue
-0.00002 -0.00004 -0.0000004 -0.356 2,33
-1.994 0.055
homogenateI
0.0267 -0.087 2,33
Mitochondria
-0.0082 -0.0430
-0.479 0.635
L
-0.0027
-0.0006
Microsomes
-0.0016
-0.484 2,33
-3.164 0.003**
Total protein amount measured using BCA Assay. Regression was adjusted for gender.
Superscript indicates dependent variable transformed for linear regression, with
transformed regression output reported: L logarithm ** P <0.01

Figure 5-2: Percent composition of the three major phospholipid classes within the
mitochondrial (left) and microsomal (right) fractions in normal human hippocampus.
Values are the mean ± SEM for the entire cohort. The microsomal membranes showed
significantly higher amounts of total phosphatidylcholine (PC) compared to
mitochondria (p < 0.001, Wilcoxon signed-rank test), while the mitochondria contained
more phosphatidylethanolamine (PE) (p < 0.001, Wilcoxon signed-rank test). There
were no differences between fractions for phosphatidylserine (PS).
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5.2.3

Changes in mitochondrial phospholipids with age

5.2.3.1 Phosphatidylcholines
The composition of PC, PE and PS phospholipids detected in the mitochondrial
membranes of the hippocampus can be seen in (Figure 5-3).Three mitochondrial PCs
changed with age in the human hippocampus (Figure 5-4, Table 5-2). PC 16:0_18:1, the
most abundant phospholipid present in mitochondrial membranes, increased from
40.8% of total mitochondrial PC at age 20 to 42.5% at age 100, representing a 4%
increase from its initial abundance. PC 16:0_18:2 also increased in abundance with age,
but this phospholipid is only present in low-to-moderate amounts within mitochondrial
membranes (Figure 5-3). The only mitochondrial PC to decrease with age was PC
18:0_20:4, which declined in abundance by 24% from ages 20 to 100 (Figure 5-4, Table
5-2).
Regression of quantified phospholipids (pmol phospholipid/µg total protein) with age
was also performed, with no mitochondrial PCs showing any statistically significant
age-related changes (Table 5-3).
5.2.3.2 Phosphatidylethanolamines
Age-related changes were seen in several mitochondrial PEs (Figure 5-5, Table 5-2). PE
18:0_22:4 was the most abundant mitochondrial PE to decrease with age, declining by
13% in abundance over the 80 year period. This phospholipid is the third-most abundant
mitochondrial PE, comprising approximately 8% of total mitochondrial PE (Figure 5-3)
and 3% of total mitochondrial phospholipid. Three other mitochondrial PEs decreased
with age: PE 16:0_22:4, PE O-16:1_20:2 and PE O-18:1_22:3 (Figure 5-5, Table 5-2).
PE 16:0_22:4 is a moderately abundant mitochondrial PE, which contributes up to 1.5%
of mitochondrial PE (Figure 5-3) and 0.6% of total mitochondrial phospholipid. This
phospholipid decreased by 19% in abundance from ages 20 to 100 (Figure 5-5, Table
5-2). The remaining phospholipid to decline with age, PE O-16:1_20:2, is only of low
abundance in the mitochondrial membranes, comprising just over 0.4% of total
mitochondrial phospholipid.
Three mitochondrial PEs increased in percent abundance over the 80 year period: PE
18:1_22:6 lyso-PE 22:6 and lyso-PE 18:1. PE 18:1_22:6 is a moderately abundant
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Figure 5-3: Phospholipids detected within PC, PE and PS in the mitochondrial fraction
of human hippocampus (as a percent of total phospholipid within each class).
Phospholipids were quantified as described in materials and methods. Values are mean
across the cohort ± SEM.
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Figure 5-4: Mitochondrial PCs changing significantly with age (as a percent of total PC)
in normal human hippocampus (n = 33-36). Regression model was adjusted for gender:
males (●), females (○). Regression parameters are shown in Table 5-2.
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Table 5-2: Mitochondrial phospholipids (percent of phospholipid within phospholipid
class) changing significantly with age in the human hippocampus.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
0.0005
0.0456
PC 16:0_18:1
0.0230
0.405 2,31
2.083 0.046*
0.0005
0.0060
PC 16:0_18:2
0.0033
0.459 2,31
2.416 0.022*
-0.0211
-0.0042 -0.496 2,33
PC 18:0_20:4
-0.0127
-3.049 0.005**
Phosphatidylethanolamine
0.0005
0.0062
Lyso-PE 18:1
0.0034
0.438 2,33
2.411 0.022*
0.0005
0.0069
Lyso-PE 22:6
0.0037
0.431 2,33
2.338 0.026*
-0.0071
-0.0007 -0.453 2,30
PE 16:0_22:4
-0.0039
-2.510 0.018*
I
-0.0004
-0.00002
PE 18:0_22:4
-0.0002
-0.371 2,33
-2.221 0.033*
0.0040
0.0108
PE 18:1_22:6
0.0074
0.668 2,32
4.442 0.0001***
-0.0098
-0.0013 -0.502 2,29
PE O-16:1_20:2
-0.0055
-2.654 0.013*
Phosphatidylserine
-0.0039 -0.00001 -0.383 2,32
PS 18:0_20:1L
-0.0019
-2.048 0.0489*
-0.0253
-0.0070 -0.614 2,30
PS 18:0_20:4
-0.0161
-3.589 0.0016**
-0.0362
-0.0009 -0.381 2,32
PS 18:0_22:4
-0.0186
-2.138 0.040*
0.0014
0.2320
PS 18:0_22:6
0.1167
0.384 2,32
2.062 0.047*
-0.0094
-0.0005
PS 18:1_20:0
-0.0049
-0.416 2,32
-2.259 0.031*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: L logarithm, I reciprocal.
* P <0.05 ** P <0.01 *** P <0.001
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Table 5-3: Quantified mitochondrial phospholipids (pmol/µg total membrane protein)
changing significantly with age in the human hippocampus.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylethanolamine
-0.0035 -0.588 2,29
PE O-16:1_20:2
-0.0097 -0.0158
-3.200 0.003**
Phosphatidylserine
-0.0002 -0.427 2,32
PS 18:0_18:1L
-0.0024 -0.0045
-2.266 0.030*
-0.0053 -0.654 2,31
PS 18:0_20:1
-0.0111 -0.0170
-3.864 0.0005***
-0.0025 -0.497 2,24
PS 18:0_20:2
-0.0116 -0.0206
-2.630 0.015*
-0.0149 -0.709 2,30
PS 18:0_20:4
-0.0278 -0.0407
-4.403 0.0001***
PS 18:1_20:0
-0.0052 -0.0103
-0.0001 -0.394 2,32
-2.097 0.044*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: L logarithm.
* P <0.05 ** P <0.01 *** P <0.001
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Figure 5-5: Mitochondrial PEs changing significantly with age (as a percent of total PE)
in normal human hippocampus (n = 32-36). Regression model was adjusted for sex:
males (●), females (○). T indicates dependent variable transformed for linear regression,
with transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 5-2.
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phospholipid in the mitochondrial membranes, comprising approximately 1% of total
mitochondrial phospholipids. PE 18:1_22:6 increased from 2.3% of total mitochondrial
PE to 2.9% from ages 20 to 100, representing an increase in abundance of 26%. The
two other lyso-PEs showing increases with age, lyso-PE 22:6 and lyso-PE 18:1,
comprised less than 1.7% of total mitochondrial PE when combined (Figure 5-3).
Analysis of the quantified phospholipids (pmol phospholipid/µg membrane protein)
showed similar trends for all mitochondrial PEs identified as changing significantly in
their percent abundance with age, but only a single mitochondrial PE reached statistical
significance: PE O-16:1_20:2 (Table 5-3). PE O-16:1_20:2 decreased with age from
1.150 pmol/µg membrane protein to 0.374 pmol/µg membrane protein from ages 20 to
100.
5.2.3.3 Phosphatidylserines
Within the mitochondrial membranes, five PS phospholipids changed in percent
abundance with age (Figure 5-6, Table 5-2). The most abundant phospholipid to show
an age-related change was PS 18:0_22:6, which increased from 37.0% of total
mitochondrial PS to 46.3% from ages 20 to 100. The remaining four phospholipids all
decreased with age in the mitochondrial membranes. PS 18:0_22:4, a moderately
abundant mitochondrial phospholipid, declined by 17% over the 80 year period (Figure
5-6, Table 5-2). PS 18:0_20:4, PS 18:0_20:1 and PS 18:1_20:0 are all low abundance
mitochondrial phospholipids, and decreased respectively by 39%, 30% and 35% from
age 20 to 100.
Three of these mitochondrial PSs also declined significantly in quantified amount (pmol
phospholipid/µg membrane protein) with age: PS 18:0_20:4, PS 18:0_20:1 and PS
18:1_20:0 (Table 5-3). A further two mitochondrial PS also decreased significantly in
quantified amount with age, PS 18:0_18:1 and PS 18:0_20:2.
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Figure 5-6: Mitochondrial PSs changing significantly with age (as a percent of total PS)
in normal human hippocampus (n = 33-35). Regression model was adjusted for sex:
males (●), females (○). T indicates dependent variable transformed for linear regression,
with transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 5-2.
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5.2.4

Changes in microsomal phospholipids with age

5.2.4.1 Phosphatidylcholines
The composition of PC, PE and PS phospholipids detected in the microsomal
membranes of the hippocampus can be seen in (Figure 5-7).Two microsomal PCs
changed with age (Figure 5-8, Table 5-4). Decreases with age were observed in PC
18:0_18:1, the third most abundant microsomal PC. PC 18:0_18:1 comprises 10% of
total microsomal PC (Figure 5-7) and 4% of total microsomal phospholipids, and
declined by 15% from ages 20 to 100 (Figure 5-8, Table 5-4). An age-related increase
of 35% in abundance was found for PC 15:0_16:0/O-16:0_16:0 (Figure 5-8, Table 5-4),
but this phospholipid comprises only 0.2% of total microsomal phospholipid.
PC 15:0_16:0/O-16:0_16:0 also increased in quantified amount with age within the
microsomal membranes, doubling from 0.78 pmol/µg membrane protein at age 20 to 1.6
pmol/µg membrane protein by age 100 (Table 5-5).
5.2.4.2 Phosphatidylethanolamines
Three microsomal PEs changed with age in their percent composition (percent of total
microsomal PE) in the hippocampus (Figure 5-9, Table 5-4). The most abundant
microsomal PE showing age-related changes was PE 18:0_22:4, which decreased by
18% in abundance across the 80 year period. PE 18:0_22:4 is the third most abundant
microsomal PE, comprising 8% of total microsomal PE (Figure 5-7). The two
remaining microsomal PEs increased significantly in percent abundance with age. PE
18:1_22:6, a moderately abundant microsomal PE, increased from 1.9% of microsomal
PE to 2.5% from ages 20 to 100, representing an increase of 27% in abundance (Figure
5-9, Table 5-4). PE 15:0_22:6/O-16:0_22:6 rose by a little over 70% across the 80 year
period, but this phospholipid is only of low abundance in microsomal membranes
(Figure 5-7). PE 15:0_22:6/O-16:0_22:6 also increased with age in quantified amount,
rising from 0.8 pmol/µg membrane protein at age 20 to 1.5 pmol/µg membrane protein
at age 100 (Table 5-5).
5.2.4.3 Phosphatidylserines
Only a single PS phospholipid changed in its percent composition with age in the
microsomal membranes: PS 18:0_20:4 (Figure 5-10, Table S3). PS 18:0_20:4 decreased
from 3.3% of microsomal PS to 2.3% over the 80 year period studied, representing a
loss of one-third in abundance.
91 | P a g e

CHAPTER 5

Figure 5-7: Phospholipids detected within PC, PE and PS in the microsomal fraction of
human hippocampus (as a percent of total phospholipid with each class). Phospholipids
were quantified as described in materials and methods. Values are mean across the
cohort ± SEM.
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Figure 5-8: Microsomal PCs changing significantly with age (as a percent of total PC)
in normal human hippocampus (n = 36). Regression model was adjusted for sex: males
(●), females (○). T indicates dependent variable transformed for linear regression, with
transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 5-4.

Table 5-4: Microsomal phospholipids (percent of phospholipid within phospholipid
class) changing significantly with age in the human hippocampus.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
PC 18:0_18:1
-0.0212 -0.0380 -0.0044 -0.461 2,33
-2.566 0.015*
PC 15:0_16:0
0.0008
0.0004
0.0012
0.642 2,33
4.059 0.0003***
/O-16:0_16:0I
Phosphatidylethanolamine
PE 18:0_22:4
-0.0190 -0.0360 -0.0020 -0.396 2,33
-2.275 0.030*
0.0027
0.0104
PE 18:1_22:6
0.0065
0.588 2,32
3.443 0.0016**
PE 15:0_22:6
0.0036
0.0006
0.0067
0.460 2,31
2.460 0.020*
/O-16:0_22:6
Phosphatidylserine
PS 18:0_20:4
-0.0123 -0.0239 -0.0008 -0.426 2,29
-2.184 0.037*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: I reciprocal. * P <0.05
** P <0.01 *** P <0.001
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Table 5-5: Quantified microsomal phospholipids (pmol/µg total membrane protein)
changing significantly with age in the human hippocampus.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
0.0038
PC 14:0_16:0L
0.0019 0.00006
0.382 2,33
2.102 0.043*
0.0057
0.0332
PC 16:0_18:2
0.0195
0.491 2,30
2.889 0.006**
0.0034
PC 18:1_18:1
0.0017 0.00005
0.363 2,33
2.098 0.044*
PC 15:0_16:0
0.0107
0.0030
0.0183
0.483 2,33
2.835 0.003**
/O-16:0_16:0
PC 15:0_18:1
0.0013
0.0002
0.0025
0.439 2,31
2.324 0.027*
/O-16:0_18:1I
Phosphatidylethanolamine
0.0037
PE 18:1_20:3I
0.0021 -0.0006
0.522 2,29
2.922 0.007**
PE 15:0_22:6
0.0090
0.0005
0.0174
0.405 2,31
2.151 0.039*
/O-16:0_22:6
0.0010
0.0446
PE O-18:1_22:5
0.0228
0.398 2,33
2.128 0.041*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: L logarithm, I reciprocal. * P
<0.05 ** P <0.01 *** P <0.001
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Figure 5-9: Microsomal PEs changing significantly with age (as a percent of total PE) in
normal human hippocampus (n = 34-36). Regression model was adjusted for sex: males
(●), females (○). Regression parameters are shown in Table 5-4.
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Figure 5-10: Microsomal PSs changing significantly with age (as a percent of total PS)
in normal human hippocampus (n = 32). Regression model was adjusted for sex: males
(●), females (○). Regression parameters are shown in Table 5-4.
There were no microsomal PSs that changed significantly in quantified amount over the
80 year period (pmol phospholipid/µg membrane protein, Table 5-5).

5.3 Discussion
Examination of the mitochondrial and microsomal membranes of the human
hippocampus showed that many phospholipids underwent significant changes during
normal ageing. These changes were not limited to any single class of phospholipid or a
single membrane fraction. Rather, the age-related changes in the hippocampus occurred
in a broad range of phospholipids in both the mitochondrial and microsomal
membranes, with many of these changes occurring in low-to-moderately abundant
phospholipids. In particular, phospholipids containing a 22:4 fatty acid (adrenic acid)
underwent consistent age-related decreases in both membrane fractions across the 80
year period studied, while those containing a 22:6 fatty acid (DHA) increased across the
adult lifespan.
PE 18:0_22:4 is the third most abundant PE in both the mitochondria and microsomes
(Figure 5-3 & Figure 5-7), and a decrease of approximately 13% and 18% in percent
abundance with age was found in both membranes fractions respectively (Figure 5-5 &
Figure 5-9, Table 5-2 & Table 5-4). Several other phospholipids with a 22:4 fatty acid
also declined in percent abundance with age in the mitochondrial membranes: PE
16:0_22:4 and PS 18:0_22:4 declined by 19% and 17% respectively from ages 20 to
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100 (Figure 5-5 & Figure 5-6, Table 5-2). The 22:4 fatty acid can be putatively assigned
as being adrenic acid, an n-6 PUFA, based on its synthesis via the elongation and
desaturation pathway (see Chapter 2, Figure 2-4) [56]. Adrenic acid is the product of
elongation of the n-6 PUFA 20:4 (AA) by two carbons. Two isomers of 20:4 can exist:
an n-3 and an n-6 isomer (AA) which differ only by the position of their double bonds.
As discussed in Chapter 4 (section 4.3), the mass spectrometry method used in this
thesis cannot determine double bond position. However, previous studies of fatty acids
within the phospholipids of human hippocampus that used gas chromatography have not
detected any n-3 20:4, so we can assume that the 20:4 detected is primarily AA
[90,93,122,123]. Many phospholipids containing AA also decreased with age in the
mitochondrial and microsomal membranes. Common between both membrane fractions
was a decline in the percent abundance of PS 18:0_20:4 with age, by 39% and 30% in
mitochondrial and microsomal membranes respectively (Figure 5-6 & Figure 5-10,
Table 5-2 & Table 5-4). Age-related decreases were also seen in mitochondrial PC
18:0_20:4, which declined by 24% over the 80 year period (Figure 5-4, Table 5-2).
Due to these age-related declines in mitochondrial and microsomal phospholipids
containing the n-6 fatty acids adrenic acid or AA, additional regressions were conducted
to check for changes in fatty acid content with age in the hippocampus (Table 5-6 &
Table 5-7). Decreases with age in AA were seen in the combined phospholipids of the
mitochondrial membranes (Table 5-6). When phospholipids containing either AA or
adrenic acid were pooled together, an even greater loss with age was revealed in the
combined mitochondrial phospholipids. In the microsomal membranes, only the pooled
AA and adrenic acid declined with age in the combined phospholipids (Table 5-7).
Together, these results indicate that there is a significant loss of long-chain n-6 fatty
acids in both membrane fractions within the hippocampus over the adult lifespan.
Despite significant age-related losses of PE 18:0_22:4 in both membrane fractions
(Figure 5-5 & Figure 5-9) there were no changes seen with age to either PE-adrenic acid
or to pooled PE-AA and PE-adrenic acid in either the mitochondrial or microsomal
membranes (Table 5-6 & Table 5-7). Instead most of the age-related declines in adrenic
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Table 5-6: Linear regression of most abundant polyunsaturated fatty acids (percent of
total fatty acids within phospholipid class) in the mitochondrial membranes with age in
human hippocampus
95% CI
Mitochondrial
Slope
β
df
t
P value
fatty acids
Lower
Upper
Combined phospholipids
-0.0044 -0.00003 -0.385 2,33
20:4LR
-0.0022
-2.065 0.047*
-0.0178 -0.0009 -0.324 2,33
22:4
-0.0084
-1.835 0.076
LR
-0.0070 -0.0006 -0.429 2,33
20:4 + 22:4
-0.0038
-2.443 0.020*
-0.0065
0.0486
22:6
0.0211
0.299 2,33
1.556 0.129
Phosphatidylcholine
-0.0165
0.0010 -0.320 2,32
20:4
-0.0077
-1.794 0.082
-0.0033
0.0038
22:4
0.0003
0.028 2,33
0.146 0.885
-0.0178
0.0037 -0.243 2,32
20:4 + 22:4
-0.0071
-1.341 0.189
-0.0036
0.0047
22:6
0.0006
0.057 2,33
0.289 0.775
Phosphatidylethanolamine
-0.0247
0.0110 -0.151 2,33
20:4
-0.0068
0.781 0.440
-0.0298
0.0044 -0.285 2,33
22:4
-0.0127
0.140 0.140
-0.0437
0.0047 -0.315 2,33
20:4 + 22:4
-0.0195
-1.642 0.110
-0.0021
0.0512
22:6
0.0245
0.356 2,33
1.877 0.069
Phosphatidylserine
-0.0127 -0.0035 -0.614 2,30
20:4LR
-0.0081
-3.589 0.001**
I
0.0008 -0.00001 -0.352 2,33
22:4
-0.0004
-1.969 0.057
L
-0.0025 -0.0004 -0.494 2,33
20:4 + 22:4
-0.0015
-2.869 0.007**
0.0302
0.1305
22:6
0.0804
0.568 2,31
3.265 0.003**
Fatty acids calculated from phospholipid molecular species data. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression: L logarithm, LR reflect and logarithm, I reciprocal. * P <0.05 ** P <0.01
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Table 5-7: Linear regression of most abundant polyunsaturated fatty acids (percent of
total fatty acids within phospholipid class) in the microsomal membranes with age in
human hippocampus
95% CI
Microsomal
Slope
β
df
t
P value
fatty acids
Lower
Upper
Combined phospholipids
0.0049 -0.201 2,33
20:4
-0.0060 -0.0169
-1.125 0.269
22:4
-0.0103 -0.0208 -0.0003 -0.363 2,33
-1.986 0.055
20:4 + 22:4
-0.0163 -0.0300 -0.0026 -0.395 2,33
-2.249 0.021*
-0.0250
0.0223
22:6
-0.0014
-0.023 2,32
-0.118 0.907
Phosphatidylcholine
0.0141 -0.031 2,33
20:4
-0.0012 -0.0165
-0.164 0.871
22:4
-0.0035 -0.0147 -0.0078 -0.124 2,33
-0.626 0.536
-0.0131
0.0037
20:4 + 22:4
-0.0047
-0.195 2,33
-1.134 0.265
0.0034 -0.046 2,33
22:6
-0.0004 -0.0042
-0.232 0.818
Phosphatidylethanolamine
0.0113 -0.154 2,32
20:4
-0.0071 -0.0255
-0.783 0.440
-0.0309
0.0047
22:4
-0.0131
-0.287 2,33
-1.150 0.143
0.0061 -0.292 2,32
20:4 + 22:4
-0.0173 -0.0407
-1.504 0.142
0.0305
22:6
0.0025 -0.0254
0.037 2,32
0.186 0.854
Phosphatidylserine
0.0089 -0.016 2,33
20:4
-0.0004 -0.0097
-0.087 0.931
22:4
-0.0095 -0.0189 -0.0001 -0.373 2,30
-2.072 0.047*
20:4 + 22:4
-0.0112 -0.0265 -0.0041
-0.260 2,31
-1.492 0.146
0.0961
22:6
-0.0394 -0.0173
0.274 2,33
1.413 0.167
Fatty acids calculated from phospholipid molecular species data. Regression was
adjusted for gender. * P <0.05
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acid and AA were seen in PS, with mitochondrial and microsomal PS-adrenic acids
declining significantly over the 80 year period, alongside considerable losses of
mitochondrial PS-AA. In the mitochondria this loss of PS-adrenic acid and PS-AA were
driven predominantly by declines in PS 18:0_22:4 and PS 18:0_20:4 respectively
(Figure 5-6, Table 5-2), while in the microsomal membranes there were losses with age
of PS 18:0_22:4 (Figure 5-10, Table 5-4). These results emphasise that age-related
changes in individual phospholipids are not necessarily reflected in the total
contribution of a given fatty acid within a class of phospholipid. Previous studies using
combinations of thin-layer chromatography and gas chromatography to examine the
changes with age to phospholipids and their fatty acids as separate entities would not
have seen these age-related changes.
Interestingly we saw substantial increases in mitochondrial PS 18:0_22:6 over the adult
lifespan in the human hippocampus (Figure 5-6, Table 5-2). This finding is similar to
what was reported in Chapter 4 (section 4.2) for the mitochondrial and microsomal
fractions of the human prefrontal cortex. In Chapter 4 (section 4.3) the importance of
DHA within PS phospholipids of the human brain was discussed. Several other lowabundance phospholipids containing DHA also increased with age in both membrane
fractions of the hippocampus, including mitochondrial and microsomal PE 18:1_22:6
(Figure 5-5 & Figure 5-9, Table 5-2 & Table 5-4), mitochondrial lyso-PE 22:6 (Figure
5-4, Table 5-2) and microsomal PE 15:0_22:6/O-16:0_22:6 (Figure 5-9, Table 5-4).
Increases in mitochondrial PS-DHA were also seen with age in the human hippocampus
(Table 5-6), but this age-related increase in DHA was not reflected in combined
mitochondrial phospholipids. This suggests that the increase in DHA across the adult
lifespan within the hippocampus is not as extensive as that seen in the human prefrontal
cortex, but that this smaller increase in mitochondrial PS-DHA still may exhibit a
neuroprotective effect leading to increased longevity.
The largest change in any single phospholipid of the human hippocampus occurred in
mitochondrial PC 16:0_18:1, the predominant phospholipid present in the mitochondrial
membranes (Figure 5-7). Mitochondrial PC 16:0_18:1 increased from 40.8% of total
mitochondrial PC to 42.5% from ages 20 to 100, representing a 4% increase in initial
abundance over the 80 year period (Figure 5-4, Table 5-2). In the previous chapter, we
also saw age-related increases in mitochondrial PC 16:0_18:1 within the prefrontal
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cortex. As discussed in Chapter 4 section 4.3, the role of this particular molecular
phospholipid is largely unknown; however, its high abundance could suggest a
structural or scaffolding role in cellular membranes. Evidence is also available that
suggests a role for PC 16:0_18:1 in modulating membrane fluidity [192,193], as well as
participating in the formation of lipid raft domains [201].
Two previous studies have examined changes in the phospholipids of the human
hippocampus during normal ageing. Similar to the present study, Söderberg et al. [90]
reported decreases in total protein concentration (mg/g of wet tissue) in the human
hippocampus with age. However, unlike this thesis Söderberg et al. [90] did not perform
a fractionation step and so was unable to pinpoint the loss of protein with age to a
particular subcellular fraction (Figure 5-2). Both studies by Söderberg et al. [90,93]
reported decreases with age in the concentration of total phospholipids (mg/g wet
tissue) in the hippocampus from ages 50-60 years, a finding that was not seen in this
region in the present thesis. Between the two studies by Söderberg et al. there were
conflicting results for age-related changes to phospholipid classes. Söderberg et al. [90]
reported no changes in concentration to either total PC or PE with age in the
hippocampus, while Söderberg et al. [93] found age-related decreases in both total PC
and PE. In the present chapter, no changes with age were seen for any phospholipid
class, either in percent abundance or quantified amount. Söderberg et al. [93] also
examined changes in hippocampal PC and PE fatty acids with no age-related changes
with age being found.
In summary, there were several phospholipids containing either adrenic acid or AA that
decreased with age in the mitochondrial and microsomal membranes of the human
hippocampus. The most abundant phospholipid of this type was PE 18:0_22:4 in both
membrane fractions, which decreased by approximately 13-18% in abundance from
ages 20 to 100. Analysis of total fatty acids found that both adrenic acid and AA
decreased with age in the combined phospholipids in both membrane fractions, but no
age-related changes were seen specifically in the PE class for either fatty acid. Similar
to our previous finding for the human prefrontal cortex in Chapter 4, significant agerelated increases were seen in mitochondrial PS 18:0_22:6 within the hippocampus.
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Chapter 6 The Entorhinal Cortex
The following chapter is an amended version of the manuscript submitted for
publication: Hancock SE, Friedrich MG, Mitchell TW, Truscott RJW, Else PL
(2015), “The phospholipid composition of the human entorhinal cortex remains
relatively stable over 80 years of adult aging”.

6.1 Introduction
This chapter will examine the changes seen during normal ageing in PC, PE and PS
phospholipids present in the mitochondrial and microsomal membranes of the
entorhinal cortex.
The entorhinal cortex is located in the medial temporal lobe in the anterior portion of
the parahippocampal gyrus, and is considered to be the interface between the
hippocampal formation and the neocortex (see Chapter 1, Figure 1-2). Within the
hippocampal formation, there are circuits of interconnected neurons between the layers
of the entorhinal cortex and regions of the hippocampus that form the perforant pathway
involved in encoding episodic memory [202]. There is some disagreement in the
literature as to whether this region is subject to significant age-related changes during
normal ageing, with some studies finding significant declines in volume with age
[17,19] while others have reported no age-related changes [203]. The entorhinal cortex
also undergoes a loss in volume during the earliest stages of AD [203–205]. Both the
Aβ plaques and tau NFTs characteristic of AD appear in this region in early stages of
the disease [7]. Despite the significant changes occurring in the entorhinal cortex in AD
surprisingly few studies have looked at alterations to phospholipid composition
specifically in the entorhinal cortex [116], although others have examined the entire
parahippocampal gyrus [121,123]. To date, there have been no studies conducted that
test if any changes occur in the phospholipids of this region during normal ageing.
Therefore, the aim of this chapter was to characterise the age-related changes occurring
to the phospholipid composition of the mitochondrial and microsomal membranes of the
human entorhinal cortex.
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6.2 Results
6.2.1

Age-related changes to total protein content in subcellular fractions

No changes with age in total protein concentration (mg/g tissue) were seen in the whole
tissue homogenate, or in the mitochondrial and microsomal membranes.
6.2.2

Major phospholipid classes of mitochondrial and microsomal fractions

Each of the three phospholipids classes measured in this study (PC, PE and PS) reported
as a fraction of total phospholipid detected in the mitochondrial and microsomal
membranes are shown in Figure 6-1. The most abundant of the three phospholipid
classes in both membrane fractions was PC, making up around 50% of the total
phospholipids detected, followed by PE at 30% and PS at just under 20%.
When the percent composition of each phospholipid class was compared with each
fraction, the mitochondria contained slightly less PC compared to the microsomes (p <
0.05), and slightly more PE (p < 0.001). No differences were seen in PS content
between the fractions. The quantified amounts of each phospholipid class (as pmol of
phospholipid/µg membrane protein) were also analysed, with approximately 20% more

Figure 6-1: Percent composition of the three major phospholipid classes within the
mitochondrial (left) and microsomal (right) fractions in normal human entorhinal
cortex. Values are the mean ± SEM for the entire cohort. The microsomal membranes
showed significantly higher amounts of total phosphatidylcholine (PC) compared to
mitochondria (p < 0.05, Wilcoxon signed-rank test), while the mitochondria contained
more phosphatidylethanolamine (PE) (p < 0.001, Wilcoxon signed-rank test). There
were no differences between fractions for phosphatidylserine (PS).
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Figure 6-2: Phospholipid classes changing significantly with age (as a percent of total
phospholipid) in normal human entorhinal cortex (n = 36). Regression model was
adjusted for sex: males (●), females (○). Regression parameters are shown in Table 6-1.

Table 6-1: Phospholipid classes changing significantly with age in the normal human
entorhinal cortex
95% CI
β
df
t
P value
Lower
Upper
Percent composition (% total phospholipid)
Mitochondrial PC
0.0700 0.0061
0.1339
0.394 2,33
2.232 0.033*
Mitochondrial PE
-0.0487 -0.0953 -0.0019 -0.367 2,33
-2.122 0.042*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. * P <0.05
Phospholipid

Slope
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PC, PS and total phospholipid being present in the microsomal fraction (p < 0.01, data
not shown).
Regressions with age were carried out for each of the phospholipids classes in both the
mitochondrial and microsomal membranes. Mitochondrial PC increased by 12% in
abundance over the 80 years (Figure 6-2, Table 6-1). Conversely, mitochondrial PE
declined by 11% in abundance from ages 20 to 100. No changes with age were reported
for any of the quantified phospholipid classes (as pmol of phospholipid/µg membrane
protein) in either membrane fraction, including total mitochondrial and microsomal
phospholipid.
6.2.3

Changes in mitochondrial phospholipids with age

6.2.3.1 Phosphatidylcholines
The composition of PC, PE and PS phospholipids detected in the mitochondrial
membranes of the entorhinal cortex can be seen in Figure 6-3. A significant age-related
increase was found for the most abundant phospholipid of the mitochondrial fraction:
PC 16:0_18:1 (Figure 6-4, Table 6-2). PC 16:0_18:1 increased from 42% of total
mitochondrial PC at age 20 to 44% at age 100. Due to the high abundance of this
phospholipid, this represents one of the largest age-related changes for any single
mitochondrial phospholipid in the human entorhinal cortex.
Only one other mitochondrial PC increased with age in its percent composition, PC
16:0_18:2, which increased in abundance by 73% across the 80 years. However, this
phospholipid is relatively low in abundance, making up only 0.5% of total
mitochondrial PC. Only PC 16:0_18:2 maintained its age-related increase when
analysed as quantified data (pmol of phospholipid/µg membrane protein, Table 6-3).
6.2.3.2 Phosphatidylethanolamines
A total of six mitochondrial PEs increased in abundance over the 80 year period studied
when expressed as a percent of total PE (Figure 6-5, Table 6-2). Four of these
phospholipids contained a 22:6 fatty acid: PE 16:0_22:6, PE 18:1_22:6, PE O18:1_22:6, and PE 17:0_22:6/O-18:0_22:6. Only three mitochondrial PEs containing a
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Figure 6-3: Phospholipids detected within PC, PE and PS in the mitochondrial fraction
of human entorhinal cortex (as a percent of total phospholipid within each class).
Phospholipids were quantified as described in materials and methods. Values are mean
across the cohort ± SEM.
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Figure 6-4: Mitochondrial PCs changing significantly with age (as a percent of total PC)
in normal human entorhinal cortex (n = 30-36). Regression model was adjusted for sex:
males (●), females (○). Regression parameters are shown in Table 6-2.
22:6 fatty acid did not show any age-related increases. These were lyso-PE 22:6, PE
15:0_22:6/O-16:0_22:6 and PE 18:0_22:6, the most abundant PE present in the
mitochondria (Figure 6-3).
PE 16:0_22:6 is the fourth-most abundant mitochondrial PE, comprising just under 6%
of total mitochondrial PE (Figure 6-3) and 1.8% of total mitochondrial phospholipid.
An increase of 17% in abundance was observed for this phospholipid over the 80 year
period (Figure 6-5, Table 6-2). Of the remaining 22:6-containing mitochondrial PEs, PE
18:1_22:6 increased by 18%, PE O-18:1_22:6 by 15%, and PE 17:0_22:6/O-18:0_22:6
by 251% from ages 20 to 100. Though seemingly large increases in abundance were
seen in PE 17:0_22:6/O-18:0_22:6 with age, this phospholipid is of low abundance in
the mitochondria, making up only 0.7% of total mitochondrial PE (Figure 6-3). Aside
from these age-related increases seen in 22:6-containing PEs, two other mitochondrial
PEs increased with age in their percent composition: PEs 16:0_18:1 (25%), 16:0_20:1
(30%) (Figure 6-5, Table 6-2).
Only PE 17:0_22:6/O-18:0_22:6 maintained an increase with age when analysed as a
quantified amount (pmol of phospholipid/µg membrane protein, Table 6-3). Two other
mitochondrial PEs decreased in quantified amount with age in the human entorhinal
cortex, PE 18:0_22:4 and PE O-18:1_22:4.
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Table 6-2: Mitochondrial phospholipids (percent of phospholipid within phospholipid
class) changing significantly with age in the human entorhinal cortex.

Phospholipid

Slope

95% CI
Lower Upper

β

df

t

P value

Phosphatidylcholine
0.0086 0.0511
PC 16:0_18:1
0.0298
0.482 2,32
2.861 0.007**
0.0023 0.0111
PC 16:0_18:2
0.0067
0.547 2,29
3.131 0.004**
Phosphatidylethanolamine
0.0022 0.0161
PE 16:0_18:1
0.0091
0.470 2,31
2.690 0.011*
PE 16:0_20:1
0.0026 0.000003 0.0053
0.386 2,27
2.054 0.0498*
0.0020 0.0197
PE 16:0_22:6
0.0109
0.450 2,31
2.505 0.018*
0.0009 0.0089
PE 18:1_22:6
0.0049
0.452 2,30
2.511 0.018*
PE 17:0_22:6
0.0085
0.0029 0.0141
0.612 2,26
3.116 0.004**
/O-18:0_22:6
PE O-18:1_22:6
0.0033 0.00002 0.0067
0.328 2,32
2.051 0.0485*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. * P <0.05 ** P <0.01

Table 6-3: Quantified mitochondrial phospholipids (pmol/µg total membrane protein)
changing significantly with age in the human entorhinal cortex.
Phospholipid

Slope

95% CI
Lower Upper

β

df

t

P value

Phosphatidylcholine
0.0030 0.0246
PC 16:0_18:2
0.0138
0.483 2,32
2.614 0.014*
Phosphatidylethanolamine
PE 18:0_22:4
-0.0502 -0.0882 -0.0123 -0.488 2,33
-2.702 0.011*
PE 17:0_22:6
0.0099
0.0010 0.0188
0.482 2,30
2.297 0.030*
/O-18:0_22:6
PE O-18:1_22:4
-0.0085 -0.0165 -0.0005 -0.384 2,33
-2.160 0.038*
Phosphatidylserine
PS 18:0_22:4
-0.0253 -0.0484 -0.0022 -0.404 2,33
-2.226 0.033*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. * P <0.05
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Figure 6-5: Mitochondrial PEs changing significantly with age (as a percent of total PE)
in normal human entorhinal cortex (n = 30-36). Regression model was adjusted for sex:
males (●), females (○). Regression parameters are shown in Table 6-2.
6.2.3.3 Phosphatidylserines
No PS phospholipids changed with age in either percent abundance (percent of total PS)
or quantified amount (pmol phospholipid/µg membrane protein) in the mitochondrial
fraction.
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6.2.4
6.2.4.1

Changes in microsomal phospholipids with age
Phosphatidylcholines

The percent composition of each microsomal phospholipid within PC, PE and PS can be
seen in Figure 6-6. There were three microsomal PCs observed to undergo age-related
changes, all of which increased in abundance (Figure 6-7, Table 6-4). The most
abundant of these was PC 18:1_18:1, a phospholipid that is found in moderate amounts
in the microsomal membranes of the human entorhinal cortex (Figure 6-6). PC
18:1_18:1 increased from 2.7% of microsomal PC to 3.6% from ages 20 to 100 (Figure
6-7, Table 6-4). The remaining two microsomal PCs increasing in abundance with age
were PC 14:0_16:0 and PC 15:0_16:0/O-16:0_16:0, which rose by 23% and 38% in
abundance over the 80 year period. However, both of these phospholipids are only of
low abundance making up less than 1% of the total microsomal phospholipid when
combined.
No age-related changes were observed for the quantified microsomal PC phospholipids
(pmol phospholipid/µg membrane protein) in the entorhinal cortex.
6.2.4.2 Phosphatidylethanolamines
Analysis of the microsomal PEs of the entorhinal cortex found three phospholipids that
changed with age (Figure 6-8, Table 6-4). Two of these phospholipids increased with
age, PE 18:1_22:6 and PE 16:0_22:5, by 28% and 25% in abundance respectively over
the 80 years. PE 16:0_20:1 decreased by 22% in abundance over the same period. All
three phospholipids are of low abundance in the microsomal membranes, however,
making up less than 1.4% of the total microsomal phospholipid when combined (Figure
6-6).
Only a single microsomal PE changed with age when quantified phospholipids (pmol
phospholipid/µg membrane protein) were analysed (Table 6-5). PE 18:1_22:4 increased
from 2.0 pmol/µg membrane protein at age 20 to 2.6 pmol phospholipid/µg membrane
protein at age 100.
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Figure 6-6: Phospholipids detected within PC, PE and PS in the microsomal fraction of
human entorhinal cortex (as a percent of total phospholipid within each class).
Phospholipids were quantified as described in materials and methods. Values are mean
across the cohort ± SEM.
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Figure 6-7: Microsomal PCs changing significantly with age (as a percent of total PC)
in normal human entorhinal cortex (n = 30-36). Regression model was adjusted for sex:
males (●), females (○). Regression parameters are shown in Table 6-4.
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Table 6-4: Microsomal phospholipids (percent of phospholipid within phospholipid
class) changing significantly with age in the human entorhinal cortex.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
0.0002 0.0058
PC 14:0_16:0
0.0030
0.400 2,32
2.168 0.038*
0.0020 0.0211
PC 18:1_18:1
0.0115
0.443 2,32
2.452 0.020*
PC 15:0_16:0
0.0021
0.0008 0.0033
0.570 2,31
3.271 0.003**
/O-16:0_16:0
Phosphatidylethanolamine
PE 16:0_20:1
-0.0029 -0.0055 -0.0003 -0.456 2,24
-2.273 0.032*
0.0006 0.0080
PE 16:0_22:5
0.0043
0.409 2,28
2.395 0.024*
0.0024 0.0115
PE 18:1_22:6
0.0069
0.517 2,31
3.096 0.004**
Phosphatidylserine
PS 18:0_22:4
-0.0203 -0.0382 -0.0023 -0.418 2,32
-2.301 0.028*
PS 18:1_20:1
0.0071
0.0011 0.0131
0.440 2,32
2.421 0.021*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. * P <0.05 ** P <0.01

Table 6-5: Quantified microsomal phospholipids (pmol/µg total membrane protein)
changing significantly with age in the human entorhinal cortex.

Phospholipid

Slope

95% CI
Lower Upper

β

df

t

P value

Phosphatidylethanolamine
PE 18:1_22:4
0.0264 0.0020 0.0508 0.413 2,29
2.216 0.035*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. * P <0.05
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Figure 6-8: Microsomal PEs changing significantly with age (as a percent of total PE) in
normal human entorhinal cortex (n = 30-36). Regression model was adjusted for sex:
males (●), females (○). Regression parameters are shown in Table 6-4.
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6.2.4.3 Phosphatidylserines
Only two PS phospholipids changed with age in the microsomal fraction: PS 18:0_22:4
and PS 18:1_20:1 (Figure 6-9, Table 6-4). PS 18:0_22:4, a moderately abundant
phospholipid making up 7% of microsomal PS (Figure 6-6) and 1.4% of total
microsomal phospholipids, decreased in percent composition by 20% from ages 20 to
100 (Figure 6-8, Table 6-4). PS 18:1_20:1 increased its percent composition, by 180%
over the 80 year period. While a seemingly large increase with age, PS 18:1_20:1 is
only found in low amounts in microsomal membranes, making up only 0.7% of
microsomal PS (Figure 6-6).
No microsomal PS changed in quantified amount (pmol phospholipid/µg membrane
protein) with age in the human entorhinal cortex.

Figure 6-9: Microsomal PSs changing significantly with age (as a percent of total PS) in
normal human entorhinal cortex (n = 30-36). Regression model was adjusted for sex:
males (●), females (○). Regression equations are presented in Table 6-4.
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6.3 Discussion
In the present chapter, a number of phospholipids underwent changes in the
mitochondrial and microsomal membranes of the human entorhinal cortex during
normal ageing. Similar to what was reported for the prefrontal cortex (Chapter 4) and
hippocampus (Chapter 5), the changes observed in the entorhinal cortex were not
limited to a particular class of phospholipid, nor were they limited to either the
mitochondrial or microsomal fraction. Many age-related increases were seen
specifically in mitochondrial PE phospholipids containing a 22:6 fatty acid (DHA), a
finding similar to that previously reported in the prefrontal cortex (Chapter 4) and, to a
lesser extent, the hippocampus (Chapter 5).
The most interesting age-related change in the phospholipids of the entorhinal cortex
was found within the mitochondrial PE phospholipids. Four of the six mitochondrial
PEs that changed significantly in percent composition with age contained a DHA: PE
16:0_22:6, PE 18:1_22:6, PE O-18:1_22:6, and PE 17:0_22:6/O-18:0_22:6 (Figure 6-5,
Table 6-2). There were only three PE phospholipids containing a 22:6 fatty acid that did
not change with age in the mitochondrial fraction: lyso-PE 22:6, PE 15:0_22:6/O16:0_22:6 and the most abundant mitochondrial PE, PE 18:0_22:6. As discussed in
previous chapters, the 22:6 fatty acid can be putatively classified as the n-3 fatty acid
DHA based on its synthesis via the elongation and desaturation pathway (see Chapter 2,
Figure 2-4) [56]. DHA is the most abundant n-3 fatty acid present in the brain; other n-3
fatty acids such as 20:5 (EPA) are typically only found in trace amounts in the human
brain. Indeed, no phospholipids with this fatty acid were found in any of the three
regions examined so far. DHA has a number of important biological roles in neuronal
cellular membranes, including neurite growth, membrane fluidity, synaptic transmission
and the production of anti-inflammatory eicosanoids [77]. The importance of
phospholipids containing DHA with a PS head group in neuron survival and longevity
was discussed previously in Chapter 4, but no changes with age to PS 18:0_22:6 were
observed in the entorhinal cortex in either membrane fraction. Conversely, the specific
cellular role of PE phospholipids containing DHA is widely unknown. The only
available evidence suggests a role for some PE-DHA fatty acids as preferential
precursors for the synthesis of PS-DHA phospholipids via PSS2 [46]. PSS2 is located in
the mitochondria-region of the endoplasmic reticulum and is highly expressed in both
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brain and testes in mammals. Increases in PS synthesis via serine-base exchanges have
been reported in aged rats in the cerebellum and cerebral cortex, both with and without
the addition of exogenous calcium [47]; however, if this also occurs in humans then we
would expect levels of PE-DHA to decrease with age with a corresponding increase in
PS-DHA. More research is needed to elucidate the mechanism and significance of PEDHA phospholipids increasing with age in this region of the brain.
Due to the number of mitochondrial PEs containing DHA increasing in their percent
composition with age, additional analysis was carried out to examine if any changes
with age occurred to the most abundant PUFA across both the mitochondrial (Table
6-6) and microsomal membranes (Table 6-7). Surprisingly no age-related changes were
seen in DHA in any of the phospholipid classes in the mitochondrial membranes despite
the finding that many mitochondrial PEs containing DHA increased with age (Table
6-6). Examination of individual mitochondrial PE phospholipids showed that the lack of
age-related changes to total PE-DHA could be attributed to a lack of age-related
changes in the most abundant mitochondrial PE phospholipid, PE 18:0_22:6. This PE
makes up 31% of total mitochondrial PE (Figure 6-3), which is nearly three times the
combined amount of the four mitochondrial PE-DHA phospholipids that increased with
age. Interestingly there were also decreases reported for total mitochondrial PC-22:4
fatty acids with age despite no single mitochondrial PC with a 22:4 fatty acid changing
significantly with age (Figure 6-4). These results emphasise that significant age-related
changes in specific phospholipids may be masked by examining fatty acids in isolation
using techniques such as GC.
The phospholipid that underwent one of the largest age-related changes in the entorhinal
cortex was mitochondrial PC 16:0_18:1, the most abundant phospholipid present in this
fraction (Figure 6-3). While only a 6% increase in abundance was found for PC
16:0_18:1 over the 80 year period (Figure 6-4, Table 6-2), this phospholipid comprises
approximately 42% of total mitochondrial PC (Figure 6-3) and 21% of total
mitochondrial phospholipids, making this one of the largest changes in membrane
composition reported in this region. A similar age-related change in the abundance of
PC 16:0_18:1 was reported in the mitochondria of the prefrontal cortex (Chapter 4)
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Table 6-6: Linear regression of most abundant polyunsaturated fatty acids (percent of
total fatty acids within phospholipid class) in the mitochondrial membranes with age in
human entorhinal cortex
95% CI
Mitochondrial
Slope
β
fatty acids
Lower
Upper
Combined phospholipids
-0.0148
0.0069 -0.144
20:4
-0.0039
-0.0256 -0.0034 -0.441
22:4
-0.0145
-0.0338 -0.0031 -0.417
20:4 + 22:4
-0.0184
-0.0250
0.0228 -0.019
22:6
-0.0011
Phosphatidylcholine
-0.0108
0.0094 -0.028
20:4
-0.0007
-0.0191 -0.0004 -0.387
22:4
-0.0098
-0.0200 -0.0010 -0.400
20:4 + 22:4
-0.0105
-0.0051
0.0026 -0.130
22:6
-0.0013
Phosphatidylethanolamine
-0.0219
0.0161 -0.061
20:4
-0.0029
-0.0369
0.0101 -0.216
22:4
-0.0134
-0.0448
0.0121 -0.222
20:4 + 22:4
-0.0163
-0.0080
0.0482
22:6
0.0202
0.278
Phosphatidylserine
-0.0025
0.0097
20:4
0.0036
0.231
-0.0206
0.0017
22:4
-0.0095
-0.321
-0.0160
0.0042 -0.219
20:4 + 22:4
-0.0059
-0.0418
0.0128
22:6
0.0432
0.196
Fatty acids calculated from phospholipid molecular species
adjusted for gender. * P <0.05 ** P <0.01 *** P <0.001

df

t

P value

2,32
2,32
2,32
2,32

-0.739
-2.653
-2.447
-0.096

0.465
0.012*
0.020*
0.924

2,31
2,32
2,31
2,32

-0.140
-2.129
-2.264
-0.665

0.889
0.041*
0.031*
0.511

2,32
2,32
2,32
2,32

-0.310
-1.162
-1.168
1.460

0.758
0.254
0.252
0.154

2,31
1.197 0.240
2,31
-1.722 0.094
2,31
-1.183 0.245
2,30
1.034 0.308
data. Regression was
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Table 6-7: Linear regression of most abundant polyunsaturated fatty acids (percent of
total fatty acids within phospholipid class) in the microsomal membranes with age in
human entorhinal cortex
95% CI
Mitochondrial
Slope
β
df
fatty acids
Lower
Upper
Combined phospholipids
0.0037 -0.239 2,32
20:4
-0.0056 -0.0149
0.0026 -0.260 2,32
22:4
-0.0056 -0.0138
0.0028 -0.307 2,32
20:4 + 22:4
-0.0112 -0.0252
0.0247 -0.012 2,32
22:6
-0.0008 -0.0262
Phosphatidylcholine
0.0072 -0.092 2,31
20:4
-0.0021 -0.0114
0.0008 -0.314 2,30
22:4
-0.0027 -0.0062
0.0075 -0.104 2,32
20:4 + 22:4
-0.0027 -0.0128
-0.0046
0.0045 -0.002 2,32
22:6
-0.00003
Phosphatidylethanolamine
0.0051 -0.270 2,32
20:4
-0.0145 -0.0341
0.0088 -0.136 2,30
22:4
-0.0051 -0.0190
-0.0354
0.0177 -0.134 2,32
20:4 + 22:4
-0.0089
0.0422
22:6
0.0152 -0.0118
0.220 2,32
Phosphatidylserine
0.0065 -0.041 2,32
20:4
-0.0007 -0.0080
-0.0230
-0.0020
22:4
-0.0125
-0.440 2,32
20:4 + 22:4
-0.0132 -0.0233 -0.0031 -0.476 2,32
0.1157
22:6
0.0319 -0.0520
0.148 2,32
Fatty acids calculated from phospholipid molecular species data.
adjusted for gender. * P <0.05 ** P <0.01 *** P <0.001

t

P value

-1.235
-1.383
-1.632
-0.060

0.226
0.176
0.113
0.952

-0.470
-1.586
-0.537
-0.012

0.641
0.123
0.595
0.990

-1.506
-0.750
-0.680
1.148

0.142
0.459
0.501
0.259

-0.207 0.837
-2.417 0.022*
-2.660 0.012*
0.774 0.445
Regression was
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and the hippocampus (Chapter 5). As discussed previously in Chapter 4 and Chapter 5,
the function of this particular phospholipid is currently unknown, but its high abundance
in both the mitochondrial and microsomal membranes suggests a structural role.
However, it has been hypothesised that this particular phospholipid could play a role in
modulating the fluidity of the membrane bilayer [192,193] as well as participate in the
formation of lipid rafts [201].
Despite reports of decreases in the volume of the entorhinal cortex during normal
ageing [17,19] there have been no published studies to date that have examined agerelated changes to the phospholipids of this region, which prevent any comparisons
being made with this study. The entorhinal cortex has also not been extensively studied
for changes in membrane phospholipids in AD despite this region displaying losses in
volume and significant tau and Aβ deposition in the early to mid-stages of the disease
[203–205]. Only one study has specifically examined the entorhinal cortex for any
changes its phospholipids in AD, finding no changes in either total PC, PE or PS
phospholipid [116]. However, a further two other studies have examined the entire
parahippocampal gyrus, looking at total phospholipid-fatty acids [121] and fatty acids
separated by phospholipid class [123]. Skinner et al. [121] reported increases in total
18:1 and 22:4 in AD, with no changes being reported for DHA. Conversely, Prasad et
al.

[123]

observed

decreases

in

several

PE-fatty

acids

in

the

hippocampus/parahippocampal gyrus, including both AA and DHA. Although the
current evidence is relatively sparse, if the loss of PE-DHA in the entorhinal cortex and
greater parahippocampal gyrus is indeed indicative of AD then the rise in several PE
phospholipids containing DHA seen in the present chapter during normal ageing in the
entorhinal cortex could be protective against the disease. More extensive research will
be needed to see if there is a substantial loss of DHA in AD specifically in the
entorhinal cortex to confirm this hypothesis.
In summary, there were many age-related increases seen in the entorhinal cortex in both
the mitochondrial and microsomal membranes, including the rise of several
mitochondrial PE phospholipids containing DHA. These PE-DHA phospholipids
included PE 16:0_22:6, PE 18:1_22:6, PE O-18:1_22:6, and PE 17:0_22:6/O18:0_22:6; however, the most abundant DHA-containing mitochondrial PE, PE
18:0_22:6, did not change with age. These contralateral changes in mitochondrial PEs
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containing DHA led to no significant age-related changes being observed overall for
total mitochondrial PE-DHA. Out of the three regions analysed so far, the entorhinal
cortex has displayed the fewest number of changes to phospholipids during normal,
adult ageing in both the mitochondrial and microsomal membranes.
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Chapter 7 The Cerebellum
7.1 Introduction
This chapter will examine age-related changes in PC, PE and PS phospholipids in the
mitochondrial and microsomal membranes of the human cerebellum.
Latin for the “the little brain”, the cerebellum is located at the bottom of the brain (see
Chapter 1, Figure 1-2) and has a primary role in the coordination and precision of motor
activity The cytoarchitecture of the cerebellum consists of three layers: a superficial
molecular layer, a layer of Purkinje cells and a granular layer comprised of small,
densely-packed granular cells. The cerebellum is thought to be largely spared during the
pathogenesis of AD, with only small amounts of Aβ plaques characteristic of the
disease being found in the molecular layer of the cerebellum [206,207]. The NFTs also
characteristic of AD are largely absent in the cerebellum in affected individuals
[206,207]. Likewise, many studies examining changes in phospholipids within the
cerebellum during the pathogenesis of AD have found few to no changes as a result of
the disease [85,111,112,115,116,123]. A recent stereological study found no changes in
either Purkinje or granule cell number or density in AD, but a significant reduction in
total cerebellar volume was seen in the AD group [208]. Due to the small amount of
reported changes in the cerebellum in AD described above this region is often used as a
control brain region.
Significant losses in cerebellar volume have also been reported during normal ageing,
particularly in advanced age, using both stereological and in vivo imaging techniques
[209]. Despite these reported changes, only a single study has looked at any changes to
membrane lipids with age [90]. Söderberg et al. [90] found no changes during normal
ageing in the levels of total phospholipid, PC or PE. Therefore, the aim of this chapter
was to identify if any changes are occurring to the molecular phospholipids of the
mitochondrial and microsomal membranes of the human cerebellum during normal
ageing.
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7.2 Results
7.2.1

Changes in total protein concentration during normal ageing

The total protein content (mg/g wet tissue) of both the mitochondrial and microsomal
fractions declined significantly with age (Figure 7-1, Table 7-1). Mitochondrial protein
concentration fell by 54%, decreasing from 7.9 to 3.7 mg protein/g wet tissue from ages
20 to 100, while microsomal protein decreased from 1.5 to 0.9 mg/g wet tissue, a loss of
38%. The concentration of total protein within the whole tissue showed a trend towards
decreased abundance with advanced age, but this failed to reach statistical significance
(p = 0.076).
7.2.2

Major phospholipid classes of mitochondrial and microsomal fractions

The proportion of PC, PE and PS detected in the mitochondrial and microsomal
fractions (as a percent of total phospholipid) is shown in Figure 7-2. The most abundant
phospholipid class present in the two membrane fractions was PC, which comprised
around 45% of total phospholipids in the two fractions, followed by PE at
approximately 35% of total phospholipids and PS at 20%. The microsomal membranes
contained more PC than the mitochondrial (p < 0.001) while the mitochondrial
membranes contained more PE and PS (p < 0.001). The quantified amount (pmol/µg
membrane protein) of each phospholipid in all three classes was also analysed, with
higher levels of total PC (p < 0.01) , PE and PS (p < 0.001) found in the mitochondria,
as well as higher levels of total quantified phospholipid (p < 0.001). Each phospholipid
class was also assessed for any changes with age in both the mitochondrial and
microsomal membranes, with no age-related effect found in either membrane fraction
for any phospholipid class measured as percent abundance (% total phospholipid) or as
quantified phospholipids (pmol phospholipid/µg membrane protein). Likewise, no
statistically significant changes with age were found in either membrane fraction for
total quantified phospholipid.
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Figure 7-1: Linear regression of total protein amount (mg/g wet tissue) measured in
whole tissue homogenate and subcellular fractions derived from normal human
cerebellum against age. Total protein was measured using BCA assay as described in
methods and materials. Regression model was adjusted for sex: males (●), females (○).
T
indicates dependent variable transformed for linear regression, with transformed betacoefficient and p-value reported on original scatterplot for comparison. Regression
parameters are shown in Table 7-1.
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Table 7-1: Significant linear regression results of total protein (mg/g of tissue) with age
in the subcellular fractions of neurologically normal human cerebellum

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Whole tissue
-0.00002 -0.00005 -0.0000002 -0.331 2,33
-1.833 0.076
homogenateI
-0.0155 -0.472 2,33
Mitochondria
-0.0534 -0.0913
-2.865 0.007**
-0.0018 -0.462 2,33
Microsomes
-0.0072 -0.0126
-2.708 0.011*
Total protein amount measured using BCA Assay. Regression was adjusted for gender.
Superscript indicates dependent variable transformed for linear regression, with
transformed regression output reported: I reciprocal. * P <0.05 ** P <0.01

Figure 7-2: Relative percentage contribution of the three major phospholipid classes
within the mitochondrial (left) and microsomal (right) fractions in neurologically
normal cerebellum. Values are the mean ± SEM for the entire cohort. The microsomal
membranes showed significantly higher amounts of total phosphatidylcholine (PC)
compared to mitochondria (p < 0.001, Wilcoxon signed-rank test), while the
mitochondria contained more phosphatidylethanolamine (PE) (p < 0.001, Wilcoxon
signed-rank test) and phosphatidylserine (PS) (p<0.001, Wilcoxon signed-rank test).
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7.2.3

Changes in mitochondrial phospholipids with age

7.2.3.1 Phosphatidylcholines
The percent composition of all phospholipids detected in the mitochondrial membranes
is shown in Figure 7-3. Four mitochondrial PCs underwent statistically significant
changes with age in the human cerebellum (Figure 7-4, Table 7-2). The most abundant
mitochondrial PC to change with age was PC 16:0_22:6, which increased from 3.6% of
total mitochondrial PC at age 20 to 4.3% at 100 years of age. This represents an
increase of 20% from its initial abundance. Only one other mitochondrial PC showed an
age-related increase, PC 16:0_18:2, which rose by 39% in abundance over the 80 year
period. However, PC 16:0_18:2 is only of low abundance in the mitochondrial
membranes, comprising only 1.1% of mitochondrial PC (Figure 7-3) and 0.5% of total
mitochondrial phospholipid.
The remaining statistically significant mitochondrial PCs decreased with age as follows:
PC 16:0_22:4 by 25%, and PC 16:0_20:1 by 27% over the 80 year period (Figure 7-4,
Table 7-2). PC 16:0_22:4 is a moderately abundant phospholipid, comprising 2.9% of
mitochondrial PC, while PC 16:0_20:1 is of lower abundance making up less than 1.5%
of mitochondrial PC (Figure 7-3). Of these four mitochondrial PCs only PC 16:0_18:2
maintained its increase with age when analysed as quantified amount (pmol
phospholipid/µg membrane protein; Table 7-3).
7.2.3.2 Phosphatidylethanolamines
Within the mitochondria, eleven PEs changed in percent composition with age (Figure
7-5, Table 7-2). The mitochondrial PE with the largest age-related change was PE
18:0_22:6, the most abundant PE present in the mitochondria (Figure 7-3).
Mitochondrial PE 18:0_22:6 increased from 26.0% of total mitochondrial PE to 31.5%
over the 80-year period. Four other mitochondrial PEs containing a 22:6 fatty acid also
increased with age: PE 16:0_22:6, PE 18:1_22:6, PE O-18:1_22:6 and PE 15:0_22:6/O16:0_22:6 (Figure 7-5, Table 7-3). PE 16:0_22:6, the third-most abundant mitochondrial
PE, increased by 34% in percent composition from ages 20 to 100. Both PE 18:1_22:6
and O-18:1_22:6 are moderately abundant phospholipids (Figure 7-3) that increased by
33% and 22% in abundance respectively over the 80 year period (Figure 7-5, Table
7-2). PE 15:0_22:6/O-16:0_22:6 more than tripled in abundance from ages 20 to 100,
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Figure 7-3: Phospholipids detected within PC, PE and PS in the mitochondrial fraction
of human cerebellum (as a percent of total phospholipid within each class).
Phospholipids were quantified as described in materials and methods. Values are mean
across the cohort ± SEM.
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Figure 7-4: Mitochondrial PCs changing significantly with age (as a percent of total PC)
in normal human cerebellum (n = 33-35). Regression model was adjusted for sex:
males (●), females (○). T indicates dependent variable transformed for linear regression,
with transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 7-2.
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Table 7-2: Mitochondrial phospholipids (percent of phospholipid within phospholipid
class) changing significantly with age in the human cerebellum.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
0.0004
0.0086
PC 16:0_18:2
0.0045
0.412 2,31
2.218 0.034*
-0.0002 -0.410 2,30
PC 16:0_20:1
-0.0053 -0.0104
-2.126 0.042*
I
PC 16:0_22:4
-0.0010 -0.0019 -0.00003 -0.391 2,32
-2.102 0.044*
0.0019
0.0164
PC 16:0_22:6
0.0091
0.478 2,31
2.575 0.015*
Phosphatidylethanolamine
-0.0001 -0.394 2,33
Lyso-PE 22:4
-0.0035 -0.0069
-2.116 0.042*
0.0114
0.0279
PE 16:0_22:6
0.0197
0.708 2,30
4.883 0.00003***
-0.0186
-0.0041
PE 18:0_18:1
-0.0114
-0.539 2,32
-3.205 0.003**
-0.0281 -0.600 2,32
PE 18:0_20:4
-0.0606 -0.0931
-3.799 0.0006***
PE 18:0_22:4
-0.0214 -0.0332
-0.0096 -0.616 2,33
-3.694 0.0008***
0.0132
0.1244
PE 18:0_22:6
0.0688
0.460 2,33
2.518 0.017*
0.0054
0.0158
PE 18:1_22:6
0.0106
0.606 2,33
4.122 0.0002***
PE 15:0_22:6
0.0210
0.0097
0.0323
0.669 2,32
3.785 0.0006***
/O-16:0_22:6
PE 17:0_22:4
-0.0095 -0.0157
-0.0034 -0.542 2,33
-3.171 0.003**
/O-18:0_22:4
-0.0060 -0.647 2,33
PE O-16:1_22:5
-0.0124 -0.0188
-3.936 0.0004***
0.0007
0.0123
PE O-18:1_22:6
0.0065
0.421 2,33
2.268 0.030*
Phosphatidylserine
-0.0246 -0.445 2,33
PS 18:0_18:1
-0.1269 -0.2293
-2.523 0.017*
L
-0.0015 -0.735 2,32
PS 18:0_22:4
-0.0025 -0.0036
-4.856 0.00003***
L
0.0012
0.0032
PS 18:0_22:6
0.0022
0.681 2,33
4.451 0.00009***
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: L logarithm, I reciprocal. * P
<0.05 ** P <0.01 *** P <0.001
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Table 7-3: Quantified mitochondrial phospholipids (pmol/µg membrane protein)
changing significantly with age in the human cerebellum.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
0.0024
0.0160
PC 16:0_18:2
0.0092
0.494 2,31
2.768 0.009**
Phosphatidylethanolamine
0.0008
PE 16:0_22:6I
0.0004 0.00004
0.422 2,31
2.243 0.032*
-0.0451
-0.0007
PE 18:0_22:4
-0.0230
-0.380 2,32
-2.101 0.044*
0.0002
0.0015
PE 18:1_22:6I
0.0008
0.473 2,33
2.642 0.013*
PE 15:0_22:6
0.0260
0.0095
0.0425
0.610 2,32
3.219 0.003**
/O-16:0_22:6
PE 17:0_22:4
-0.0106 -0.0197 -0.0015 -0.434 2,33
-2.363 0.024*
/O-18:0_22:4
PE O-16:1_22:5
-0.0122 -0.0203 -0.0042 -0.544 2,33
-3.098 0.004**
I
0.00001
0.0012
PE O-18:1_22:6
0.0006
0.388 2,33
2.079 0.046*
Phosphatidylserine
PS 18:0_22:4
-0.0237 -0.0448 -0.0026 -2.284 2,32
-2.284 0.029*
0.0585
0.3410
PS 18:0_22:6
0.1998
2.877 2,33
2.877 0.007**
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: I reciprocal.
* P <0.05 ** P <0.01
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but this phospholipid is only present in low amounts in the mitochondria (Figure 7-3).
The remaining statistically significant mitochondrial PEs all decreased in abundance
over the 80 year period. The second-most abundant mitochondrial PE, PE 18:0_20:4,
fell from 19.0% of mitochondrial PE to 14.2% from ages 20 to 100 (Figure 7-5, Table
7-2). Two moderately abundant mitochondrial PEs decreased in abundance over the 80
year period: PE 18:0_22:4 by 39% and PE 18:0_18:1 by 28%. The remaining three
mitochondrial PEs decreasing with age, PE 17:0_22:4/O-18:0_22:4, PE O-16:1_22:5
and lyso-PE 22:4 are all low abundance phospholipids, making up just over 1.0% of
total mitochondrial phospholipid when combined.
Seven of these mitochondrial PEs maintained age-related changes when examined as
quantified amount (pmol/µg membrane protein, Table 7-3). Increases with age were
seen in quantified PE 16:0_22:6, PE 18:1_22:6, PE O-18:1_226, and PE 15:0_22:6/O16:0_22:6. Phospholipids decreasing in both percent abundance and quantified amount
with age included PE 18:0_22:4, PE 17:0_22:4/O-18:0_22:4 and PE O-16:1_22:5
7.2.3.3 Phosphatidylserines
There were three mitochondrial PSs that changed significantly with age in the
cerebellum (Figure 7-6, Table 7-2). PS 18:0_22:6, the most abundant mitochondrial PS
(Figure 7-3), increased considerably from 34.3% of total mitochondrial PS to 51.4%
from ages 20 to 100 (Figure 7-6, Table 7-2). The remaining two PS phospholipids, PS
18:0_18:1 and PS 18:0_22:4 both decreased in abundance with age in the mitochondria,
by 30% and 37% respectively over the 80 year period. PS 18:0_18:1 is the second most
abundant PS in the mitochondria, making up 28.9% of total mitochondrial PS (Figure
7-3) and 6.3% of total mitochondrial phospholipid. PS 18:0_22:4 is a moderately
abundant phospholipid, comprising approximately 6.3% of total mitochondrial PS.
Two of these three mitochondrial PSs also showed changes with age in quantified
amount (pmol/µg membrane protein; Table 7-3). PS 18:0_22:6 retained its increase with
age in the mitochondria, rising from 20.5 pmol/µg membrane protein to 36.5 pmol/µg
membrane protein from ages 20 to 100, representing a 78% increase from its initial
abundance. PS 18:0_22:4 also maintained a loss with advanced age, decreasing by 35%
in abundance over the 80 year period.
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Figure 7-5: Mitochondrial PEs changing significantly with age (as a percent of total PE)
in normal human cerebellum (n = 33-36). Regression model was adjusted for sex: males
(●), females (○). Regression parameters are shown in Table 7-2
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Figure 7-6: Mitochondrial PSs changing significantly with age (as a percent of total PS)
in normal human cerebellum (n = 35-36). Regression model was adjusted for sex: males
(●), females (○). T indicates dependent variable transformed for linear regression, with
transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 7-2.
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7.2.4

Changes in microsomal phospholipids with age

7.2.4.1 Phosphatidylcholines
All phospholipids detected in the microsomal fraction are presented as a percent of
phospholipid within each phospholipid class in Figure 7-7. There were seven
microsomal PCs that changed with age in the cerebellum, with two of these
phospholipids increasing with age (Figure 7-8, Table 7-4). The second-most abundant
phospholipid present in microsomal membranes, PC 16:0_16:0, increased from 11.8%
to 15.3% of total microsomal PC from ages 20 to 100. Only one other microsomal PC
increased with age in the cerebellum: PC 16:0_18:2. However, this phospholipid is only
of low abundance in the microsomes, making up less than 1.2% of microsomal PC
(Figure 7-7) and 0.6% of total microsomal phospholipids. PC 16:0_18:2 increased by
54% in abundance over the 80 year period studied (Figure 7-8, Table 7-4).
The remaining five phospholipids, PC 18:0_18:1, PC 16:0_22:4, PC 16:0_20:1, PC
18:1_22:6, and lyso-PC 18:1, all decreased in abundance with age (Figure 7-8, Table
7-4). PC 18:0_18:1 is the third-most abundant microsomal PC (Figure 7-7), and it
decreased by 18% from ages 20 to 100 (Figure 7-8, Table 7-4). PC 16:0_22:4, a
moderately abundant microsomal phospholipid, decreased from 2.7% of microsomal PC
to 2.1% from ages 20 to 100. The remaining three significant microsomal PCs, PC
16:0_20:1, PC 18:1_22:6 and lyso-PC 18:1 are all of low abundance within microsomal
membranes, and they decreased in abundance by 23%, 59% and 10% respectively over
the 80 year period. There were no microsomal PCs that changed significantly with age
when analysed as quantified mount (pmol phospholipid/µg membrane protein).
7.2.4.2 Phosphatidylethanolamines
There were eight microsomal PEs that changed in their percent composition with age
(Figure 7-9, Table 7-4). The most abundant PE in microsomes, PE 18:0_22:6, increased
with age, rising from 26.0% of total microsomal PE to 31.1% from ages 20 to 100.
Three other microsomal PEs containing a 22:6 fatty acid also increased with age,
including PE 16:0_22:6, PE 18:1_22:6 and PE 15:0_22:6/O-16:0_22:6. PE 16:0_22:6 is
the third-most abundant microsomal PE, making up 6.2% of microsomal PE (Figure
7-7) and 2.1% of the total microsomal phospholipid. PE 16:0_22:6 increased by 25% in
percent abundance over the 80 year period (Figure 7-9, Table 7-4). PE
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Figure 7-7: Phospholipids detected within PC, PE and PS in the microsomal fraction of
human cerebellum (as a percent of total phospholipid within each class). Phospholipids
were quantified as described in materials and methods. Values are mean across the
cohort ± SEM.
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Figure 7-8: Microsomal PCs changing significantly with age (as a percent of total PC)
in normal human cerebellum (n = 32-36). Regression model was adjusted for sex: males
(●), females (○). T indicates dependent variable transformed for linear regression, with
transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 7-4

Table 7-4: Microsomal phospholipids (percent of phospholipid within phospholipid
class) changing significantly with age in the human cerebellum.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
Lyso-PC 18:1I
-0.0007 -0.0013 -0.00004 -0.395 2,32
-2.166 0.038*
0.0147
0.0715
PC 16:0_16:0
0.0431
0.527 2,33
3.088 0.004**
0.0019
0.0102
PC 16:0_18:2
0.0061
0.521 2,32
2.980 0.005**
-0.0001 -0.399 2,31
PC 16:0_20:1
-0.0043 -0.0086
-2.089 0.045*
-0.0018 -0.446 2,29
PC 16:0_22:4
-0.0081 -0.0145
-2.608 0.014*
-0.0014 -0.402 2,32
PC 18:0_18:1
-0.0182 -0.0351
-2.203 0.035*
-0.0009 -0.469 2,33
PC 18:1_22:6
-0.0040 -0.0072
-2.620 0.013*
Phosphatidylethanolamine
-0.0017 -0.534 2,32
PE 16:0_22:4
-0.0052 -0.0088
-3.023 0.005**
0.0072
0.0269
PE 16:0_22:6
0.0171
0.597 2,30
3.550 0.001**
-0.0039 -0.530 2,33
PE 18:0_18:1
-0.0110 -0.0181
-3.125 0.004**
-0.0102 -0.502 2,33
PE 18:0_20:4
-0.0348 -0.0595
-2.872 0.007**
PE 18:0_22:4
-0.0202 -0.0335
-0.0069 -0.548 2,32
-3.094 0.004**
0.0075
0.1206
PE 18:0_22:6
0.0641
0.427 2,33
2.305 0.028*
0.0039
0.0130
PE 18:1_22:6
0.0084
0.589 2,33
3.757 0.0007***
PE 15:0_22:6
0.0099
0.0015
0.0183
0.428 2,33
2.403 0.022*
/O-16:0_22:6
Phosphatidylserine
-0.0929 -0.662 2,32
PS 18:0_18:1
-0.1699 -0.2468
-4.498 0.00008***
-0.0403
-0.0009
PS 18:0_20:1
-0.0206
-0.396 2,31
-2.136 0.041*
-0.0004 -0.472 2,27
PS 18:0_20:2L
-0.0026 -0.0047
-2.412 0.023*
L
-0.0003 -0.445 2,33
PS 18:0_22:4
-0.0018 -0.0033
-2.428 0.021*
0.1160
0.2968
PS 18:0_22:6
0.2064
0.692 2,32
4.652 0.00005***
0.0077
0.0281
PS 18:1_20:1
0.0179
0.570 2,32
3.574 0.001**
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: L logarithm, I reciprocal.
* P <0.05 ** P <0.01 *** P <0.001
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Table 7-5: Quantified microsomal phospholipids (pmol/µg membrane protein) changing
significantly with age in the human cerebellum.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylethanolamine
-0.0002 -0.398 2,30
PE 16:0_22:4
-0.0044 -0.0087
-2.139 0.041*
Phosphatidylserine
-0.0006 -0.454 2,33
PS 18:0_18:1L
-0.0031 -0.0055
-2.568 0.015*
-0.0251
-0.0033
PS 18:0_20:1
-0.0142
-0.464 2,31
-2.658 0.012*
-0.0008 -0.536 2,27
PS 18:0_20:2I
-0.0030 -0.0051
-2.834 0.009**
L
-0.0002 -0.419 2,33
PS 18:0_22:4
-0.0024 -0.0045
-2.263 0.030*
-0.0036 -0.548 2,22
PS 18:0_22:5
-0.0212 -0.0389
-2.493 0.021*
0.0002
0.0033
PS 18:1_20:1
0.0017
0.413 2,32
2.241 0.032*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: L logarithm, I reciprocal.
* P <0.05 ** P <0.01
18:1_22:6 is a moderately abundant phospholipid comprising 2.9% of microsomal PE
(Figure 7-7), and it increased in abundance by 26% from ages 20 to 100 (Figure 7-9,
Table 7-4). The final microsomal PE containing a 22:6 fatty acid that increased with
age, PE 15:0_22:6/O-16:0_22:6, showed a large increase in abundance with age of 61%.
However, this phospholipid is only present in low amounts in the microsomes
comprising less than 1.7% of microsomal PE (Figure 7-7) and 0.6% of total microsomal
phospholipids.
Four microsomal PEs decreased in abundance with age in the cerebellum (Figure 7-9,
Table 7-4). The most abundant microsomal PE to decline with age in was PE 18:0_20:4,
the second-most abundant PE in the microsomes (Figure 7-7). This phospholipid
comprised 16.0% of microsomal PE and 5.3% of the total microsomal phospholipid and
declined by 16% in abundance over the 80 year period studied (Figure 7-9, Table 7-4).
Two moderately abundant microsomal PEs decreased with age, PE 18:0_22:4 and PE
18:0_18:1, decreasing by 36% and 27% respectively over the 80 year period. The final
microsomal PE to decline with age was PE 16:0_22:4, a low abundance phospholipid
which fell by 38% from ages 20 to 100.
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Figure 7-9: Microsomal PEs changing significantly with age (as a percent of total PE) in
normal human cerebellum (n = 33-36). Regression model was adjusted for sex: males
(●), females (○). Regression parameters are shown in Table 7-4.
Only a single microsomal PE maintained its decrease with age when analysed as
quantified amount (pmol/µg membrane protein), PE 16:0_22:4 (Table 7-5). This
phospholipid decreased from 0.9 pmol/µg membrane protein at age 20 to 0.5 pmol/µg
membrane protein at 100 years of age.
7.2.4.3 Phosphatidylserines
Six microsomal PSs changed with age in the cerebellum (Figure 7-10, Table 7-4). The
most abundant PS in the microsomes, PS 18:0_22:6, increased from 34.5% of
microsomal PS to 51.0%. Only one other microsomal PS increased significantly with
age, PS 18:1_20:1, which doubled in abundance over the 80 year period studied. PS
18:1_20:1 is a low abundance phospholipid, however, making up only 1.9% of
microsomal PS (Figure 7-7) and 0.3% of the total microsomal phospholipid.
Four microsomal PS phospholipids decreased with age (Figure 7-10, Table 7-4). The
second-most abundant microsomal PS, PS 18:0_18:1, shrank by 38% from ages 20 to
100. PS 18:0_22:4 and PS 18:0_20:1, both moderately abundant microsomal PS
phospholipids, decreased by 28% and 56% in abundance over the 80 year period
respectively. The final PS phospholipid to change with age, PS 18:0_20:2, is of low
abundance in microsomal membranes, comprising just about 1% of microsomal PS
(Figure 7-7) and 0.2% of total microsomal phospholipid. PS 18:0_20:1 decreased from
its initial abundance by 38% from ages 20 to 100.
Five of these microsomal PS phospholipids also changed with age in their quantified
amount (pmol/µg membrane protein; Table 7-5). These included PS 18:0_18:1, PS
18:0_20:1, PS 18:0_20:2, PS 18:0_22:4 and PS 18:1_20:1. A sixth microsomal PS was
also found to decline in quantified amount with age, PS 18:0_22:5, which decreased
from 2.9 pmol/µg membrane protein to 1.2 pmol/µg membrane protein from ages 20 to
100.
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Figure 7-10: Microsomal PSs changing significantly with age (as a percent of total PS)
in normal human cerebellum (n = 30-36). Regression model was adjusted for sex: males
(●), females (○). T indicates dependent variable transformed for linear regression, with
transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 7-4.
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7.3 Discussion
There were many changes in PC, PE and PS phospholipids in the mitochondrial and
microsomal membranes of the human cerebellum during normal ageing. In effect, the
cerebellum experienced the highest number of changes to its phospholipids with age
compared to any other region of the brain studied so far in this thesis. Of particular note
were age-related increases in both mitochondrial and microsomal PS 18:0_22:6 and PE
18:0_22:6 over the 80 year period, as well as age-related increases in many other
phospholipids containing DHA in both membrane fractions.
Both mitochondrial and microsomal PS 18:0_22:6 increased by approximately half their
initial abundance from ages 20 to 100 (Figure 7-6, Figure 7-10). PS 18:0_22:6 is the
most abundant PS present in both the mitochondrial and microsomal membranes,
making up approximately 42% of mitochondrial and microsomal PS (Figure 7-3, Figure
7-7), and approximately 8-9% of total phospholipid in each fraction. Due to the high
abundance of PS 18:0_22:6, these age-related increases in mitochondrial and
microsomal PS 18:0_22:6 represent a substantial shift in the phospholipid composition
of both membrane fractions in the cerebellum during normal ageing. Increases of a
similar magnitude in PS 18:0_22:6 with age were also previously seen in the
mitochondrial and microsomal membranes of the prefrontal cortex (Chapter 4), and in
the mitochondria of the human hippocampus (Chapter 5). Other highly abundant
phospholipids containing DHA also increased with age, including both mitochondrial
and microsomal PE 18:0_22:6, a phospholipid that is equally as abundant as PS
18:0_22:6 (Figure 7-3, Figure 7-7). Both mitochondrial and microsomal PE 18:0_22:6
increased by one-fifth in abundance from ages 20 to 100 (Figure 7-5, Figure 7-9). This
is the first instance of increasing amounts of mitochondrial and microsomal PE
18:0_22:6 with age in any brain region studied so far. Other phospholipids with DHA
showing age-related increases included both mitochondrial and microsomal PE
16:0_22:6, PE 18:1_22:6, and PE 15:0_22:6/O-16:0_22, and microsomal PE O18:1_22:6. The essentiality of DHA within the brain was established in Chapter 2
(section 2.1.4). As discussed in Chapter 4, DHA preferentially incorporates itself into
phospholipids with a PS head group during biosynthesis in the brain [210], and
increased PS 18:0_22:6 within neural cells is thought to promote longevity and decrease
cellular apoptosis [191]. Unlike PS 18:0_22:6 there is little information available on the
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possible role of PE 18:0_22:6 within cellular membranes, aside from its preference as a
substrate for the synthesis of PS phospholipids with DHA by PSS2 (Chapter 6).
Increases in PS synthesis by both PSS1 and PSS2 have been reported in the cerebellum
of aged rats [47]; however, if this were also true for humans then we would expect to
see a corresponding decrease in PE 18:0_22:6 and/or PC 16:0_22:6 with age and not the
age-related increases observed for these phospholipids in this chapter
Due to the increased levels of phospholipids containing DHA in the mitochondrial and
microsomal membranes of the cerebellum in older individuals, additional regressions
with age were carried on the dominate PUFA in this region for both mitochondrial
(Table 7-6) and microsomal (Table 7-7) membranes. Increases in total DHA were seen
in both the PE and PS classes, as well as in the combined phospholipids of both the
mitochondrial and microsomal membranes (Table 7-6 & Table 7-7). The increases in
DHA with age in the combined phospholipids of the mitochondria occur at nearly twice
the rate of that seen in the corresponding microsomal membranes. Looking at individual
phospholipid classes, this disparity in the rate of increases in DHA between the two
membrane fractions arises from PE-DHA phospholipids and not from PS-DHA. Both
mitochondrial and microsomal PS phospholipids have a similar rate of increase with
age, with both mitochondrial and microsomal PS-DHA increasing in amount within the
PS class by 0.10% per year. Mitochondrial PE-DHA increased within the PE class by
0.09% per year (Table 7-6), however, a rate that is one-third higher than that seen for
microsomal PE-DHA (0.06% per year, Table 7-7). Between the two membrane fractions
a similar number of phospholipids increased with age, with the mitochondrial fraction
only experiencing one more significant PE-DHA phospholipid: PE O-18:1_22:6 (Figure
7-5, Table 7-2). PE O-18:1_22:6 is not of high abundance within either the
mitochondrial membranes, however, so it is unlikely that this single phospholipid is
responsible for the large differences seen in the rate of increase between the
mitochondrial and microsomal PE-DHA. Rather, each PE-DHA phospholipid in the
mitochondrial fraction increased at a slightly higher rate per year than its microsomal
counterpart (Table 7-2, Table 7-4). The only phospholipid class to not show any agerelated changes in DHA in both the mitochondrial and microsomal fractions was PC, a
phospholipid class that contains negligible amounts of DHA.
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Table 7-6: Linear regression of most abundant polyunsaturated fatty acids (percent of
total fatty acids within phospholipid class) in the mitochondrial membranes with age in
human cerebellum
95% CI
Mitochondrial
Slope
β
df
t
P value
fatty acids
Lower
Upper
Combined phospholipids
-0.0227 0.00001 -0.379 2,32
20:4
-0.0114
-2.034 0.050
-0.0276 -0.0094 -0.666 2,33
22:4
-0.0185
-4.146 0.0002***
-0.0471 -0.0137 -0.615 2,32
20:4 + 22:4
-0.0304
-3.717 0.0008***
0.0337
0.0797
22:6
0.0567
0.749 2,33
5.023 0.00002***
Phosphatidylcholine
-0.0050
0.0147
20:4
0.0049
0.196 2,33
1.002 0.324
-0.0252 -0.00210 -0.423 2,33
22:4
-0.0137
-2.403 0.022*
-0.0180
0.0004 -0.327 2,33
20:4 + 22:4
-0.0088
-1.939 0.061
-0.0011
0.0133
22:6
0.0061
0.320 2,33
1.711 0.096
Phosphatidylethanolamine
-0.0566 -0.0151 -0.589 2,32
20:4
-0.0359
-3.523 0.001**
I
-0.0010 -0.0003
22:4
-0.0006
0.594 2,33
3.512 0.001**
-0.0865
-0.0300
20:4 + 22:4
-0.0582
-0.675 2,32
-4.194 0.0002***
0.0545
0.1315
22:6
0.0930
0.734 2,33
4.916 0.00002***
Phosphatidylserine
-0.0120
0.0052 -0.158 2,33
20:4
-0.0034
-0.802 0.429
-0.0394
-0.0064
22:4
-0.0229
-0.506 2,33
-2.825 0.008**
-0.0458 -0.0068 -0.494 2,33
20:4 + 22:4
-0.0263
-2.744 0.0097**
0.0625
0.1474
22:6
0.1050
0.742 2,32
5.036 0.00002***
Fatty acids calculated from phospholipid molecular species data. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression: I reciprocal. * P <0.05 ** P <0.01 *** P <0.001
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Table 7-7: Linear regression of most abundant polyunsaturated fatty acids (percent of
total fatty acids within phospholipid class) in the microsomal membranes with age in
human cerebellum
95% CI
Microsomal
Slope
β
df
t
P value
fatty acids
Lower
Upper
Combined phospholipids
0.0054 -0.166 2,33
20:4
-0.0039 -0.0132
-0.853 0.400
22:4
-0.0142 -0.0242 -0.0041 -0.511 2,33
-2.872 0.007**
20:4 + 22:4
-0.0181 -0.0332 -0.0029 -0.422 2,33
-2.428 0.021*
0.0073
0.0564
22:6
0.0319
0.477 2,33
2.637 0.013*
Phosphatidylcholine
0.0089 -0.079 2,33
20:4
-0.0023 -0.0135
-0.417 0.679
0.0025 -0.270 2,33
22:4
-0.0055 -0.0135
-1.392 0.173
0.0024 -0.288 2,33
20:4 + 22:4
-0.0078 -0.0180
-1.559 0.129
22:6
-0.0033 -0.0117 -0.0050 -0.154 2,33
-0.812 0.423
Phosphatidylethanolamine
0.0038 -0.311 2,33
20:4
-0.0151 -0.0339
-1.625 0.114
22:4
-0.0223 -0.0422 -0.0024 -0.419 2,33
-2.281 0.029*
20:4 + 22:4
-0.0374 -0.0660 -0.0088 -0.478 2,33
-2.657 0.012*
0.0308
0.0976
22:6
0.0642
0.644 2,33
3.910 0.0004***
Phosphatidylserine
0.0082 -0.046 2,32
20:4
-0.0011 -0.0104
-0.238 0.814
22:4
-0.0193 -0.0341 -0.0046 -0.481 2,33
-2.664 0.012*
20:4 + 22:4
-0.0207 -0.0406 -0.0009 -0.394 2,33
-2.126 0.041*
0.0580
0.1484
22:6
0.1032
0.692 2,33
4.652 0.00005***
Fatty acids calculated from phospholipid molecular species data. Regression was
adjusted for gender. * P <0.05 ** P <0.01 *** P <0.001
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In the brain regions previously analysed in this thesis decreases with age were
commonly seen in phospholipids containing either 20:4 or 22:4 fatty acids. Both 22:4
and 20:4 fatty acids can be putatively classified as the n-6 fatty acids adrenic acid and
AA (Chapter 4, section 4.3). Decreases in adrenic acid and, less frequently, in AA with
age were also seen across all three classes of phospholipid in both the mitochondrial and
microsomal fractions of the cerebellum, (Table 7-6, Table 7-7). Losses of adrenic acid
with age were seen in all three phospholipid classes individually, as well as in the
combined phospholipids classes, in both membrane fractions with the exception of
microsomal PC. Only mitochondrial PE reported losses of AA with age, however,
despite the significant losses seen in both mitochondrial and microsomal PE 18:0_20:4
(Figure 7-5, Figure 7-9). Combining the two n-6 fatty acids together resulted in losses in
both membrane fractions, with only mitochondrial and microsomal PC remaining
unaffected (Table 7-6, Table 7-7).
The cerebellum is often used as a control tissue in the study of changes in membrane
lipids during AD, a finding presumed to be due largely to the absence of any significant
burden of intra- and extracellular protein aggregates compared with other brain regions
[206,207]. Indeed, very few changes have been seen in the membrane lipids of
cerebellum

during the pathogenesis

of AD compared

with

other regions

[85,111,112,115,116,123]. Only in the white matter of the cerebellum have significant
losses of phospholipids been reported in AD [85]. Only a single study has examined
changes in cerebellar phospholipids during normal ageing, finding no changes to total
PC or PE with advanced age [90]. No changes with age to either total PC or PE
phospholipids in either the mitochondrial or microsomal membranes were observed in
the current chapter, a finding that agrees with the previous study. However, numerous
changes to molecular phospholipids were seen in all three phospholipids classes both
membrane fractions. Indeed, the cerebellum underwent the most numerous changes to
its molecular phospholipids during ageing compared to any region analysed so far in
this thesis. The sheer number of changes to phospholipids of the cerebellum during
normal ageing combined with its substantial cytoarchitectural differences to the rest of
the brain suggest that the cerebellum may not be the ideal choice as a control tissue for
studying the effects of age-related neurodegenerative diseases such as AD.
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In summary, there were many changes seen in the PC, PE and PS phospholipids of the
mitochondrial and microsomal membranes of the human cerebellum during normal
ageing. Significant age-related increases were seen in mitochondrial and microsomal PS
18:0_22:6 and mitochondrial and microsomal PE 18:0_22:6, as well as many other
phospholipids containing DHA. This led to increases with age in total DHA in PE, PS
and combined phospholipids in both the mitochondria and microsomes. Age-related
decreases were reported for total adrenic acid in all classes and membrane fraction
except for microsomal PC. Despite significant losses of mitochondrial and microsomal
PE 18:0_20:4 with age, no age-related changes were seen in either mitochondrial or
microsomal PE-AA. The multitude of changes to the phospholipids of the human
cerebellum during normal ageing compared with the other three brain regions studied
suggests that the cerebellum may not be a good choice for examining the changes
occurring to phospholipids in age-related neurodegenerative diseases such as AD.
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Chapter 8 The Motor Cortex
8.1 Introduction
This chapter will investigate age-related changes to the PC, PE and PS of the
mitochondrial and microsomal membranes in the human motor cortex.
The motor cortex is a brain region classified by closely related anatomical and
functional areas. It is located in the posterior region of the frontal lobe anterior to the
central sulcus (see Chapter 1, Figure 1-2). This area of the brain is also known as the
agranular frontal cortex because it lacks an internal granular layer (layer IV). Another
cytoarchitectural marker of the motor cortex is the presence of large neurons known as
Betz cells that, along with other cortical neurons, extend long axons down the
corticospinal tract. Many neurons from the motor cortex terminate in the brain stem,
while others form reciprocal circuits between the motor cortex and somatosensory
cortex that allow the translation of sensory information into motor action (reviewed by
Rizzolatti et al. [211]).
There is some disagreement within the literature as to whether this region undergoes
changes in grey matter volume and/or cortical thickness during normal ageing. Some
studies have reported age-related changes in grey matter volume and/or cortical
thickness within this region [16,18–23,212], while others have found the motor cortex
to be relatively spared of these changes during normal ageing [24–26,213]. As
discussed by Lemaître et al. [16], studies which have reported age-related declines in
grey matter volume and/or cortical thickness within the motor cortex have contained
large numbers of participants over the age of 60 years, suggesting that any changes
occurring in this region happen late in life. The motor cortex also experiences very few
changes in grey matter volume and/or cortical thickness until the later stages of AD
[214–216], which corresponds to a later appearance of Aβ aggregates and tau NFTs
within this region [7]. For these reasons, the motor cortex is often used as a control
region when studying the pathogenesis of AD, although not as commonly as the
cerebellum.
Currently, there are no published studies on whether the phospholipids of the primary
motor cortex undergo significant changes during normal ageing. A single study has
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examined the total phospholipid-fatty acids of an anatomically and functionally related
brain region, the premotor area (BA 4), finding no changes with age [96]. Considering
the relative stability of this region during both normal ageing and the pathogenesis of
AD, it was hypothesised that very few changes would be detected in this region.
Therefore, the aim of this chapter was to examine whether any changes occur to the
phospholipids of the motor cortex with age in both the mitochondrial and microsomal
membranes.

8.2 Results
8.2.1

Changes in total protein concentration during normal ageing

No age-related effects were observed for total protein concentration in the whole tissue
homogenate, or in either the mitochondrial or microsomal fractions.
8.2.2

Major phospholipid classes of mitochondrial and microsomal fractions

Each of the three phospholipid classes measured in the mitochondrial and microsomal
membranes of the motor cortex expressed as a percent of total detected phospholipid is
shown in Figure 8-1. Approximately 56% of detected phospholipids in both membrane
fractions were PC phospholipids, while PE and PS made up 27% & 17% respectively.
The microsomal membranes contained slightly higher amounts of total PS compared to
the mitochondrial membranes (p < 0.01). No statistically significant differences were
seen between the membrane fractions for either PC or PE. Analysis of the quantified
phospholipid classes (as pmol phospholipid/µg membrane lipid) showed similar results
to the percent composition data. There was more PS in the microsomal fraction (p <
0.05), with no significant differences seen in PC or PE between the two membrane
fractions. Total quantified phospholipids were also increased in the microsomal fraction
(p < 0.05).
Total PC, PE, PS were also assessed for any age-related changes in both mitochondrial
and microsomal membranes. No age-related changes to any class in either membrane
fraction was observed when analysed as a percent of total detected phospholipid or as
quantified phospholipids. Likewise, there were no changes with age total quantified
phospholipids in either membrane fraction.
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Figure 8-1: Percent composition of the three major phospholipid classes within the
mitochondrial (left) and microsomal (right) fractions in neurologically normal motor
cortex. Values are the mean ± SEM for the entire cohort. The microsomal membranes
showed significantly higher amounts of total phosphatidylserine (PS) compared to
mitochondria (p < 0.01, Wilcoxon signed-rank test). No statistically significant
difference was seen for phosphatidylcholine (PC) or phosphatidylethanolamine (PE)
between the mitochondria and microsomes.
8.2.3

Changes in mitochondrial phospholipids with age

8.2.3.1 Phosphatidylcholine
The composition of the PC, PE and PS phospholipids detected in the mitochondrial
fraction can be seen in Figure 8-2. Three PCs changed with age when analysed as a
percent of total mitochondrial PC: PC 16:0_20:4, PC 16:0_22:4 and PC 16:0_18:2
(Figure 8-3, Table 8-1). All three phospholipids are moderately abundant within
mitochondrial membranes, comprising 3.6%, 2.0% and 1.3% of total mitochondrial PC
respectively (Figure 8-2). Both PC 16:0_20:4 and PC 16:0_22:4 declined with age
within mitochondrial membranes, with decreases of 17% and 41% in abundance seen
respectively (Figure 8-3, Table 8-1). PC 16:0_18:2 increased with age, rising from 0.9%
of total mitochondrial PC at age 20 to 1.5% at age 100, representing an increase of 59%
from its initial abundance.
Only PC 16:0_22:4 retained its decrease with age within the mitochondria when
analysed as quantified phospholipid (pmol of phospholipid/µg membrane protein). PC
16:0_22:4 decreased from 5.3 to 2.3 pmol/µg membrane protein over the 80 year period
(Table 8-2)
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Figure 8-2: Phospholipids detected within PC, PE and PS in the mitochondrial fraction
of human motor cortex (as a percent of total phospholipid within each class).
Phospholipids were quantified as described in materials and methods. Values are mean
across the cohort ± SEM.
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Figure 8-3: Mitochondrial PCs changing significantly with age (as a percent of total PC)
in normal human motor cortex (n = 30-34). Regression model was adjusted for sex:
males (●), females (○). T indicates dependent variable transformed for linear regression,
with transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 8-1
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Table 8-1: Mitochondrial phospholipids (percent of phospholipid within phospholipid
class) changing significantly with age in the human motor cortex.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
0.0019
0.0117
PC 16:0_18:2
0.0068
0.525 2,31
2.824 0.008**
PC 16:0_20:4
-0.0080 -0.0151 -0.0008 -0.416 2,30
-2.263 0.031*
PC 16:0_22:4I
-0.0021 -0.0038 -0.0006 -0.558 2,27
-2.779 0.0098**
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: I reciprocal.
* P <0.05 ** P <0.01

Table 8-2: Quantified mitochondrial phospholipids (pmol/µg total membrane protein)
changing significantly with age in the human motor cortex.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
PC 16:0_22:4
-0.0370 -0.0707 -0.0034 -0.460 2,27
-2.260 0.032*
Phosphatidylethanolamine
PE O-18:1_20:4
-0.0048 -0.0096 -0.00003 -0.394 2,31
-2.052 0.049*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. ** P <0.01
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8.2.3.2 Phosphatidylethanolamines
No mitochondrial PEs changed with age within the motor cortex when analysed as a
percent of total PE, or when analysed as quantified mitochondrial PE (pmol of
phospholipid/µg membrane protein)
8.2.3.3 Phosphatidylserines
Similarly to mitochondrial PE, no mitochondrial PS phospholipids changed with age in
either their percent composition (percent of total mitochondrial PS) or quantified
amount (pmol/µg membrane protein) in the motor cortex.
8.2.4
8.2.4.1

Changes in microsomal phospholipids with age
Phosphatidylcholines

The composition of PC, PE and PS phospholipids within the microsomal membranes
can be seen in Figure 8-4. Within microsomal PC there were three phospholipids that
changed with age in the motor cortex (Figure 8-5, Table 8-3). PC 18:0_20:4, PC
14:0_16:0 and PC 16:0_18:2 are all moderately abundant phospholipids within
microsomal membranes. PC 18:0_20:4 comprises 1.7% of total microsomal PC (Figure
8-4), and it decreased by 28% in abundance from ages 20 to 100 (Figure 8-5, Table
8-3). Levels of both PC 14:0_16:0 and PC 16:0_18:2 rose with age within the
microsomes, with increases of 15% and 51% seen respectively over the 80 year period.
Only PC 18:0_20:4 maintained its decrease with age within the microsomal membranes
of the motor cortex when analysed as quantified phospholipid (pmol/µg membrane
protein; Table 8-4). PC 18:0_20:4 decreased by 39% in quantified amount from ages 20
to 100 years of age.
8.2.4.2 Phosphatidylethanolamines
Five microsomal PEs changed with age within the motor cortex, with four of these
phospholipids increasing in abundance with age (Figure 8-6, Table 8-3). PE O18:1_22:6 is a moderately abundant microsomal PE present at 2.0% of total microsomal
PE (Figure 8-4) and 0.5% of the total microsomal phospholipid. PE O-18:1_22:6
increased from its initial abundance by 16% from ages 20 to 100 (Figure 8-6, Table
8-3). PE O-18:1_22:5, PE 15:0_22:6/O-16:0_22:6 and PE 15:0_22:4/O-16:0_22:4 also
increased in abundance with age, by 75%, 83% and 86% respectively over the 80 year
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Figure 8-4: Phospholipids detected within PC, PE and PS in the microsomal fraction of
human motor cortex (as a percent of total phospholipid with each class). Phospholipids
were quantified as described in materials and methods. Values are mean across the
cohort ± SEM.
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Figure 8-5: Microsomal PCs changing significantly with age (as a percent of total PC)
in normal human m motor cortex (n = 30-35). Regression model was adjusted for sex:
males (●), females (○). Regression parameters are shown in Table 8-3.
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Table 8-3: Microsomal phospholipids (percent of phospholipid within phospholipid
class) changing significantly with age in the human motor cortex.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
0.0001
0.0047
PC 14:0_16:0
0.0024
0.409 2,32
2.168 0.038*
0.0018
0.0110
PC 16:0_18:2
0.0064
0.505 2,32
2.818 0.008**
PC 18:0_20:4
-0.0066 -0.0113 -0.0019 -0.521 2,27
-2.892 0.007**
Phosphatidylserine
PE 15:0_22:4
0.0020
0.0002
0.0039
0.424 2,29
2.300 0.029*
/O-16:0_22:4IR
PE 15:0_22:6
0.0053 0.00008
0.0106
0.415 2,27
2.083 0.047*
/O-16:0_22:6
PE O-16:1_22:4
-0.0039 -0.0068 -0.0011 -0.518 2,32
-2.854 0.008**
0.0004
0.0205
PE O-18:1_22:5
0.0104
0.378 2,32
2.111 0.043*
0.0001
0.0076
PE O-18:1_22:6
0.0038
0.377 2,32
2.097 0.044*
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. Superscript indicates dependent variable transformed for linear
regression, with transformed regression output reported: IR reflect and reciprocal.
* P <0.05 ** P <0.01

Table 8-4: Quantified microsomal phospholipids (pmol/µg total membrane protein)
changing significantly with age in the human motor cortex.

Phospholipid

Slope

95% CI
Lower
Upper

β

df

t

P value

Phosphatidylcholine
PC 18:0_20:4
-0.0197 -0.0332 -0.0061 -0.504 2,27
-2.974 0.006**
Phospholipid molecular species were detected using nanoelectrospray ionisation mass
spectrometry and quantified as described in materials and methods. Regression was
adjusted for gender. ** P <0.01
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Figure 8-6: Microsomal PEs changing significantly with age (as a percent of total PC)
in normal human m motor cortex (n = 30-35). Regression model was adjusted for sex:
males (●), females (○). T indicates dependent variable transformed for linear regression,
with transformed beta-coefficient and p-value reported on original scatterplot for
comparison. Regression parameters are shown in Table 8-3
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period. However these three phospholipids are only of low abundance in microsomal
membranes, comprising only 2.7% of total microsomal PE when combined (Figure
8-4). The final microsomal PE to show a change with age, PE O-16:1_22:4, decreased
in abundance from ages 20 to 100 by 45%. Similarly, PE O-16:1_22:4 is only of low
abundance within microsomal membranes, comprising only 0.5% of total microsomal
PE (Figure 8-4)
No microsomal PEs showed statistically significant changes with age when analysed as
quantified phospholipid (pmol/µg membrane protein).
8.2.4.3 Phosphatidylserines
No microsomal PS phospholipids changed with age in the motor cortex in either percent
composition (percent of total microsomal PS) or quantified amount (pmol/µg membrane
protein).

8.3 Discussion
There were very few changes seen with age in the phospholipids that make up the
mitochondrial and microsomal membranes of the human motor cortex compared to the
previously four brain regions examined. All of the changes that occurred in the
mitochondrial and microsomal membranes of the motor cortex took place in
phospholipids that were of low-to-moderate abundance.
Notably, there were no age-related changes reported for any PS phospholipids in the
motor cortex in either the mitochondrial or microsomal membranes. A similar trend was
seen in the entorhinal cortex (Chapter 6), where no mitochondrial PS phospholipids
changed with age, but the motor cortex is the only brain region examined to show no
changes to both mitochondrial and microsomal PS. PS is synthesised in the ER,
primarily within the MAM [217]. The MAM is commonly found in the mitochondrial
fraction using the subcellular fractionation method employed in this study [41,218].
Phospholipids synthesised within the MAM are sent to the mitochondrial membranes by
means of the close association between the two membranes [219]. As outlined in
Chapter 2 (2.1.3), PS is produced in the MAM by serine-exchange with PC and PE by
PSS1 and PSS2 respectively. Mitochondrial membranes also lack the ability to
synthesise PE phospholipids de novo, and only a small amount of de novo synthesis of
PE is conducted within the MAM. Instead, PSD converts PS into PE for use in the inner
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and outer mitochondrial membranes [219]. Taken together, this relative lack of change
in PS phospholipids within either the mitochondrial or microsomal membranes as well
as no changes to PE phospholipids within the mitochondria suggests that homeostasis of
PS metabolism is unperturbed in both mitochondrial and microsomal membranes within
the motor cortex of the human brain over the adult lifespan. This combined with the
lack of changes with age to the grey matter volume and/or cortical thickness of the
motor cortex described in the introduction of this chapter (section 8.1) could also
suggest that maintenance and regulation of these PS synthesis and degradation pathways
could be crucial in preserving grey matter in healthy brain ageing.
Unlike the previous four regions analysed there did not seem to be any definite trend
towards either losses with age of phospholipids containing adrenic acid (22:4) or AA
(20:4), or increases with age in phospholipids containing DHA (22:6) in either
membrane fraction within the motor cortex. Similar to the previously analysed brain
regions, further linear regression of the most abundant PUFA with age was conducted to
confirm these results for both mitochondrial (Table 8-5) and microsomal (Table 8-6)
membranes. No changes with age were observed for either AA, adrenic acid, AA
combined with adrenic or DHA in any phospholipid class or combined phospholipids in
the mitochondrial fraction (Table 8-5). However, in the microsomes losses with age
were found for AA in both PC and PE (Table 8-6). While this age-related loss of
microsomal PC-AA could be explained by the loss of microsomal PC 18:0_20:4 seen
with age (Figure 8-5, Table 8-3), no single PE phospholipid containing AA was
identified as changing significantly with age in the microsomal fraction (Figure 8-6,
Table 8-3). This finding implies that the loss of PE-AA with age seen in the microsomal
fraction is likely the net result of small losses of many microsomal PE phospholipids
containing AA with age, rather than being limited to a single, dominant phospholipid
molecular species. Both AA and adrenic acid are long-chain n-6 PUFA, and AA
combined with adrenic acid within microsomal PC and PE also declined with age
(Table 8-6). This suggests that there is a loss of long chain n-6 PUFA with age within
PC and PE in the microsomal membranes of the motor cortex, but the lack of change in
AA and adrenic acid within the combined phospholipids suggests that there is no
decline overall in total membrane long-chain n-6 PUFA with age
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Table 8-5 Linear regression of the most abundant polyunsaturated fatty acids (percent of
total fatty acids within phospholipid class) in the mitochondrial membranes with age in
human motor cortex
Mitochondrial
Slope
fatty acids
Combined phospholipids
20:4
-0.0023
22:4
-0.0078
20:4 + 22:4
-0.0101
22:6
-0.00005
Phosphatidylcholine
20:4
0.0032
22:4
-0.0089
20:4 + 22:4
-0.0057
22:6
0.0012
Phosphatidylethanolamine
20:4
-0.0137
22:4
-0.0085
20:4 + 22:4
-0.0192
22:6
0.0035
Phosphatidylserine
20:4
-0.0005
22:4
-0.0017
20:4 + 22:4
-0.0022
22:6
0.0111
Fatty acids calculated from
adjusted for gender.

95% CI
Lower
Upper

β

df

t

P value

-0.0138
-0.0188
-0.0242
-0.0351

0.0092
0.0031
0.0039
0.0350

-0.080
-0.290
-0.280
-0.001

2,32
2,32
2,32
2,32

-0.405
-1.458
-1.466
-0.003

0.688
0.155
0.152
0.998

-0.0086
-0.0186
-0.0172
-0.0076

0.0150
0.0008
0.0059
0.0100

0.111
-0.363
-0.201
0.056

2,32
2,32
2,32
2,32

-1.047
-1.860
-1.000
0.275

0.303
0.072
0.325
0.785

-0.0318
-0.0358
-0.0485
-0.0381

0.0044
0.0189
0.0102
0.0451

-0.291
-0.129
-0.261
0.035

2,31
2,32
2,31
2,31

-1.540
-0.632
-1.332
0.171

0.134
0.532
0.193
0.865

-0.0043
0.0032 -0.058 2,32
-0.0213
0.0180 -0.036 2,32
-0.0223
0.0179 -0.046 2,32
-0.0981
0.1203
0.042 2,32
phospholipid molecular species data.

-0.283 0.779
-0.175 0.862
-0.224 0.825
0.207 0.837
Regression was
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Table 8-6 Linear regression of the most abundant polyunsaturated fatty acids (percent of
total fatty acids within phospholipid class) in the microsomal membranes with age in
human motor cortex
95% CI
Microsomal
Slope
β
df
fatty acids
Lower
Upper
Combined phospholipids
0.0033 -0.278 2,32
20:4
-0.0081 -0.0196
0.0057 -0.169 2,32
22:4
-0.0042 -0.0141
0.0039 -0.276 2,32
20:4 + 22:4
-0.0012 -0.0281
0.0607
22:6
0.0050 -0.0507
0.037 2,32
Phosphatidylcholine
20:4
-0.0081 -0.0158 -0.0003 -0.400 2,32
0.0051 -0.050 2,32
22:4
-0.0007 -0.0066
20:4 + 22:4
-0.0088 -0.0160 -0.0017 -0.426 2,32
0.0066 -0.075 2,32
22:6
-0.0014 -0.0095
Phosphatidylethanolamine
20:4
-0.0166 -0.0315 -0.0017 -0.400 2,31
0.0036 -0.314 2,31
22:4
-0.0120 -0.0275
-0.0524
-0.0043
20:4 + 22:4
-0.0284
-0.431 2,32
0.0688 -0.259 2,32
22:6
0.0268 -0.0152
Phosphatidylserine
0.0024 -0.135 2,32
20:4
-0.0012 -0.0047
-0.0218
0.0236
22:4
0.0009
0.016 2,32
0.0226 -0.005 2,32
20:4 + 22:4
0.0003 -0.0231
0.1150
22:6
0.0083 -0.0983
0.032 2,32
Fatty acids calculated from phospholipid molecular species data.
adjusted for gender. * P <0.05

t

P value

-1.447
-0.867
-1.542
0.184

0.158
0.392
0.133
0.855

-2.108
0.233
-2.509
-0.365

0.043*
0.817
0.017*
0.717

-2.271
-1.569
-2.405
1.300

0.030*
0.127
0.022*
0.203

-0.660 0.514
0.080 0.937
-0.023 0.982
0.159 0.875
Regression was
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This relative lack of change in either the PUFA component of phospholipids combined
with the few age-related changes seen in both mitochondrial and microsomal
phospholipids suggests that the membrane composition of the motor cortex is the most
stable during normal ageing compared to the other four brain regions examined in this
thesis. As discussed in the introduction to this chapter, the greater motor area is thought
to remain relatively unchanged in grey matter volume and thickness throughout ageing,
and only exhibits losses in these structures with advanced age [16]. The motor cortex
also remains relatively unchanged during the pathogenesis of AD, with losses of grey
matter thickness and/or volume during the pathogenesis of AD not seen in the motor
cortex until the very late stages of the diseases [214–216]. Likewise, the characteristic
Aβ aggregates and tau NFTs also fail to appear in the motor cortex until the later stages
of the disease [7]. The only study to examine changes in phospholipids with age in the
motor cortex looked at total phospholipid fatty acids in a closely related region, the
premotor area (BA 4) [96], finding no changes with age to any fatty acids in this region.
The results of the present study combined with the relative lack of changes to grey
matter thickness and/or volume reported in the motor cortex during both normal ageing
and in diseases of ageing such as AD suggest that this region may be a good control for
comparing and contrasting both age-related and AD-related changes to phospholipids.
Indeed, the lack of age-related changes in the motor cortex make this region more
suitable than the cerebellum, the other commonly used control region, which was found
to undergo numerous changes in its phospholipids during normal ageing (Chapter 7).
In summary, there were very few changes occurring to the mitochondrial and
microsomal phospholipids of the human motor cortex during normal ageing. All
phospholipids that changed in composition with age were of low-to-moderate
abundance within both the mitochondrial and microsomal fractions. No changes with
age were seen in any PS phospholipid in either the mitochondrial or microsomal
membranes in the motor cortex. Likewise, no age-related changes were observed for
any mitochondrial PE phospholipids. Compared to previously studied regions, the
motor cortex showed fewer changes in phospholipids containing PUFA, but some
decreases with age in phospholipids containing AA and adrenic acid were seen in
microsomal PC and PE. Considering these and previous findings, the motor cortex may
be a better region to use as a control tissue than the cerebellum both when studying
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changes in phospholipids during normal ageing and during the pathogenesis of agerelated diseases such as AD.
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Chapter 9 Discussion and Conclusion
9.1 Introduction
The primary aim of this thesis was to determine if any age-related changes occur in
phospholipids across five regions of the human brain. This chapter analyses the changes
occurring across those brain regions in both the mitochondrial and microsomal
membranes, and compares these results to that reported previously in the literature for
both normal ageing and during the pathogenesis of the different dementias, specifically
within AD. The findings from this thesis will then be examined to see where they fit
into the two theories of ageing outlined in Chapter 2 (section 2.4); chiefly, either the
mitochondrial free radical theory of ageing or the “inflammageing” theory of ageing.
Finally, future recommendations for this research will be suggested

9.2 Regional differences in phospholipid composition during normal
ageing
9.2.1

Method

To facilitate discussion of the results from the five different regions of the human brain
examined within this thesis, the slope of the regression line for all of the statistically
significant changes with age in the PC, PE and PS phospholipids of the prefrontal
cortex, hippocampus, entorhinal cortex, cerebellum and motor cortex were collated and
converted into heat maps for both the mitochondrial (Figure 9-1) and microsomal
fractions (Figure 9-2). These heat maps were created in R (v. 3.1.1) using the “gplots”
package. An example of the script used in R to create these heat maps is included in
Appendix 1. Hierarchical clustering was used to look for any similarities in age-related
phospholipid changes across the five regions examined within the two membrane
fractions. The normalised slope of phospholipids transformed for linear regression was
calculated from the back-transformed amounts present at 20 and 100 years of age to
allow for comparison with non-transformed regressions. Phospholipids that underwent
the largest age-related changes are present at the top of the heatmap, while those that
experienced biggest decreases with age are at the bottom.
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9.2.2

Results and discussion

9.2.2.1 Age-related changes in mitochondrial phospholipids
Hierarchical clustering analysis of the mitochondrial membranes of the five brain
regions examined in this thesis found three distinct groups displaying similar changes
with age: the cerebellum alone, the hippocampus and prefrontal cortex, and the motor
and entorhinal cortices (Figure 9-1). The phospholipid with the largest age-related
increase was PS 18:0_22:6 in the hippocampus, prefrontal cortex and cerebellum,
followed by PE 18:0_22:6 in the cerebellum only. The largest decreases with age were
seen in PS 18:0_18:1 within the cerebellum, PE 18:0_20:4 in the cerebellum and
prefrontal cortex, and PS 18:0_22:4 in the cerebellum and hippocampus. Only a single
phospholipid molecular species showed statistically significant age-related changes
across all five regions of the brain: PC 16:0_18:2, which increases with age.
Surprisingly, there were two mitochondrial phospholipids that showed an opposite trend
with age between two different regions. In the entorhinal cortex PE 16:0_18:1 and PE
17:0_22:6/O-18:0_22:6 increased with age, whereas both phospholipids decreased with
age in the prefrontal cortex.
The mitochondrial phospholipids of the cerebellum appeared to share many similar
phospholipids undergoing age-related changes like those in the prefrontal cortex and
hippocampus. All three regions experienced increases with age in PS 18:0_22:6, PE
18:1_22:6, and PC 16:0_18:2, and age-related decreases in PE 18:0_22:4. The
cerebellum and prefrontal cortex share common increases with age in PC 16:0_22:6 and
PE O-18:1_22:6 and common decreases in PE 18:0_18:1 and PE 18:0_20:4. However,
in the cerebellum and hippocampus only decreases in PS 18:0_20:4 were found in
common. The main difference separating the cerebellum from the prefrontal cortex and
hippocampus is the magnitude of the age-related changes occurring. The cerebellum had
many large changes with age clustered at the top and bottom of the heat map, indicating
that these are comparatively large changes in phospholipids with age. However, both
the hippocampus and prefrontal cortex had more phospholipids present in the middle of
the heat map, which implied smaller but significant changes with age within these
regions. The hippocampus in particular had many such small but statistically significant
age-related changes, while the prefrontal cortex occupied the middle ground between
the hippocampus and cerebellum.
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Figure 9-1: Summary of significant changes seen during normal ageing in the
phospholipid composition (% of phospholipid class) in the mitochondrial fraction of the
human prefrontal cortex (PFC), hippocampus (H), entorhinal cortex (EC), cerebellum
(C), and motor cortex (MC). Increases in phospholipids with age are shown in green
and decreases in red. Hierarchical clustering of the five brain regions is shown by the
dendrogram at the top. Heat map was generated in R (v 3.1.1) using the gplots package.
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The entorhinal and motor cortices are grouped together due to a lack of age-related
changes in phospholipids within the mitochondrial membranes. Only three age-related
changes in mitochondrial phospholipids were seen in the motor cortex: increases in PC
16:0_18:2 and decreases in PE 16:0_20:4 and PS 18:0_20:1. In contrast, the entorhinal
cortex only exhibited increases with age within the mitochondrial membranes: in two
PC phospholipids and six PEs. Common between the mitochondrial membranes of the
two regions is a lack of age-related changes within the PS class. As discussed in
Chapter 8 (section 8.1), the motor cortex, in particular, is known to exhibit few changes
in grey matter volume and/or cortical thickness with age until advanced age, and so it is
unsurprising that few age-related changes were seen to phospholipids in either
membrane fraction within in this region.
9.2.2.2 Age-related changes in microsomal phospholipids
Analysis of all the statistically significant age-related changes seen in the microsomal
membranes of the five brain regions by hierarchical clustering found both similarities
and differences to that observed in the mitochondrial membranes. In the microsomes the
five regions were classified into two groups: the first group consisting of the cerebellum
only, and the second group containing the hippocampus, frontal, entorhinal and motor
cortices (Figure 9-2). Within the second group, several sub-groups were also identified,
with the entorhinal cortex and motor cortex being grouped together.
There were many similarities seen between the microsomal and mitochondrial
membranes. The largest increase with age was in microsomal PS 18:0_22:6 in the
cerebellum and prefrontal cortex, while the largest age-related decreases were seen in
cerebellar PS 18:0_18:1 and PE 18:0_20:4. Again, there were several phospholipids
showing changes with age in common between the cerebellum and prefrontal cortex.
This included increases in PS 18:0_22:6, PE 18:1_22:6 and PC 16:0_18:2, and
decreases in PE 18:0_18:1. Similar to the mitochondrial fraction, the main difference
between the cerebellum and the other four brain regions appears to be due to the vast
changes with age seen in several phospholipids of the cerebellum. Compared to the
other four regions, many large age-related changes were observed in microsomal
phospholipids of the cerebellum, as shown by the clustering of the data in the extreme
ends of the heat map. A final similarity between both membrane fractions was the
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Figure 9-2: Summary of significant changes seen during normal ageing in the
phospholipid composition (% of phospholipid class) in the microsomal fraction of the
human prefrontal cortex (PFC), hippocampus (H), entorhinal cortex (EC), cerebellum
(C), and motor cortex (MC). Increases in phospholipids with age are shown in green
while decreases are in red. Hierarchical clustering of the five brain regions is shown by
the dendrogram at the top. Heat map was generated in R (v 3.1.1) using the gplots
package.
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grouping of the entorhinal and motor cortices together on the basis of having the fewest
changes with age to their phospholipids. However, there were a higher number
phospholipids changing with age identified within the microsomal membranes of the
motor cortex compared to the mitochondria. Unlike the mitochondrial membranes, the
prefrontal cortex and hippocampus were not grouped together via hierarchical clustering
within the microsomal membranes. Only a single phospholipid had age-related changes
common to these two regions within the microsomal membranes: increases in PE
18:1_22:6. Indeed, more age-related changes were found in phospholipids common
between the cerebellum and hippocampus than prefrontal cortex and hippocampus,
including increases in PE 18:1_22:6 and PE 15:0_22:4/O-16:0_22:4, and decreases in
PE 18:0_22:4 and PC 18:0_18:1. Additionally, the hippocampus displayed fewer
overall changes with age in microsomal phospholipids compared to those seen in the
mitochondrial fraction. Finally, unlike the mitochondrial fraction there was no single
microsomal phospholipid that changed with age in all five regions with age. PC
16:0_18:2, which increased with age in the mitochondrial fraction of all five brain
regions, only increased with age in the microsomal membranes of the cerebellum, motor
and prefrontal cortices. The microsomal phospholipid with the highest number of
changes across the five regions was PE 18:1_22:6, which increased with age in the
cerebellum, hippocampus, and in the entorhinal and prefrontal cortices.

9.3 Comparison to current literature
In Chapter 2 (section 2.2) the current knowledge on changes in phospholipid
composition in the human brain during normal ageing was reviewed. There are
currently no studies available that examine changes in molecular phospholipids with
age, but others have reported analysis of total phospholipids, phospholipid classes and
phospholipid-fatty acids. Below is a brief analysis of how the results from this thesis
compare to that reported in the literature for total phospholipids, phospholipids classes,
and phospholipid-fatty acids.
9.3.1

Changes to phospholipids during normal ageing

9.3.1.1 Total phospholipids
No age-related changes were found in total quantified phospholipids within any of the
five regions examined in the present study for either the mitochondrial or microsomal
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fractions. This finding agrees with that found previously in the cerebellum [88,90], but
disagrees with that of the frontal cortex [89–91,93] and hippocampus [90,93] (Chapter
2, Table 2-1). These discrepancies could be due to the differences in methods between
the current and previous studies. All previous studies used the phosphorous assay to
determine total phospholipid content, which measures all lipids with phosphorous
present within the brain including phosphatidylglycerol, phosphatidylinositol,
phosphatidic acid, cardiolipin and sphingomyelin. While phosphatidylglycerol and
phosphatidic acid are only minor membrane constituents, phosphatidylinositol and
sphingomyelin comprise a comparatively larger proportion of the cellular membranes
within the brain [35] and significant age-related changes to either phospholipid class
could feasibly influence changes in total phospholipids with age. Similarly, age-related
changes to cardiolipin levels within the brain could affect the level of total phospholipid
measured by the phosphorous assay. While the precise amount of cardiolipin present
within mitochondria of the human brain is currently unknown, studies using rodents
have estimated it at 9-10% of total mitochondrial phospholipid [220,221].
9.3.1.2 Phospholipid classes
Generally, the findings of the present thesis agree with the previous literature in respect
to changes with age in total PC, PE and PS within the different regions of the human
brain (Chapter 2, Table 2-2). Overall, no changes were seen with age to total PC, PE or
PS within the frontal cortex, cerebellum and hippocampus, which agrees with the
weight of evidence available for these three brain regions [90,91,93]. Only the
entorhinal cortex changed with age in the amount of phospholipid classes present,
including increases in mitochondrial PC and decreases in mitochondrial PE (Chapter 6),
but no previous studies of age-related changes in phospholipids of this region are
available for comparison.
9.3.1.3 Total phospholipid fatty acids
Within the five regions examined in this study analysis was only performed for changes
with age to the predominant PUFA, and so only the current literature on these fatty
acids have been included for analysis (Chapter 2, Table 2-3). Three of the five regions
examined in this thesis have been previously studied for changes in total phospholipid
fatty acids during normal ageing: the frontal and premotor cortices, as well as the
hippocampus [92–96]. The present study agrees with previous findings of changes to
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AA, adrenic acid and DHA with age within the human brain; however, some differences
between the current and previous studies occurred. In the hippocampus, decreases in
mitochondrial AA were seen with age while no changes in AA levels had been reported
in this region previously [93]. Within the frontal cortex the present work found
decreases in mitochondrial and microsomal AA with age, a finding which agrees that of
McNamara et.al. [95]. However, this disagrees with three other studies that have
reported no change in AA levels within the frontal cortex with age [92–94]. Likewise,
increases with age in mitochondrial DHA were reported in the prefrontal cortex in the
present study, which conflicts with previous studies that found no change in DHA with
age in the frontal cortex [92–94]. The discrepancies between the current and previous
findings within the frontal cortex could be explained by differences in methods used to
identify and quantify phospholipids between the current and present studies. However,
these dissimilarities might also be explained by differences between the anatomical and
functional area of the frontal cortex examined by each study. The frontal cortex consists
of a number of cyto- and myeloarchitectural regions divided on function, histology and
white matter connections [222], all of which may have differing phospholipid
compositions. The present study examined two regions of the frontal cortex: the
dorsolateral prefrontal cortex (BA 9/46), and the primary motor cortex (BA 4). Other
studies examined the frontal eye fields (BA 8) [92], the premotor cortex (BA 6) [96],
the orbitofrontal cortex (BA 10) [95] or an undisclosed section of the frontal cortex
[93,94]. For the purposes of comparison, the previous study of the premotor cortex [96]
was grouped in with the results of this thesis for the primary motor cortex as they share
similar histological features (i.e. lack of a granular layer). Likewise, the hippocampus
proper can be divided into various subfields with different histology and connections to
other regions of the brain, and feasibly each subfield could also have differences in
phospholipid composition. This possibility was not explored in this thesis, however, due
to the limited amount of tissue available for use.
9.3.1.4 Phospholipid fatty acids by class
Only a single study has examined the changes occurring in PC and PE fatty acids by
class during normal ageing within the human brain, finding no changes with age to any
PC or PE fatty acids within the frontal cortex or hippocampus [93]. The present results
generally agree with those findings, with a few exceptions. Within the hippocampus no
changes with age were seen in any of the three PUFA examined within the PC and PE
174 | P a g e

CHAPTER 9

classes within both the mitochondria and microsomes, which agrees with the previous
findings of Söderberg et al. [93]. However, there were several changes recorded within
the PS class in the hippocampus, including decreases in mitochondrial PS-AA,
decreases in mitochondrial and microsomal PS-adrenic acid, and increases in
mitochondrial PS-DHA. Likewise, the present thesis also generally agrees with that
reported previously for PC- and PE-PUFA in the frontal cortex, with the exception of
decreases with age mitochondrial PC-adrenic acid, as well as in mitochondrial and
microsomal PE-AA. Several changes with age were also seen for the first time in the
frontal cortex in PS-fatty acids, including decreases in microsomal PS-AA and increases
in mitochondrial and microsomal PS-DHA.
9.3.2

Changes to phospholipids in dementia compared to healthy ageing

As reviewed in Chapter 2 (section 2.3), many changes to phospholipids have been
reported in the literature during the pathogenesis of the different dementias, with AD
having the most evidence for an involvement of phospholipids. The changes observed to
phospholipids in AD in previous studies could be classified into three broad categories:
changes to the amount of total phospholipid present, changes in the amount of particular
phospholipid classes, and changes to total or class-specific phospholipid-fatty acids.
The first characteristic separating the changes to phospholipids during normal ageing
versus that seen in AD is the lack of changes in total quantified phospholipids in normal
ageing. A number of changes to total phospholipids have been reported in several brain
regions in AD, including decreases in frontal grey [86,109] and white matter [109,111],
as well as in the hippocampus [86,109,110]. No changes to total phospholipid amount
were observed in either the mitochondrial or microsomal membranes for any brain
region studied in this thesis. The second factor separating the changes seen during
normal ageing and those found in AD is the lack of changes to levels of phospholipid
classes. The present work showed that the only region to exhibit any age-related
changes to phospholipid classes was the entorhinal cortex, in which increases in
mitochondrial PC and decreases in mitochondrial PE were observed (Chapter 6, Figure
6-2). Finally, and perhaps most importantly, a critical defining change was seen for the
fatty acids present in phospholipids during normal ageing versus those reported
previously for AD; namely that increases in DHA were observed during normal ageing.
While many studies provided conflicting evidence on changes to DHA in AD (Chapter
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2, section 2.3.1), most reported either a decrease [87,93,123] or no change
[86,87,96,108,121] in DHA levels in either total phospholipid or within the
phospholipid classes across various brain regions with the disease. However, in the
present study increases were noted in many molecular phospholipids containing DHA in
both membranes fraction and in nearly all of the regions studied. As stated in Chapter 2
(section 2.1.2), PUFA such as DHA have a number of important roles in cellular
membranes. An absence of DHA from cellular membranes, as seen in the peroxisomal
disorder Zellweger syndrome, results in acute neurological impairment and death within
the first year of life (Chapter 2, section 2.1.4). We know that DHA is preferentially
incorporated into PS phospholipids during biosynthesis in the brain and that an
increased level of PS-DHA leads to decreased apoptosis within neuro-2A cells (Chapter
4, section 4.3). Therefore, it is feasible that increased levels of DHA with the cellular
membranes of the human brain could be both promoting longevity and protecting
against age-related neurodegenerative disease. So far clinical trials of DHA
supplementation in the healthy elderly, elderly with mild cognitive impairment and
elderly with neurodegenerative disease such as AD have shown mixed outcomes, with
those with mild cognitive impairment showing the most consistent improvement across
studies (reviewed by [73]). Understanding how this accretion of DHA within neural
cellular membranes occurs, and how this may be influenced in order to promote healthy
ageing and prevent the development of neurodegenerative disease such as AD is likely
to be an area of interest in the future.

9.4 Theories of ageing
In Chapter 2 (section 2.4), the current theories of ageing pertaining to phospholipids
were reviewed, including the mitochondrial and free radical oxidative theory of ageing
and the “inflammageing” theory of ageing. The results of this thesis in relation to the
tenets of these two theories will be outlined below
9.4.1

Mitochondrial free radical oxidative theory of ageing

The mitochondrial free radical oxidative theory of ageing was described in detail in
Chapter 2 (section 2.4.2). Briefly, this theory proposes that ageing is the net result of
damage to macromolecules such as protein, DNA and lipids over the lifetime of an
organism by ROS produced by mitochondrial dysfunction. Within phospholipids, it is
the fatty acids that are most susceptible to damage by ROS, chiefly PUFA that contain
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more than one double bond (Chapter 2, Figure 2-7). Theoretically, the greater the
number of double bonds the more susceptible the fatty acid is to oxidative damage.
Accordingly, DHA, a PUFA with six double bonds, would be most susceptible to
oxidative damage by ROS, alongside other PUFA such as docosapentaenoic acid (n-3
and n-6), and the n-6 fatty acids AA and adrenic acid. Because ROS are primarily
generated in mitochondria, we would expect that there would be a greater loss of
PUFA-containing phospholipids within this subcellular fraction.
Within this thesis, numerous changes occurred to PUFA-containing phospholipid
molecular species in all regions of the brain. The findings generally followed the same
trend across the different regions: decreases with age were observed in long chain n-6
PUFA such as AA and/or adrenic acid, whereas age-related increases with age were
seen in phospholipids containing DHA. DHA is the only n-3 fatty acid found in
measurable amounts in phospholipids of the human brain, with only traces of EPA
(20:5n-3) known to be present. Indeed, no EPA was observed in this thesis in any region
of the brain examined. No particular preferences for age-related changes were observed
in the mitochondrial membranes versus microsomal. While the decreases in AA and
adrenic acid found in this thesis were expected under the mitochondrial free radical
oxidative theory of ageing, the increase in phospholipids containing DHA in many
regions of the brain directly contradicts this theory. Therefore, the results of the thesis
do not align with the mitochondrial free radical oxidative theory of ageing as being the
driving force behind normal ageing in the human brain. However, these findings are far
from conclusive, and require the further analysis of other molecules involved in this
pathway.
9.4.2

“Inflammageing”

The “inflammageing theory of ageing was reviewed in Chapter 2 (section 2.4.3) and is
the idea that ageing is driven by chronic, low-grade inflammation over the lifetime of an
organism. Specifically, increased levels of inflammatory markers such as interleukins
and tumour necrosis factors have been observed with advanced age [155–157].
Theoretically, phospholipids could play a role in the inflammageing theory, as AA
preferentially cleaved from phospholipids is a precursor in several pro-inflammatory
enzymatic pathways. Due to this, it is predicted by this theory that there will be a
decline in phospholipids containing AA during ageing. Age-related decreases in
177 | P a g e

CHAPTER 9

phospholipids containing other long-chain n-6 fatty acids such as adrenic and
docosapentaenoic acid are also expected under this theory, as both can undergo βoxidation within the peroxisomes to form AA (Chapter 2, Figure 2-4). Minimal changes
with age in levels of phospholipids with DHA are expected under this theory due to the
comparably low affinity of both cytosolic phospholipid A2 and COX-1/2 for DHA
(Chapter 2, section 2.4.3). Additionally, the changes with age due to chronic, low-grade
inflammation are not expected to be confined to a single membrane fraction.
Within the five regions of the human brain examined in this thesis decreases occurred
with age in numerous phospholipids containing long-chain n-6 fatty acids, particularly
AA and adrenic acid. n-6 docosapentaenoic acid was not able to be separated from its n3 isomer by the mass spectrometry method used, and so any isomer-specific age-related
changes to this fatty acid remain undiscovered. Increases with age in molecular
phospholipids containing DHA were observed in both the mitochondrial and
microsomal fractions of most of the regions of the brain examined in this thesis. The
findings of the present work correspond to that predicted by the inflammageing theory,
indicating that chronic, low-grade inflammation may by be a considerable driving force
behind normal ageing within the human brain. However, more work is needed to
confirm this finding, and any recommendations for future research to corroborate this
involvement of phospholipids in the inflammageing theory of ageing will be discussed
below.

9.5 Summary and future recommendations
The primary aim of this thesis was to quantify for the first time the changes occurring to
molecular phospholipids within the three major classes during normal ageing across five
regions of the human brain. There were three main findings that could be observed
across the five regions. Firstly, there were no changes to total quantified phospholipids
with ageing uncovered within this thesis. Secondly, few changes with age were
observed in the total amount of PC, PE or PS phospholipids within the mitochondrial or
microsomal membranes in most brain regions. The only region to experience such agerelated changes was the entorhinal cortex, in which decreases in total mitochondrial PC
and increases in total mitochondrial PE with age were observed (Chapter 6, section
6.2.2). Finally, many age-related changes were reported in a diverse range phospholipid
molecular species within both the mitochondrial and microsomal membranes, with no
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preference for changes in either membrane fraction over the other. Many phospholipids
with n-6 fatty acids decreased with age in most of the examined brain regions while
increases were seen in many phospholipids containing the n-3 fatty acid DHA. This
age-related increase in DHA within the brain was a key feature that distinguished the
changes to phospholipids during normal ageing from those reported in the literature for
dementia such as AD (section 9.3.2). Alongside the lack of change to one specific
membrane system over another (i.e. mitochondrial versus microsomal), the results of
this thesis were determined to support the inflammageing theory of ageing rather than
the mitochondrial free radical oxidative theory of ageing.
Since this is the first report of changes occurring to molecular phospholipids with age in
the human brain, the findings of this thesis should be confirmed by future studies
utilising a different, larger, cohort of subjects. The finding that DHA gradually increases
within the phospholipids of the human brain with age in particular warrants further
analysis to confirm and to establish the mechanism driving such changes. It will be
difficult, if not impossible to test if diet drives this increase in DHA with age with a
human post-mortem cohort. However, examining the changes with age in the activity of
enzymes involved in the formation of DHA from short chain precursors in post-mortem
tissue is a possibility, as well as the exploration of age-related changes in the
deacylation and reacylation pathways that remodel phospholipids to contain
predominately PUFA in the sn-2 position. All three phospholipid classes can be
produced by remodelling pathways, some of which are known to have specificity for
phospholipids containing DHA. PSS2 is such an enzyme, which synthesises PS from PE
and is known to have a preference for phospholipids with DHA in the sn-2 position
[46]. PSD, which synthesises PE preferentially from PS phospholipids with PUFA in
the sn-2 position within the inner mitochondrial membrane [48], is another phospholipid
synthesis pathway that should be targeted for future research. There is little information
overall available on the activity of enzymes involved in the synthesis of molecular
phospholipids within the human brain, and so investigating this and any age-related
changes would fill a considerable gap in the current literature.
Due to the mass spectrometry methods used in this study, the changes with age within
the brain to alkyl- and alkenyl-ether (plasmalogens) were not able to be separated from
those of their odd-chain diacyl counterparts and so any age-related changes in these
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phospholipids within the human brain remain to be discovered. Shotgun methods are
available to separate such phospholipids from each other, either by derivatisation or by
exploiting the lability of the ether-bond present. One example of such a method is the
hydrolysis of the vinyl ether bond present in plasmalogens by acid vapour, a technique
that separates plasmalogens from both isobaric alkyl-ether and odd-chain diacyl
phospholipids [184]. Another involves selective derivitisation of plasmalogens within a
lipid mixture, and the resulting mass-shift being used to identify plasmalogens
preferentially from alkyl-ether and odd-chain diacyl phospholipids [223]. Alternatively,
age-related changes to ether-phospholipids could be explored using liquid
chromatography mass spectrometry. However, such techniques would require repeating
the entire cohort and was unfeasible for the present thesis due to time and financial
constraints. All of the samples extracted for this study have been stored, and so such a
study could be conducted in the future.
The data collected within this thesis supported the predictions of the inflammageing
theory of ageing over that of the mitochondrial free radical oxidative theory of ageing.
However, to definitively determine what is driving age-related changes within the
human brain more study need to be performed. Enzymatic (inflammation) and nonenzymatic (oxidative) pathways produce different molecules which can be measured in
post-mortem tissue and quantified. Previous studies have found increases in several
lipid products of oxidative stress with age, including MDA in the brain tissue of aged
rats [139–143] and humans [144], 4-HNE in the brains of aged mice [145], senescenceaccelerated mice [146], rats [147], and dogs [148], and F2-isoprostanes in human
cerebrospinal fluid [149,150]. However, these studies are far from providing the
complete assessment of age-related changes to the levels of oxidative products with the
human brain, and much work remains to confirm these findings. A thorough literature
search for any reported age-related changes in expression or activity levels of enzymes
involved in the production of inflammatory eicosanoids from AA within any human
tissue failed to find any such data. Therefore, it remains to be confirmed if the changes
seen during normal ageing within this thesis can be directly attributed to low-grade
chronic inflammation.

180 | P a g e

BIBLIOGRAPHY

Bibliography
[1]

[2]
[3]
[4]

[5]
[6]
[7]
[8]

[9]

[10]
[11]

[12]

[13]
[14]
[15]

WHO, “Global health and ageing,” Oct-2011. [Online]. Available:
http://www.who.int/ageing/publications/global_health/en/index.html. [Accessed:
12-Feb-2014].
Australian Bureau of Statistics, Census of Population and Housing: Ageing in
Australia 2001. Canberra, Australia, 2003.
Australian Bureau of Statistics, Population Projections Australia: 2006 to 2101.
Canberra, Australia, 2008.
World Health Organisation and Alzheimer’s Disease International, “Dementia: a
public
health
priority,”
WHO,
2012.
[Online].
Available:
http://www.who.int/mental_health/publications/dementia_report_2012/en/.
[Accessed: 12-Feb-2014].
Australian Institute of Health and Welfare, Dementia in Australia. Canberra,
Australia, 2012.
H. Braak and E. Braak, “Staging of alzheimer’s disease-related neurofibrillary
changes,” Neurobiol. Aging, vol. 16, no. 3, pp. 271–278, May 1995.
H. Braak and E. Braak, “Neuropathological stageing of Alzheimer-related
changes,” Acta Neuropathol. (Berl.), vol. 82, no. 4, pp. 239–259, 1991.
R. H. Swerdlow, “Brain aging, Alzheimer’s disease, and mitochondria,” Biochim.
Biophys. Acta BBA - Mol. Basis Dis., vol. 1812, no. 12, pp. 1630–1639, Dec.
2011.
M. N. Braskie and P. M. Thompson, “Understanding cognitive deficits in
Alzheimer’s disease based on neuroimaging findings,” Trends Cogn. Sci., vol. 17,
no. 10, pp. 510–516, Oct. 2013.
K. Blennow, M. J. de Leon, and H. Zetterberg, “Alzheimer’s disease,” Lancet,
vol. 368, no. 9533, pp. 387–403, Jul. 2006.
W. J. Lukiw, M. Pappolla, R. P. Pelaez, and N. G. Bazan, “Alzheimer’s disease-a dysfunction in cholesterol and lipid metabolism,” Cell. Mol. Neurobiol., vol. 25,
no. 3–4, pp. 475–483, Jun. 2005.
M. M. Mielke and C. G. Lyketsos, “Lipids and the pathogenesis of Alzheimer’s
disease: is there a link?,” Int. Rev. Psychiatry Abingdon Engl., vol. 18, no. 2, pp.
173–186, Apr. 2006.
L. Bertram and R. E. Tanzi, “Genome-wide association studies in Alzheimer’s
disease,” Hum. Mol. Genet., vol. 18, no. R2, pp. R137–R145, Oct. 2009.
K. Bettens, K. Sleegers, and C. Van Broeckhoven, “Genetic insights in
Alzheimer’s disease,” Lancet Neurol., vol. 12, no. 1, pp. 92–104, Jan. 2013.
D. Harold, R. Abraham, P. Hollingworth, R. Sims, A. Gerrish, M. L. Hamshere,
J. S. Pahwa, V. Moskvina, K. Dowzell, A. Williams, N. Jones, C. Thomas, A.
Stretton, A. R. Morgan, S. Lovestone, J. Powell, P. Proitsi, M. K. Lupton, C.
Brayne, D. C. Rubinsztein, M. Gill, B. Lawlor, A. Lynch, K. Morgan, K. S.
Brown, P. A. Passmore, D. Craig, B. McGuinness, S. Todd, C. Holmes, D. Mann,
A. D. Smith, S. Love, P. G. Kehoe, J. Hardy, S. Mead, N. Fox, M. Rossor, J.
Collinge, W. Maier, F. Jessen, B. Schürmann, R. Heun, H. van den Bussche, I.
Heuser, J. Kornhuber, J. Wiltfang, M. Dichgans, L. Frölich, H. Hampel, M. Hüll,
D. Rujescu, A. M. Goate, J. S. K. Kauwe, C. Cruchaga, P. Nowotny, J. C. Morris,
K. Mayo, K. Sleegers, K. Bettens, S. Engelborghs, P. P. De Deyn, C. Van
Broeckhoven, G. Livingston, N. J. Bass, H. Gurling, A. McQuillin, R. Gwilliam,
P. Deloukas, A. Al-Chalabi, C. E. Shaw, M. Tsolaki, A. B. Singleton, R.
181 | P a g e

BIBLIOGRAPHY

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

Guerreiro, T. W. Mühleisen, M. M. Nöthen, S. Moebus, K.-H. Jöckel, N. Klopp,
H.-E. Wichmann, M. M. Carrasquillo, V. S. Pankratz, S. G. Younkin, P. A.
Holmans, M. O’Donovan, M. J. Owen, and J. Williams, “Genome-wide
association study identifies variants at CLU and PICALM associated with
Alzheimer’s disease,” Nat. Genet., vol. 41, no. 10, pp. 1088–1093, Oct. 2009.
H. Lemaître, A. L. Goldman, F. Sambataro, B. A. Verchinski, A. MeyerLindenberg, D. R. Weinberger, and V. S. Mattay, “Normal age-related brain
morphometric changes: nonuniformity across cortical thickness, surface area and
gray matter volume?,” Neurobiol. Aging, vol. 33, no. 3, pp. 617.e1–617.e9, Mar.
2012.
A. M. Fjell, L. T. Westlye, H. Grydeland, I. Amlien, T. Espeseth, I. Reinvang, N.
Raz, A. M. Dale, and K. B. Walhovd, “Accelerating Cortical Thinning: Unique to
Dementia or Universal in Aging?,” Cereb. Cortex, vol. 24, no. 4, pp. 919–934,
Apr. 2014.
L. J. Hogstrom, L. T. Westlye, K. B. Walhovd, and A. M. Fjell, “The Structure of
the Cerebral Cortex Across Adult Life: Age-Related Patterns of Surface Area,
Thickness, and Gyrification,” Cereb. Cortex, vol. 23, no. 11, pp. 2521–2530,
Nov. 2013.
J. Jiang, P. Sachdev, D. M. Lipnicki, H. Zhang, T. Liu, W. Zhu, C. Suo, L.
Zhuang, J. Crawford, S. Reppermund, J. Trollor, H. Brodaty, and W. Wen, “A
longitudinal study of brain atrophy over two years in community-dwelling older
individuals,” NeuroImage, vol. 86, pp. 203–211, Feb. 2014.
D. H. Salat, R. L. Buckner, A. Z. Snyder, D. N. Greve, R. S. R. Desikan, E. Busa,
J. C. Morris, A. M. Dale, and B. Fischl, “Thinning of the Cerebral Cortex in
Aging,” Cereb. Cortex, vol. 14, no. 7, pp. 721–730, Jul. 2004.
D. A. Ziegler, O. Piguet, D. H. Salat, K. Prince, E. Connally, and S. Corkin,
“Cognition in healthy aging is related to regional white matter integrity, but not
cortical thickness,” Neurobiol. Aging, vol. 31, no. 11, pp. 1912–1926, Nov. 2010.
C. D. Good, I. S. Johnsrude, J. Ashburner, R. N. A. Henson, K. J. Friston, and R.
S. J. Frackowiak, “A Voxel-Based Morphometric Study of Ageing in 465 Normal
Adult Human Brains,” NeuroImage, vol. 14, no. 1, pp. 21–36, Jul. 2001.
H. Lemaître, F. Crivello, B. Grassiot, A. Alpérovitch, C. Tzourio, and B.
Mazoyer, “Age- and sex-related effects on the neuroanatomy of healthy elderly,”
NeuroImage, vol. 26, no. 3, pp. 900–911, Jul. 2005.
H. Oh, C. Madison, S. Villeneuve, C. Markley, and W. J. Jagust, “Association of
Gray Matter Atrophy with Age, β-Amyloid, and Cognition in Aging,” Cereb.
Cortex, vol. 24, no. 6, pp. 1609–1618, Jun. 2014.
N. Raz, F. M. Gunning, D. Head, J. H. Dupuis, J. McQuain, S. D. Briggs, W. J.
Loken, A. E. Thornton, and J. D. Acker, “Selective aging of the human cerebral
cortex observed in vivo: differential vulnerability of the prefrontal gray matter.,”
Cereb. Cortex, vol. 7, no. 3, pp. 268–282, Apr. 1997.
S. M. Resnick, D. L. Pham, M. A. Kraut, A. B. Zonderman, and C. Davatzikos,
“Longitudinal Magnetic Resonance Imaging Studies of Older Adults: A
Shrinking Brain,” J. Neurosci., vol. 23, no. 8, pp. 3295–3301, Apr. 2003.
E. R. Sowell, B. S. Peterson, P. M. Thompson, S. E. Welcome, A. L. Henkenius,
and A. W. Toga, “Mapping cortical change across the human life span,” Nat.
Neurosci., vol. 6, no. 3, pp. 309–315, Mar. 2003.
J. Aanerud, P. Borghammer, M. M. Chakravarty, K. Vang, A. B. Rodell, K. Y.
Jónsdottir, A. Møller, M. Ashkanian, M. S. Vafaee, P. Iversen, P. Johannsen, and
182 | P a g e

BIBLIOGRAPHY

[29]
[30]

[31]

[32]

[33]

[34]

[35]
[36]
[37]

[38]

[39]

[40]
[41]
[42]

[43]

[44]

A. Gjedde, “Brain energy metabolism and blood flow differences in healthy
aging,” J. Cereb. Blood Flow Metab., vol. 32, no. 7, pp. 1177–1187, Jul. 2012.
S. J. Blanksby and T. W. Mitchell, “Advances in mass spectrometry for
lipidomics,” Annu. Rev. Anal. Chem. Palo Alto Calif, vol. 3, pp. 433–465, 2010.
L. Yetukuri, K. Ekroos, A. Vidal-Puig, and M. Orešič, “Informatics and
computational strategies for the study of lipids,” Mol. Biosyst., vol. 4, no. 2, pp.
121–127, Jan. 2008.
A. A. Farooqui, L. A. Horrocks, and T. Farooqui, “Glycerophospholipids in
brain: their metabolism, incorporation into membranes, functions, and
involvement in neurological disorders,” Chem. Phys. Lipids, vol. 106, no. 1, pp.
1–29, Jun. 2000.
G. van Meer, D. R. Voelker, and G. W. Feigenson, “Membrane lipids: where they
are and how they behave,” Nat. Rev. Mol. Cell Biol., vol. 9, no. 2, pp. 112–124,
Feb. 2008.
V. Frisardi, F. Panza, D. Seripa, T. Farooqui, and A. A. Farooqui,
“Glycerophospholipids and glycerophospholipid-derived lipid mediators: A
complex meshwork in Alzheimer’s disease pathology,” Prog. Lipid Res., vol. 50,
no. 4, pp. 313–330, Oct. 2011.
J. S. O’Brien and E. L. Sampson, “Lipid composition of the normal human brain:
gray matter, white matter, and myelin,” J. Lipid Res., vol. 6, no. 4, pp. 537–544,
Oct. 1965.
L. Svennerholm, “Distribution and fatty acid composition of phosphoglycerides
in normal human brain,” J. Lipid Res., vol. 9, no. 5, pp. 570–579, Sep. 1968.
A. A. Farooqui, L. A. Horrocks, and T. Farooqui, “Modulation of inflammation
in brain: a matter of fat,” J. Neurochem., vol. 101, no. 3, pp. 577–599, May 2007.
K. A. Youdim, A. Martin, and J. A. Joseph, “Essential fatty acids and the brain:
possible health implications,” Int. J. Dev. Neurosci., vol. 18, no. 4–5, pp. 383–
399, Jul. 2000.
L. A. Horrocks and A. A. Farooqui, “Docosahexaenoic acid in the diet: its
importance in maintenance and restoration of neural membrane function,”
Prostaglandins Leukot. Essent. Fatty Acids, vol. 70, no. 4, pp. 361–372, Apr.
2004.
P. C. Schmid, I. Spimrova, and H. H. O. Schmid, “Generation and remodeling of
highly polyunsaturated molecular species of rat hepatocyte phospholipids,”
Lipids, vol. 32, no. 11, pp. 1181–1187, Nov. 1997.
J. E. Vance and D. E. Vance, “Phospholipid biosynthesis in mammalian cells,”
Biochem. Cell Biol. Biochim. Biol. Cell., vol. 82, no. 1, pp. 113–128, Feb. 2004.
J. E. Vance, “Phospholipid synthesis in a membrane fraction associated with
mitochondria.,” J. Biol. Chem., vol. 265, no. 13, pp. 7248–7256, May 1990.
P. C. Schmid, E. Deli, and H. H. O. Schmid, “Generation and Remodeling of
Phospholipid Molecular Species in Rat Hepatocytes,” Arch. Biochem. Biophys.,
vol. 319, no. 1, pp. 168–176, May 1995.
A. Yamashita, Y. Hayashi, Y. Nemoto-Sasaki, M. Ito, S. Oka, T. Tanikawa, K.
Waku, and T. Sugiura, “Acyltransferases and transacylases that determine the
fatty acid composition of glycerolipids and the metabolism of bioactive lipid
mediators in mammalian cells and model organisms,” Prog. Lipid Res., vol. 53,
pp. 18–81, Jan. 2014.
S. J. Stone and J. E. Vance, “Phosphatidylserine Synthase-1 and -2 Are Localized
to Mitochondria-associated Membranes,” J. Biol. Chem., vol. 275, no. 44, pp.
34534–34540, Nov. 2000.
183 | P a g e

BIBLIOGRAPHY

[45] M. O. Bergo, B. J. Gavino, R. Steenbergen, B. Sturbois, A. F. Parlow, D. A.
Sanan, W. C. Skarnes, J. E. Vance, and S. G. Young, “Defining the Importance of
Phosphatidylserine Synthase 2 in Mice,” J. Biol. Chem., vol. 277, no. 49, pp.
47701–47708, Dec. 2002.
[46] A. K. Kimura and H.-Y. Kim, “Phosphatidylserine synthase 2: high efficiency for
synthesizing phosphatidylserine containing docosahexaenoic acid,” J. Lipid Res.,
vol. 54, no. 1, pp. 214–222, Jan. 2013.
[47] M. . Ilincheta de Boschero, M. . Roque, G. . Salvador, and N. . Giusto,
“Alternative pathways for phospholipid synthesis in different brain areas during
aging,” Exp. Gerontol., vol. 35, no. 5, pp. 653–668, Aug. 2000.
[48] O. B. Bleijerveld, J. F. H. M. Brouwers, A. B. Vaandrager, J. B. Helms, and M.
Houweling, “The CDP-ethanolamine Pathway and Phosphatidylserine
Decarboxylation Generate Different Phosphatidylethanolamine Molecular
Species,” J. Biol. Chem., vol. 282, no. 39, pp. 28362–28372, Sep. 2007.
[49] D. H. Kim, S. H. Yeo, J.-M. Park, J. Y. Choi, T.-H. Lee, S. Y. Park, M. S. Ock, J.
Eo, H.-S. Kim, and H.-J. Cha, “Genetic markers for diagnosis and pathogenesis
of Alzheimer’s disease,” Gene, vol. 545, no. 2, pp. 185–193, Jul. 2014.
[50] D. E. Vance and J. E. Vance, “Physiological consequences of disruption of
mammalian phospholipid biosynthetic genes,” J. Lipid Res., vol. 50, no.
Supplement, pp. S132–S137, Dec. 2008.
[51] J. E. Vance, “Thematic Review Series: Glycerolipids. Phosphatidylserine and
phosphatidylethanolamine in mammalian cells: two metabolically related
aminophospholipids,” J. Lipid Res., vol. 49, no. 7, pp. 1377–1387, Jul. 2008.
[52] Z. Cui, J. E. Vance, M. H. Chen, D. R. Voelker, and D. E. Vance, “Cloning and
expression of a novel phosphatidylethanolamine N-methyltransferase. A specific
biochemical and cytological marker for a unique membrane fraction in rat liver.,”
J. Biol. Chem., vol. 268, no. 22, pp. 16655–16663, Aug. 1993.
[53] C. J. Walkey, L. Yu, L. B. Agellon, and D. E. Vance, “Biochemical and
Evolutionary Significance of Phospholipid Methylation,” J. Biol. Chem., vol.
273, no. 42, pp. 27043–27046, Oct. 1998.
[54] X.-H. Bi, H.-L. Zhao, Z.-X. Zhang, and J.-W. Zhang, “PEMT G523A (V175M) is
associated with sporadic Alzheimer’s disease in a Chinese population,” J. Mol.
Neurosci. MN, vol. 46, no. 3, pp. 505–508, Mar. 2012.
[55] Z.-Z. Guan, Y.-N. Wang, K.-Q. Xiao, P.-S. Hu, and J.-L. Liu, “Activity of
phosphatidylethanolamine-N-methyltransferase in brain affected by Alzheimers
disease,” Neurochem. Int., vol. 34, no. 1, pp. 41–47, Jan. 1999.
[56] H. Sprecher, “Metabolism of highly unsaturated n-3 and n-6 fatty acids,”
Biochim. Biophys. Acta BBA - Mol. Cell Biol. Lipids, vol. 1486, no. 2–3, pp. 219–
231, Jul. 2000.
[57] A. Voss, M. Reinhart, S. Sankarappa, and H. Sprecher, “The metabolism of
7,10,13,16,19-docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in
rat liver is independent of a 4-desaturase.,” J. Biol. Chem., vol. 266, no. 30, pp.
19995–20000, Oct. 1991.
[58] M. Martinez, “Abnormal profiles of polyunsaturated fatty acids in the brain, liver,
kidney and retina of patients with peroxisomal disorders,” Brain Res., vol. 583,
no. 1–2, pp. 171–182, Jun. 1992.
[59] M. Martinez and I. Mougan, “Fatty acid composition of brain
glycerophospholipids in peroxisomal disorders,” Lipids, vol. 34, no. 7, pp. 733–
740, Jul. 1999.
184 | P a g e

BIBLIOGRAPHY

[60] E. Christensen, B. Woldseth, T. A. Hagve, B. T. Poll-The, R. J. Wanders, H.
Sprecher, O. Stokke, and B. O. Christophersen, “Peroxisomal β-oxidation of
polyunsaturated long chain fatty acids in human fibroblasts. The polyunsaturated
and the saturated long chain fatty acids are retroconverted by the same acyl-CoA
oxidase,” Scand. J. Clin. Lab. Investig. Suppl., vol. 215, pp. 61–74, 1993.
[61] S. A. Moore, E. Hurt, E. Yoder, H. Sprecher, and A. A. Spector,
“Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal
retroconversion of tetracosahexaenoic acid.,” J. Lipid Res., vol. 36, no. 11, pp.
2433–2443, Nov. 1995.
[62] H. P. Cho, M. T. Nakamura, and S. D. Clarke, “Cloning, Expression, and
Nutritional Regulation of the Mammalian Δ-6 Desaturase,” J. Biol. Chem., vol.
274, no. 1, pp. 471–477, Jan. 1999.
[63] S. I. Rapoport and M. Igarashi, “Can the rat liver maintain normal brain DHA
metabolism in the absence of dietary DHA?,” Prostaglandins Leukot. Essent.
Fatty Acids, vol. 81, no. 2–3, pp. 119–123, Aug. 2009.
[64] S. A. Moore, E. Yoder, S. Murphy, G. R. Dutton, and A. A. Spector, “Astrocytes,
not neurons, produce docosahexaenoic acid (22:6 omega-3) and arachidonic acid
(20:4 omega-6),” J. Neurochem., vol. 56, no. 2, pp. 518–524, Feb. 1991.
[65] C. Bénistant, M. P. Dehouck, J. C. Fruchart, R. Cecchelli, and M. Lagarde, “Fatty
acid composition of brain capillary endothelial cells: effect of the coculture with
astrocytes.,” J. Lipid Res., vol. 36, no. 11, pp. 2311–2319, Nov. 1995.
[66] N. Bernoud, L. Fenart, C. Bénistant, J. F. Pageaux, M. P. Dehouck, P. Molière,
M. Lagarde, R. Cecchelli, and J. Lecerf, “Astrocytes are mainly responsible for
the polyunsaturated fatty acid enrichment in blood–brain barrier endothelial cells
in vitro,” J. Lipid Res., vol. 39, no. 9, pp. 1816–1824, Sep. 1998.
[67] J. T. Brenna, N. Salem Jr., A. J. Sinclair, and S. C. Cunnane, “α-Linolenic acid
supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in
humans,” Prostaglandins Leukot. Essent. Fatty Acids, vol. 80, no. 2–3, pp. 85–
91, Feb. 2009.
[68] G. C. Burdge, Y. E. Finnegan, A. M. Minihane, C. M. Williams, and S. A.
Wootton, “Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty
acid composition, conversion of [13C]α-linolenic acid to longer-chain fatty acids
and partitioning towards β-oxidation in older men,” Br. J. Nutr., vol. 90, no. 02,
pp. 311–321, 2003.
[69] H. D. Le, J. A. Meisel, V. E. de Meijer, K. M. Gura, and M. Puder, “The
essentiality of arachidonic acid and docosahexaenoic acid,” Prostaglandins
Leukot. Essent. Fatty Acids, vol. 81, no. 2–3, pp. 165–170, Aug. 2009.
[70] M. Martínez and I. Mougan, “Fatty Acid Composition of Human Brain
Phospholipids During Normal Development,” J. Neurochem., vol. 71, no. 6, pp.
2528–2533, Dec. 1998.
[71] S. M. Innis, “Dietary (n-3) Fatty Acids and Brain Development1,2,” J. Nutr., vol.
137, no. 4, pp. 855–9, Apr. 2007.
[72] R. S. Kuipers, M. F. Luxwolda, P. J. Offringa, E. Rudi Boersma, D. A. J. DijckBrouwer, and F. A. J. Muskiet, “Fetal intrauterine whole body linoleic,
arachidonic and docosahexaenoic acid contents and accretion rates,”
Prostaglandins Leukot. Essent. Fatty Acids, vol. 86, no. 1–2, pp. 13–20, Jan.
2012.
[73] C. I. F. Janssen and A. J. Kiliaan, “Long-chain polyunsaturated fatty acids
(LCPUFA) from genesis to senescence: The influence of LCPUFA on neural
185 | P a g e

BIBLIOGRAPHY

[74]

[75]
[76]

[77]

[78]
[79]

[80]

[81]

[82]

[83]

[84]

[85]

[86]

[87]

development, aging, and neurodegeneration,” Prog. Lipid Res., vol. 53, pp. 1–17,
Jan. 2014.
L. N. Nguyen, D. Ma, G. Shui, P. Wong, A. Cazenave-Gassiot, X. Zhang, M. R.
Wenk, E. L. K. Goh, and D. L. Silver, “Mfsd2a is a transporter for the essential
omega-3 fatty acid docosahexaenoic acid,” Nature, vol. 509, no. 7501, pp. 503–
506, May 2014.
J. A. Hamilton and K. Brunaldi, “A Model for Fatty Acid Transport into the
Brain,” J. Mol. Neurosci., vol. 33, no. 1, pp. 12–17, Jul. 2007.
R. P. Bazinet and S. Layé, “Polyunsaturated fatty acids and their metabolites in
brain function and disease,” Nat. Rev. Neurosci., vol. 15, no. 12, pp. 771–85,
Dec. 2014.
N. Parletta, C. M. Milte, and B. J. Meyer, “Nutritional modulation of cognitive
function and mental health,” J. Nutr. Biochem., vol. 24, no. 5, pp. 725–743, May
2013.
N. Nagan and R. A. Zoeller, “Plasmalogens: biosynthesis and functions,” Prog.
Lipid Res., vol. 40, no. 3, pp. 199–229, May 2001.
N. E. Braverman and A. B. Moser, “Functions of plasmalogen lipids in health and
disease,” Biochim. Biophys. Acta BBA - Mol. Basis Dis., vol. 1822, no. 9, pp.
1442–1452, Sep. 2012.
P. Brites, H. R. Waterham, and R. J. A. Wanders, “Functions and biosynthesis of
plasmalogens in health and disease,” Biochim. Biophys. Acta BBA - Mol. Cell
Biol. Lipids, vol. 1636, no. 2–3, pp. 219–231, Mar. 2004.
T. Lee, “Biosynthesis and possible biological functions of plasmalogens,”
Biochim. Biophys. Acta BBA - Lipids Lipid Metab., vol. 1394, no. 2–3, pp. 129–
145, Nov. 1998.
M. Honsho, Y. Yagita, N. Kinoshita, and Y. Fujiki, “Isolation and
characterization of mutant animal cell line defective in alkyldihydroxyacetonephosphate synthase: Localization and transport of plasmalogens
to post-Golgi compartments,” Biochim. Biophys. Acta BBA - Mol. Cell Res., vol.
1783, no. 10, pp. 1857–1865, Oct. 2008.
L. J. Pike, X. Han, K.-N. Chung, and R. W. Gross, “Lipid Rafts Are Enriched in
Arachidonic Acid and Plasmenylethanolamine and Their Composition Is
Independent of Caveolin-1 Expression: A Quantitative Electrospray
Ionization/Mass Spectrometric Analysis†,” Biochemistry (Mosc.), vol. 41, no. 6,
pp. 2075–2088, Feb. 2002.
A. Broniec, R. Klosinski, A. Pawlak, M. Wrona-Krol, D. Thompson, and T.
Sarna, “Interactions of plasmalogens and their diacyl analogs with singlet oxygen
in selected model systems,” Free Radic. Biol. Med., vol. 50, no. 7, pp. 892–898,
Apr. 2011.
X. Han, D. M. Holtzman, and D. W. McKeel Jr, “Plasmalogen deficiency in early
Alzheimer’s disease subjects and in animal models: molecular characterization
using electrospray ionization mass spectrometry,” J. Neurochem., vol. 77, no. 4,
pp. 1168–1180, May 2001.
Z. Guan, Y. Wang, N. J. Cairns, P. L. Lantos, G. Dallner, and P. J. Sindelar,
“Decrease and structural modifications of phosphatidylethanolamine plasmalogen
in the brain with Alzheimer disease,” J. Neuropathol. Exp. Neurol., vol. 58, no. 7,
pp. 740–747, Jul. 1999.
M. Igarashi, K. Ma, F. Gao, H.-W. Kim, S. I. Rapoport, and J. S. Rao, “Disturbed
choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer’s
186 | P a g e

BIBLIOGRAPHY

[88]

[89]

[90]

[91]

[92]

[93]

[94]

[95]

[96]

[97]

[98]

[99]

[100]

disease prefrontal cortex,” J. Alzheimers Dis. JAD, vol. 24, no. 3, pp. 507–517,
2011.
L. Svennerholm, K. Boström, and B. Jungbjer, “Changes in weight and
compositions of major membrane components of human brain during the span of
adult human life of Swedes,” Acta Neuropathol. (Berl.), vol. 94, no. 4, pp. 345–
352, Oct. 1997.
L. Svennerholm, K. Boström, C. G. Helander, and B. Jungbjer, “Membrane lipids
in the aging human brain,” J. Neurochem., vol. 56, no. 6, pp. 2051–2059, Jun.
1991.
M. Söderberg, C. Edlund, K. Kristensson, and G. Dallner, “Lipid compositions of
different regions of the human brain during aging,” J. Neurochem., vol. 54, no. 2,
pp. 415–423, Feb. 1990.
L. Svennerholm, K. Boström, B. Jungbjer, and L. Olsson, “Membrane Lipids of
Adult Human Brain: Lipid Composition of Frontal and Temporal Lobe in
Subjects of Age 20 to 100 Years,” J. Neurochem., vol. 63, no. 5, pp. 1802–1811,
1994.
V. Martín, N. Fabelo, G. Santpere, B. Puig, R. Marín, I. Ferrer, and M. Díaz,
“Lipid alterations in lipid rafts from Alzheimer’s disease human brain cortex,” J.
Alzheimers Dis. JAD, vol. 19, no. 2, pp. 489–502, 2010.
M. Söderberg, C. Edlund, K. Kristensson, and G. Dallner, “Fatty acid
composition of brain phospholipids in aging and in Alzheimer’s disease,” Lipids,
vol. 26, no. 6, pp. 421–425, Jun. 1991.
J. D. Carver, V. J. Benford, B. Han, and A. B. Cantor, “The relationship between
age and the fatty acid composition of cerebral cortex and erythrocytes in human
subjects,” Brain Res. Bull., vol. 56, no. 2, pp. 79–85, Sep. 2001.
R. K. McNamara, Y. Liu, R. Jandacek, T. Rider, and P. Tso, “The aging human
orbitofrontal cortex: Decreasing polyunsaturated fatty acid composition and
associated increases in lipogenic gene expression and stearoyl-CoA desaturase
activity,” Prostaglandins Leukot. Essent. Fatty Acids, vol. 78, no. 4–5, pp. 293–
304, Apr. 2008.
T. Fraser, H. Tayler, and S. Love, “Fatty acid composition of frontal, temporal
and parietal neocortex in the normal human brain and in Alzheimer’s disease,”
Neurochem. Res., vol. 35, no. 3, pp. 503–513, Mar. 2010.
G. Barceló-Coblijn, E. Hőgyes, K. Kitajka, L. G. Puskás, Á. Zvara, L. Hackler,
C. Nyakas, Z. Penke, and T. Farkas, “Modification by docosahexaenoic acid of
age-induced alterations in gene expression and molecular composition of rat brain
phospholipids,” Proc. Natl. Acad. Sci., vol. 100, no. 20, pp. 11321–11326, Sep.
2003.
S. Favrielère, S. Stadelmann-Ingrand, F. Huguet, D. De Javel, A. Piriou, C.
Tallineau, and G. Durand, “Age-related changes in ethanolamine
glycerophospholipid fatty acid levels in rat frontal cortex and hippocampus,”
Neurobiol. Aging, vol. 21, no. 5, pp. 653–660, Oct. 2000.
S. J. Little, M. A. Lynch, M. Manku, and A. Nicolaou, “Docosahexaenoic acidinduced changes in phospholipids in cortex of young and aged rats: A lipidomic
analysis,” Prostaglandins Leukot. Essent. Fatty Acids, vol. 77, no. 3–4, pp. 155–
162, Oct. 2007.
G. H. López, M. G. Ilincheta de Boschero, P. I. Castagnet, and N. M. Giusto,
“Age-associated changes in the content and fatty acid composition of brain
glycerophospholipids,” Comp. Biochem. Physiol. B Biochem. Mol. Biol., vol.
112, no. 2, pp. 331–343, Oct. 1995.
187 | P a g e

BIBLIOGRAPHY

[101] B. M. McGahon, D. S. D. Martin, D. F. Horrobin, and M. A. Lynch, “Age-related
changes in synaptic function: analysis of the effect of dietary supplementation
with ω-3 fatty acids,” Neuroscience, vol. 94, no. 1, pp. 305–314, Sep. 1999.
[102] L. Ulmann, V. Mimouni, S. Roux, R. Porsolt, and J.-P. Poisson, “Brain and
hippocampus fatty acid composition in phospholipid classes of aged-relative
cognitive deficit rats,” Prostaglandins Leukot. Essent. Fatty Acids, vol. 64, no. 3,
pp. 189–195, Mar. 2001.
[103] L. Yang, Y. Zhang, S. Wang, W. Zhang, and R. Shi, “Decreased liver
peroxisomal β-oxidation accompanied by changes in brain fatty acid composition
in aged rats,” Neurol. Sci., vol. 35, no. 2, pp. 289–293, Feb. 2014.
[104] Lihe Jiang, Yan Shi, Yin Long, and Zhirong Yang, “The influence of orally
administered docosahexaenoic acid on monoamine neurotransmitter, nerve
growth factor, and brain-derived neurotrophic factor in aged mice,” Pharm. Biol.,
vol. 47, no. 7, pp. 584–591, Jul. 2009.
[105] H. R. Modi, S. S. Katyare, and M. A. Patel, “Ageing-Induced Alterations in
Lipid/Phospholipid Profiles of Rat Brain and Liver Mitochondria: Implications
for Mitochondrial Energy-Linked Functions,” J. Membr. Biol., vol. 221, no. 1,
pp. 51–60, Jan. 2008.
[106] I. Rappley, D. S. Myers, S. B. Milne, P. T. Ivanova, M. J. LaVoie, H. A. Brown,
and D. J. Selkoe, “Lipidomic profiling in mouse brain reveals differences
between ages and genders, with smaller changes associated with α-synuclein
genotype,” J. Neurochem., vol. 111, no. 1, pp. 15–25, 2009.
[107] N. Fabelo, V. Martín, R. Marín, G. Santpere, E. Aso, I. Ferrer, and M. Díaz,
“Evidence for Premature Lipid Raft Aging in APP/PS1 Double-Transgenic Mice,
a Model of Familial Alzheimer Disease,” J. Neuropathol. Exp. Neurol., vol. 71,
no. 10, pp. 868–81, Oct. 2012.
[108] B. W. Brooksbank and M. Martinez, “Lipid abnormalities in the brain in adult
Down’s syndrome and Alzheimer’s disease,” Mol. Chem. Neuropathol. Spons.
Int. Soc. Neurochem. World Fed. Neurol. Res. Groups Neurochem. Cerebrospinal
Fluid, vol. 11, no. 3, pp. 157–185, Dec. 1989.
[109] L. Svennerholm and C. G. Gottfries, “Membrane lipids, selectively diminished in
Alzheimer brains, suggest synapse loss as a primary event in early-onset form
(type I) and demyelination in late-onset form (type II),” J. Neurochem., vol. 62,
no. 3, pp. 1039–1047, Mar. 1994.
[110] C. G. Gottfries, I. Karlsson, and L. Svennerholm, “Membrane components
separate early-onset Alzheimer’s disease from senile dementia of the Alzheimer
type,” Int. Psychogeriatrics IPA, vol. 8, no. 3, pp. 365–372, 1996.
[111] M. Söderberg, C. Edlund, I. Alafuzoff, K. Kristensson, and G. Dallner, “Lipid
composition in different regions of the brain in Alzheimer’s disease/senile
dementia of Alzheimer’s type,” J. Neurochem., vol. 59, no. 5, pp. 1646–1653,
Nov. 1992.
[112] J. W. Pettegrew, K. Panchalingam, R. L. Hamilton, and R. J. McClure, “Brain
membrane phospholipid alterations in Alzheimer’s disease,” Neurochem. Res.,
vol. 26, no. 7, pp. 771–782, Jul. 2001.
[113] K. Wells, A. A. Farooqui, L. Liss, and L. A. Horrocks, “Neural membrane
phospholipids in alzheimer disease,” Neurochem. Res., vol. 20, no. 11, pp. 1329–
1333, Nov. 1995.
[114] S. C. Cunnane, J. A. Schneider, C. Tangney, J. Tremblay-Mercier, M. Fortier, D.
A. Bennett, and M. C. Morris, “Plasma and brain fatty acid profiles in mild
188 | P a g e

BIBLIOGRAPHY

[115]

[116]

[117]

[118]

[119]

[120]
[121]

[122]

[123]

[124]

[125]

[126]

cognitive impairment and Alzheimer’s disease,” J. Alzheimers Dis. JAD, vol. 29,
no. 3, pp. 691–697, 2012.
M. O. W. Grimm, S. Grösgen, M. Riemenschneider, H. Tanila, H. S. Grimm, and
T. Hartmann, “From brain to food: Analysis of phosphatidylcholins, lysophosphatidylcholins and phosphatidylcholin–plasmalogens derivates in
Alzheimer’s disease human post mortem brains and mice model via mass
spectrometry,” J. Chromatogr. A, vol. 1218, no. 42, pp. 7713–7722, Oct. 2011.
R. B. Chan, T. G. Oliveira, E. P. Cortes, L. S. Honig, K. E. Duff, S. A. Small, M.
R. Wenk, G. Shui, and G. Di Paolo, “Comparative lipidomic analysis of mouse
and human brain with Alzheimer disease,” J. Biol. Chem., vol. 287, no. 4, pp.
2678–2688, Jan. 2012.
R. M. Nitsch, J. K. Blusztajn, A. G. Pittas, B. E. Slack, J. H. Growdon, and R. J.
Wurtman, “Evidence for a membrane defect in Alzheimer disease brain.,” Proc.
Natl. Acad. Sci., vol. 89, no. 5, pp. 1671–1675, Mar. 1992.
D. A. Butterfield and C. M. Lauderback, “Lipid peroxidation and protein
oxidation in Alzheimer’s disease brain: potential causes and consequences
involving amyloid β-peptide-associated free radical oxidative stress,” Free Radic.
Biol. Med., vol. 32, no. 11, pp. 1050–1060, Jun. 2002.
C. M. Milte, N. Sinn, and P. R. Howe, “Polyunsaturated fatty acid status in
attention deficit hyperactivity disorder, depression, and Alzheimer’s disease:
towards an omega-3 index for mental health?,” Nutr. Rev., vol. 67, no. 10, pp.
573–590, Oct. 2009.
P. L. Wood, “Lipidomics of Alzheimer’s disease: current status,” Alzheimers Res.
Ther., vol. 4, no. 1, p. 5, Feb. 2012.
E. R. Skinner, C. Watt, J. a. O. Besson, and P. V. Best, “Differences in the fatty
acid composition of the grey and white matter of different regions of the brains of
patients with Alzheimer’s disease and control subjects,” Brain, vol. 116, no. 3,
pp. 717–725, Jun. 1993.
F. M. Corrigan, D. F. Horrobin, E. R. Skinner, J. A. Besson, and M. B. Cooper,
“Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the
phosphoglycerides and cholesterol esters of parahippocampal cortex from
Alzheimer’s disease patients and its relationship to acetyl CoA content,” Int. J.
Biochem. Cell Biol., vol. 30, no. 2, pp. 197–207, Feb. 1998.
M. R. Prasad, M. A. Lovell, M. Yatin, H. Dhillon, and W. R. Markesbery,
“Regional membrane phospholipid alterations in Alzheimer’s disease,”
Neurochem. Res., vol. 23, no. 1, pp. 81–88, Jan. 1998.
D. Cheng, A. M. Jenner, G. Shui, W. F. Cheong, T. W. Mitchell, J. R. Nealon, W.
S. Kim, H. McCann, M. R. Wenk, G. M. Halliday, and B. Garner, “Lipid
Pathway Alterations in Parkinson’s Disease Primary Visual Cortex,” PLoS ONE,
vol. 6, no. 2, p. e17299, Feb. 2011.
S. M. Lam, Y. Wang, X. Duan, M. R. Wenk, R. N. Kalaria, C. P. Chen, M. K. P.
Lai, and G. Shui, “The brain lipidomes of subcortical ischemic vascular dementia
and mixed dementia,” Neurobiol. Aging, vol. 35, no. 10, pp. 2369–2381, Oct.
2014.
L. Ginsberg, S. Rafique, J. H. Xuereb, S. I. Rapoport, and N. L. Gershfeld,
“Disease and anatomic specificity of ethanolamine plasmalogen deficiency in
Alzheimer’s disease brain,” Brain Res., vol. 698, no. 1–2, pp. 223–226, Nov.
1995.

189 | P a g e

BIBLIOGRAPHY

[127] Y. Tamai, H. Kojima, F. Ikuta, and T. Kumanishi, “Alterations in the
composition of brain lipids in patients with Creutzfeldt-Jakob disease,” J. Neurol.
Sci., vol. 35, no. 1, pp. 59–76, Jan. 1978.
[128] A. Federico, P. Annunziata, and G. Malentacchi, “Neurochemical changes in
Creutzfeldt-Jakob disease,” J. Neurol., vol. 223, no. 2, pp. 135–146, 1980.
[129] B. T. Weinert and P. S. Timiras, “Invited Review: Theories of aging,” J. Appl.
Physiol., vol. 95, no. 4, pp. 1706–1716, Oct. 2003.
[130] N.-G. Larsson, “Somatic Mitochondrial DNA Mutations in Mammalian Aging,”
Annu. Rev. Biochem., vol. 79, no. 1, pp. 683–706, 2010.
[131] M. Lagouge and N.-G. Larsson, “The role of mitochondrial DNA mutations and
free radicals in disease and ageing,” J. Intern. Med., vol. 273, no. 6, pp. 529–543,
Jun. 2013.
[132] P. Mecocci, U. MacGarvey, A. E. Kaufman, D. Koontz, J. M. Shoffner, D. C.
Wallace, and M. F. Beal, “Oxidative damage to mitochondrial DNA shows
marked age-dependent increases in human brain,” Ann. Neurol., vol. 34, no. 4,
pp. 609–616, 1993.
[133] T. Finkel and N. J. Holbrook, “Oxidants, oxidative stress and the biology of
ageing,” Nature, vol. 408, no. 6809, pp. 239–247, Nov. 2000.
[134] S. Hekimi, J. Lapointe, and Y. Wen, “Taking a ‘good’ look at free radicals in the
aging process,” Trends Cell Biol., vol. 21, no. 10, pp. 569–576, Oct. 2011.
[135] S. I. Liochev, “Reactive oxygen species and the free radical theory of aging,”
Free Radic. Biol. Med., vol. 60, pp. 1–4, Jul. 2013.
[136] D. Harman, “Aging: A Theory Based on Free Radical and Radiation Chemistry,”
J. Gerontol., vol. 11, no. 3, pp. 298–300, Jul. 1956.
[137] J. M. McCord and I. Fridovich, “Superoxide Dismutase AN ENZYMIC
FUNCTION FOR ERYTHROCUPREIN (HEMOCUPREIN),” J. Biol. Chem.,
vol. 244, no. 22, pp. 6049–6055, Nov. 1969.
[138] B. Halliwell and J. Gutteridge, Free Radicals in Biology and Medicine, 4th
edition. Oxford ; New York: Oxford University Press, 2007.
[139] E. Babusikova, J. Hatok, D. Dobrota, and P. Kaplan, “Age-related Oxidative
Modifications of Proteins and Lipids in Rat Brain,” Neurochem. Res., vol. 32, no.
8, pp. 1351–1356, Aug. 2007.
[140] B. S. Baek, H. J. Kwon, K. H. Lee, M. A. Yoo, K. W. Kim, Y. Ikeno, B. P. Yu,
and H. Y. Chung, “Regional difference of ROS generation, lipid peroxidaton, and
antioxidant enzyme activity in rat brain and their dietary modulation,” Arch.
Pharm. Res., vol. 22, no. 4, pp. 361–366, Aug. 1999.
[141] E. M. Kawamoto, A. R. Vasconcelos, S. Degaspari, A. E. Böhmer, C. Scavone,
and T. Marcourakis, “Age-related changes in nitric oxide activity, cyclic GMP,
and TBARS levels in platelets and erythrocytes reflect the oxidative status in
central nervous system,” AGE, vol. 35, no. 2, pp. 331–342, Apr. 2013.
[142] I. R. Siqueira, C. Fochesatto, A. de Andrade, M. Santos, M. Hagen, A. BelloKlein, and C. A. Netto, “Total antioxidant capacity is impaired in different
structures from aged rat brain,” Int. J. Dev. Neurosci., vol. 23, no. 8, pp. 663–671,
Dec. 2005.
[143] P. D. A. Woźniak, P. D. G. Drewa, P. D. B. Woźniak, and P. D. D. O.
Schachtschabel, “Activity of antioxidant enzymes and concentration of lipid
peroxidation products in selected tissues of mice of different ages, both healthy
and melanoma-bearing,” Z. Für Gerontol. Geriatr., vol. 37, no. 3, pp. 184–189,
Jun. 2004.
190 | P a g e

BIBLIOGRAPHY

[144] R. Dei, A. Takeda, H. Niwa, M. Li, Y. Nakagomi, M. Watanabe, T. Inagaki, Y.
Washimi, Y. Yasuda, K. Horie, T. Miyata, and G. Sobue, “Lipid peroxidation and
advanced glycation end products in the brain in normal aging and in Alzheimer’s
disease,” Acta Neuropathol. (Berl.), vol. 104, no. 2, pp. 113–122, Aug. 2002.
[145] H. M. Abdul, R. Sultana, D. K. St. Clair, W. R. Markesbery, and D. A.
Butterfield, “Oxidative damage in brain from human mutant APP/PS-1 double
knock-in mice as a function of age,” Free Radic. Biol. Med., vol. 45, no. 10, pp.
1420–1425, Nov. 2008.
[146] H. F. Poon, G. Joshi, R. Sultana, S. A. Farr, W. A. Banks, J. E. Morley, V.
Calabrese, and D. A. Butterfield, “Antisense directed at the Aβ region of APP
decreases brain oxidative markers in aged senescence accelerated mice,” Brain
Res., vol. 1018, no. 1, pp. 86–96, Aug. 2004.
[147] L. K. Gilmer, M. A. Ansari, K. N. Roberts, and S. W. Scheff, “Age-related
changes in mitochondrial respiration and oxidative damage in the cerebral cortex
of the Fischer 344 rat,” Mech. Ageing Dev., vol. 131, no. 2, pp. 133–143, Feb.
2010.
[148] I. K. Hwang, Y. S. Yoon, K.-Y. Yoo, H. Li, J. H. Choi, D. W. Kim, S. S. Yi, J. K.
Seong, I. S. Lee, and M.-H. Won, “Differences in Lipid Peroxidation and Cu,ZnSuperoxide Dismutase in the Hippocampal CA1 Region Between Adult and Aged
Dogs,” J. Vet. Med. Sci., vol. 70, no. 3, pp. 273–277, 2008.
[149] J. Guest, R. Grant, T. A. Mori, and K. D. Croft, “Changes in Oxidative Damage,
Inflammation and [NAD(H)] with Age in Cerebrospinal Fluid,” PLoS ONE, vol.
9, no. 1, p. e85335, Jan. 2014.
[150] T. J. Montine, M. D. Neely, J. F. Quinn, M. F. Beal, W. R. Markesbery, L. J.
Roberts, and J. D. Morrow, “Lipid peroxidation in aging brain and Alzheimer’s
disease,” Free Radic. Biol. Med., vol. 33, no. 5, pp. 620–626, Sep. 2002.
[151] J. A. Youssef, L. S. Birnbaum, L. L. Swift, J. D. Morrow, and M. Z. Badr, “Ageindependent, gray matter-localized, brain-enhanced oxidative stress in male
fischer 344 rats: brain levels of F2-isoprostanes and F4-neuroprostanes,” Free
Radic. Biol. Med., vol. 34, no. 12, pp. 1631–1635, Jun. 2003.
[152] X. Wang, W. Wang, L. Li, G. Perry, H. Lee, and X. Zhu, “Oxidative stress and
mitochondrial dysfunction in Alzheimer’s disease,” Biochim. Biophys. Acta BBA
- Mol. Basis Dis., vol. 1842, no. 8, pp. 1240–1247, Aug. 2014.
[153] F. Missirlis, J. Hu, K. Kirby, A. J. Hilliker, T. A. Rouault, and J. P. Phillips,
“Compartment-specific Protection of Iron-Sulfur Proteins by Superoxide
Dismutase,” J. Biol. Chem., vol. 278, no. 48, pp. 47365–47369, Nov. 2003.
[154] F. L. Muller, Y. Liu, and H. V. Remmen, “Complex III Releases Superoxide to
Both Sides of the Inner Mitochondrial Membrane,” J. Biol. Chem., vol. 279, no.
47, pp. 49064–49073, Nov. 2004.
[155] C. Franceschi, M. Bonafè, S. Valensin, F. Olivieri, M. De Luca, E. Ottaviani, and
G. De Benedictis, “Inflamm-aging: An Evolutionary Perspective on
Immunosenescence,” Ann. N. Y. Acad. Sci., vol. 908, no. 1, pp. 244–254, Jun.
2000.
[156] C. Franceschi, M. Capri, D. Monti, S. Giunta, F. Olivieri, F. Sevini, M. P.
Panourgia, L. Invidia, L. Celani, M. Scurti, E. Cevenini, G. C. Castellani, and S.
Salvioli, “Inflammaging and anti-inflammaging: A systemic perspective on aging
and longevity emerged from studies in humans,” Mech. Ageing Dev., vol. 128,
no. 1, pp. 92–105, Jan. 2007.

191 | P a g e

BIBLIOGRAPHY

[157] C. Franceschi and J. Campisi, “Chronic Inflammation (Inflammaging) and Its
Potential Contribution to Age-Associated Diseases,” J. Gerontol. A. Biol. Sci.
Med. Sci., vol. 69, no. Suppl 1, pp. S4–S9, Jun. 2014.
[158] Quibik, Pathways in biosynthesis of eicosanoids from arachidonic acid: there are
parallel paths from EPA & DGLA. 2007.
[159] E. A. Dennis, “The growing phospholipase A2 superfamily of signal transduction
enzymes,” Trends Biochem. Sci., vol. 22, no. 1, pp. 1–2, Jan. 1997.
[160] M. A. Balboa, I. Varela-Nieto, K. Killermann Lucas, and E. A. Dennis,
“Expression and function of phospholipase A2 in brain,” FEBS Lett., vol. 531,
no. 1, pp. 12–17, Oct. 2002.
[161] E. A. Dennis, J. Cao, Y.-H. Hsu, V. Magrioti, and G. Kokotos, “Phospholipase
A2 Enzymes: Physical Structure, Biological Function, Disease Implication,
Chemical Inhibition, and Therapeutic Intervention,” Chem. Rev., vol. 111, no. 10,
pp. 6130–6185, Oct. 2011.
[162] E. Ricciotti and G. A. FitzGerald, “Prostaglandins and Inflammation,”
Arterioscler. Thromb. Vasc. Biol., vol. 31, no. 5, pp. 986–1000, May 2011.
[163] J.-H. Won, “Cyclooxygenase-2: A Potential Target in Human Cancer,” Cancer
Res. Treat. Off. J. Korean Cancer Assoc., vol. 36, no. 3, pp. 161–162, Jun. 2004.
[164] J. R. Vane, Y. S. Bakhle, and R. M. Botting, “Cyclooxygenases 1 and 2,” Annu.
Rev. Pharmacol. Toxicol., vol. 38, no. 1, pp. 97–120, 1998.
[165] K. Yamagata, K. I. Andreasson, W. E. Kaufmann, C. A. Barnes, and P. F.
Worley, “Expression of a mitogen-inducible cyclooxygenase in brain neurons:
Regulation by synaptic activity and glucocorticoids,” Neuron, vol. 11, no. 2, pp.
371–386, Aug. 1993.
[166] Y. Kitamura, S. Shimohama, H. Koike, J. Kakimura, Y. Matsuoka, Y. Nomura,
P. J. Gebicke-Haerter, and T. Taniguchi, “Increased Expression of
Cyclooxygenases and Peroxisome Proliferator-Activated Receptor-γ in
Alzheimer’s Disease Brains,” Biochem. Biophys. Res. Commun., vol. 254, no. 3,
pp. 582–586, Jan. 1999.
[167] L. Minghetti, “Cyclooxygenase-2 (COX-2) in Inflammatory and Degenerative
Brain Diseases,” J. Neuropathol., vol. 63, no. 9, pp. 901–910, 2004.
[168] P. Casolini, A. Catalani, A. R. Zuena, and L. Angelucci, “Inhibition of COX-2
reduces the age-dependent increase of hippocampal inflammatory markers,
corticosterone secretion, and behavioral impairments in the rat,” J. Neurosci.
Res., vol. 68, no. 3, pp. 337–343, May 2002.
[169] A. A. Farooqui and T. Farooqui, Eds., Molecular Aspects of Neurodegeneration
and Neuroprotection. Bentham Science Publishers, 2012.
[170] A. J. Vecchio, B. J. Orlando, R. Nandagiri, and M. G. Malkowski, “Investigating
Substrate Promiscuity in Cyclooxygenase-2 THE ROLE OF ARG-120 AND
RESIDUES LINING THE HYDROPHOBIC GROOVE,” J. Biol. Chem., vol.
287, no. 29, pp. 24619–24630, Jul. 2012.
[171] A. J. Vecchio, D. M. Simmons, and M. G. Malkowski, “Structural Basis of Fatty
Acid Substrate Binding to Cyclooxygenase-2,” J. Biol. Chem., vol. 285, no. 29,
pp. 22152–22163, Jul. 2010.
[172] S. C. Dyall, “Long-chain omega-3 fatty acids and the brain: a review of the
independent and shared effects of EPA, DPA and DHA,” Front. Aging Neurosci.,
vol. 7, Apr. 2015.
[173] S. Aïd and F. Bosetti, “Gene expression of cyclooxygenase-1 and Ca2+independent phospholipase A2 is altered in rat hippocampus during normal
aging,” Brain Res. Bull., vol. 73, no. 1–3, pp. 108–113, Jun. 2007.
192 | P a g e

BIBLIOGRAPHY

[174] G. R. Weerasinghe, S. L. Coon, A. K. Bhattacharjee, G. J. Harry, and F. Bosetti,
“Regional protein levels of cytosolic phospholipase A2 and cyclooxygenase-2 in
Rhesus monkey brain as a function of age,” Brain Res. Bull., vol. 69, no. 6, pp.
614–621, May 2006.
[175] P. G. Kopf, D. X. Zhang, K. M. Gauthier, K. Nithipatikom, X.-Y. Yi, J. R. Falck,
and W. B. Campbell, “Adrenic Acid Metabolites as Endogenous EndotheliumDerived and Zona Glomerulosa-Derived Hyperpolarizing Factors,” Hypertension,
vol. 55, no. 2, pp. 547–554, Feb. 2010.
[176] B. Cox and A. Emili, “Tissue subcellular fractionation and protein extraction for
use in mass-spectrometry-based proteomics,” Nat. Protoc., vol. 1, no. 4, pp.
1872–1878, 2006.
[177] S. Gandhi, M. M. K. Muqit, L. Stanyer, D. G. Healy, P. M. Abou-Sleiman, I.
Hargreaves, S. Heales, M. Ganguly, L. Parsons, a J. Lees, D. S. Latchman, J. L.
Holton, N. W. Wood, and T. Revesz, “PINK1 protein in normal human brain and
Parkinson’s disease.,” Brain J. Neurol., vol. 129, no. Pt 7, pp. 1720–31, Jul. 2006.
[178] L. Bourova, J. Stohr, V. Lisy, V. Rudajev, J. Novotny, and P. Svoboda, “Isolation
of plasma membrane compartments from rat brain cortex; detection of agoniststimulated G protein activity,” Med. Sci. Monit., vol. 15, no. 4, pp. BR111–
BR122, Mar. 2009.
[179] R. Lund, R. Leth-Larsen, O. N. Jensen, and H. J. Ditzel, “Efficient Isolation and
Quantitative Proteomic Analysis of Cancer Cell Plasma Membrane Proteins for
Identification of Metastasis-Associated Cell Surface Markers research articles,” J.
Proteome Res., vol. 8, no. 6, pp. 3078–3090, Jun. 2009.
[180] J. Folch, M. Lees, and G. H. Sloane Stanley, “A simple method for the isolation
and purification of total lipides from animal tissues,” J. Biol. Chem., vol. 226, no.
1, pp. 497–509, May 1957.
[181] J. M. Deeley, T. W. Mitchell, X. Wei, J. Korth, J. R. Nealon, S. J. Blanksby, and
R. J. W. Truscott, “Human lens lipids differ markedly from those of commonly
used experimental animals,” Biochim. Biophys. Acta, vol. 1781, no. 6–7, pp. 288–
298, Jul. 2008.
[182] K. A. Kayganich and R. C. Murphy, “Fast atom bombardment tandem mass
spectrometric identification of diacyl, alkylacyl, and alk-1-enylacyl molecular
species of glycerophosphoethanolamine in human polymorphonuclear
leukocytes,” Anal. Chem., vol. 64, no. 23, pp. 2965–2971, Dec. 1992.
[183] K. Ekroos, C. S. Ejsing, U. Bahr, M. Karas, K. Simons, and A. Shevchenko,
“Charting molecular composition of phosphatidylcholines by fatty acid scanning
and ion trap MS3 fragmentation,” J. Lipid Res., vol. 44, no. 11, pp. 2181–2192,
Nov. 2003.
[184] K. A. Z. Berry and R. C. Murphy, “Electrospray ionization tandem mass
spectrometry of glycerophosphoethanolamine plasmalogen phospholipids,” J.
Am. Soc. Mass Spectrom., vol. 15, no. 10, pp. 1499–1508, Oct. 2004.
[185] J. M. Deeley, M. C. Thomas, R. J. W. Truscott, T. W. Mitchell, and S. J.
Blanksby, “Identification of Abundant Alkyl Ether Glycerophospholipids in the
Human Lens by Tandem Mass Spectrometry Techniques,” Anal. Chem., vol. 81,
no. 5, pp. 1920–1930, Mar. 2009.
[186] T. W. Mitchell, R. Buffenstein, and A. J. Hulbert, “Membrane phospholipid
composition may contribute to exceptional longevity of the naked mole-rat
(Heterocephalus glaber): A comparative study using shotgun lipidomics,” Exp.
Gerontol., vol. 42, no. 11, pp. 1053–1062, Nov. 2007.
193 | P a g e

BIBLIOGRAPHY

[187] G. Liebisch, J. A. Vizcaíno, H. Köfeler, M. Trötzmüller, W. J. Griffiths, G.
Schmitz, F. Spener, and M. J. O. Wakelam, “Shorthand notation for lipid
structures derived from mass spectrometry,” J. Lipid Res., vol. 54, no. 6, pp.
1523–1530, Jun. 2013.
[188] B. L. Miller and J. L. Cummings, Human Frontal Lobes : Functions and
Disorders (2nd Edition). New York, NY, USA: Guilford Press, 2006.
[189] S. C. Cunnane, R. Chouinard-Watkins, C. A. Castellano, and P. BarbergerGateau, “Docosahexaenoic acid homeostasis, brain aging and Alzheimer’s
disease: Can we reconcile the evidence?,” Prostaglandins Leukot. Essent. Fatty
Acids, vol. 88, no. 1, pp. 61–70, Jan. 2013.
[190] H.-Y. Kim, B. X. Huang, and A. A. Spector, “Phosphatidylserine in the brain:
Metabolism and function,” Prog. Lipid Res., vol. 56, pp. 1–18, Oct. 2014.
[191] H.-Y. Kim, M. Akbar, and Y.-S. Kim, “Phosphatidylserine-dependent
neuroprotective signaling promoted by docosahexaenoic acid,” Prostaglandins
Leukot. Essent. Fat. Acids PLEFA, vol. 82, no. 4–6, pp. 165–172, Apr. 2010.
[192] E. Hassan-Zadeh, E. Baykal-Caglar, M. Alwarawrah, and J. Huang, “Complex
Roles of Hybrid Lipids in the Composition, Order, and Size of Lipid Membrane
Domains,” Langmuir, vol. 30, no. 5, pp. 1361–1369, Feb. 2014.
[193] C. Klose, M. A. Surma, and K. Simons, “Organellar lipidomics — background
and perspectives,” Curr. Opin. Cell Biol., vol. 25, no. 4, pp. 406–413, Aug. 2013.
[194] L. Nadel, A. Hupbach, R. Gomez, and K. Newman-Smith, “Memory formation,
consolidation and transformation,” Neurosci. Biobehav. Rev., vol. 36, no. 7, pp.
1640–1645, Aug. 2012.
[195] T. Kitamura and K. Inokuchi, “Role of adult neurogenesis in hippocampalcortical memory consolidation,” Mol. Brain, vol. 7, p. 13, Feb. 2014.
[196] E. I. Moser, E. Kropff, and M.-B. Moser, “Place Cells, Grid Cells, and the
Brain’s Spatial Representation System,” Annu. Rev. Neurosci., vol. 31, no. 1, pp.
69–89, 2008.
[197] N. C. Fox, W. R. Crum, R. I. Scahill, J. M. Stevens, J. C. Janssen, and M. N.
Rossor, “Imaging of onset and progression of Alzheimer’s disease with voxelcompression mapping of serial magnetic resonance images,” The Lancet, vol.
358, no. 9277, pp. 201–205, Jul. 2001.
[198] R. I. Scahill, J. M. Schott, J. M. Stevens, M. N. Rossor, and N. C. Fox, “Mapping
the evolution of regional atrophy in Alzheimer’s disease: Unbiased analysis of
fluid-registered serial MRI,” Proc. Natl. Acad. Sci., vol. 99, no. 7, pp. 4703–
4707, Apr. 2002.
[199] R. I. Scahill, C. Frost, R. Jenkins, J. L. Whitwell, M. N. Rossor, and N. C. Fox,
“A longitudinal study of brain volume changes in normal aging using serial
registered magnetic resonance imaging,” Arch. Neurol., vol. 60, no. 7, pp. 989–
994, Jul. 2003.
[200] M. Ewers, P. Insel, W. J. Jagust, L. Shaw, J. Q. T. J, P. Aisen, R. C. Petersen, N.
Schuff, and M. W. Weiner, “CSF Biomarker and PIB-PET–Derived BetaAmyloid Signature Predicts Metabolic, Gray Matter, and Cognitive Changes in
Nondemented Subjects,” Cereb. Cortex, vol. 22, no. 9, pp. 1993–2004, Sep.
2012.
[201] O. Szekely, Y. Schilt, A. Steiner, and U. Raviv, “Regulating the Size and
Stabilization of Lipid Raft-like Domains and Using Calcium Ions as Their
Probe,” Langmuir, vol. 27, no. 24, pp. 14767–14775, Dec. 2011.
[202] M. Gallagher and M. T. Koh, “Episodic memory on the path to Alzheimer’s
disease,” Curr. Opin. Neurobiol., vol. 21, no. 6, pp. 929–934, Dec. 2011.
194 | P a g e

BIBLIOGRAPHY

[203] J. L. Price, A. Ko I., M. J. Wade, S. K. Tsou, D. W. McKeel, and J. C. Morris,
“Neuron number in the entorhinal cortex and ca1 in preclinical alzheimer
disease,” Arch. Neurol., vol. 58, no. 9, pp. 1395–1402, Sep. 2001.
[204] J. L. Whitwell, S. A. Przybelski, S. D. Weigand, D. S. Knopman, B. F. Boeve, R.
C. Petersen, and C. R. Jack, “3D maps from multiple MRI illustrate changing
atrophy patterns as subjects progress from mild cognitive impairment to
Alzheimer’s disease,” Brain, vol. 130, no. 7, pp. 1777–1786, Jul. 2007.
[205] L. E. M. Wisse, G. J. Biessels, S. M. Heringa, H. J. Kuijf, D. (H. ) L. Koek, P. R.
Luijten, and M. I. Geerlings, “Hippocampal subfield volumes at 7T in early
Alzheimer’s disease and normal aging,” Neurobiol. Aging, vol. Article in Press,
2014.
[206] S. E. Arnold, J. B. Toledo, D. H. Appleby, S. X. Xie, L.-S. Wang, Y. Baek, D. A.
Wolk, E. B. Lee, B. L. Miller, V. M.-Y. Lee, and J. Q. Trojanowski,
“Comparative survey of the topographical distribution of signature molecular
lesions in major neurodegenerative diseases,” J. Comp. Neurol., vol. 521, no. 18,
pp. 4339–4355, Dec. 2013.
[207] H. Braak, E. Braak, J. Bohl, and W. Lang, “Alzheimer’s disease: amyloid plaques
in the cerebellum,” J. Neurol. Sci., vol. 93, no. 2–3, pp. 277–287, Nov. 1989.
[208] K. Andersen, B. B. Andersen, and B. Pakkenberg, “Stereological quantification
of the cerebellum in patients with Alzheimer’s disease,” Neurobiol. Aging, vol.
33, no. 1, pp. 197.e11–197.e20, Jan. 2012.
[209] J. A. Bernard and R. D. Seidler, “Moving forward: Age effects on the cerebellum
underlie cognitive and motor declines,” Neurosci. Biobehav. Rev., vol. 42, pp.
193–207, May 2014.
[210] H.-Y. Kim, J. Bigelow, and J. H. Kevala, “Substrate Preference in
Phosphatidylserine Biosynthesis for Docosahexaenoic Acid Containing Species,”
Biochemistry (Mosc.), vol. 43, no. 4, pp. 1030–1036, Feb. 2004.
[211] G. Rizzolatti, G. Luppino, and M. Matelli, “The organization of the cortical
motor system: new concepts,” Electroencephalogr. Clin. Neurophysiol., vol. 106,
no. 4, pp. 283–296, Apr. 1998.
[212] L. Su, L. Wang, F. Chen, H. Shen, B. Li, and D. Hu, “Sparse Representation of
Brain Aging: Extracting Covariance Patterns from Structural MRI,” PLoS One,
vol. 7, no. 5, May 2012.
[213] A. M. Fjell, L. T. Westlye, I. Amlien, T. Espeseth, I. Reinvang, N. Raz, I. Agartz,
D. H. Salat, D. N. Greve, B. Fischl, A. M. Dale, and K. B. Walhovd, “High
Consistency of Regional Cortical Thinning in Aging across Multiple Samples,”
Cereb. Cortex, vol. 19, no. 9, pp. 2001–2012, Sep. 2009.
[214] J. C. Baron, G. Chételat, B. Desgranges, G. Perchey, B. Landeau, V. de la
Sayette, and F. Eustache, “In Vivo Mapping of Gray Matter Loss with VoxelBased Morphometry in Mild Alzheimer’s Disease,” NeuroImage, vol. 14, no. 2,
pp. 298–309, Aug. 2001.
[215] X. Guo, K. Chen, Y. Zhang, Y. Wang, and L. Yao, “Regional covariance patterns
of gray matter alterations in Alzheimer’s disease and its replicability evaluation,”
J. Magn. Reson. Imaging, vol. 39, no. 1, pp. 143–149, Jan. 2014.
[216] P. M. Thompson, M. S. Mega, R. P. Woods, C. I. Zoumalan, C. J. Lindshield, R.
E. Blanton, J. Moussai, C. J. Holmes, J. L. Cummings, and A. W. Toga, “Cortical
Change in Alzheimer’s Disease Detected with a Disease-specific Populationbased Brain Atlas,” Cereb. Cortex, vol. 11, no. 1, pp. 1–16, Jan. 2001.
[217] J. E. Vance and R. Steenbergen, “Metabolism and functions of
phosphatidylserine,” Prog. Lipid Res., vol. 44, no. 4, pp. 207–234, Jul. 2005.
195 | P a g e

BIBLIOGRAPHY

[218] A. E. Rusiñol, Z. Cui, M. H. Chen, and J. E. Vance, “A unique mitochondriaassociated membrane fraction from rat liver has a high capacity for lipid synthesis
and contains pre-Golgi secretory proteins including nascent lipoproteins.,” J.
Biol. Chem., vol. 269, no. 44, pp. 27494–27502, Nov. 1994.
[219] Y. J. Shiao, G. Lupo, and J. E. Vance, “Evidence that phosphatidylserine is
imported into mitochondria via a mitochondria-associated membrane and that the
majority of mitochondrial phosphatidylethanolamine is derived from
decarboxylation of phosphatidylserine,” J. Biol. Chem., vol. 270, no. 19, pp.
11190–11198, May 1995.
[220] T. Melo, R. A. Videira, S. André, E. Maciel, C. S. Francisco, A. M. OliveiraCampos, L. M. Rodrigues, M. R. M. Domingues, F. Peixoto, and M. Manuel
Oliveira, “Tacrine and its analogues impair mitochondrial function and
bioenergetics: a lipidomic analysis in rat brain,” J. Neurochem., vol. 120, no. 6,
pp. 998–1013, Mar. 2012.
[221] M. A. Kiebish, X. Han, and T. N. Seyfried, “Examination of the Brain
Mitochondrial Lipidome Using Shotgun Lipidomics,” Methods Mol. Biol. Clifton
NJ, vol. 579, pp. 3–18, 2009.
[222] K. Zilles and K. Amunts, “Centenary of Brodmann’s map — conception and
fate,” Nat. Rev. Neurosci., vol. 11, no. 2, pp. 139–145, Feb. 2010.
[223] C. J. Fhaner, S. Liu, X. Zhou, and G. E. Reid, “Functional Group Selective
Derivatization and Gas-Phase Fragmentation Reactions of Plasmalogen
Glycerophospholipids,” Mass Spectrom., vol. 2, no. Spec Iss, 2013.

196 | P a g e

APPENDICES

Appendices
Appendix 1

R Script for generation of heatmaps

197 | P a g e

